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1  
GENERAL INTRODUCTION 
 
Medical treatments can be quite successful for some individuals, while not for others. The 
rapid development of high-dimensional analytical laboratory technologies is expected to 
provide novel biomarkers or biomarker profiles for specific diseases. These techniques allow 
for examination of a patient at molecular level in unprecedented detail. This way, more 
personalized diagnosis and treatment plans may be applied. This is referred to as precision 
medicine. Data analysis is a crucial step in such personalized health care since the acquired 
data is often extremely large and complex. Unfortunately, many traditional methods have 
been designed for analysis of much smaller data sets and are not applicable. Therefore, 
development of novel data analysis approaches is essential to effectively use all the new 
information that is being gathered for the benefit of the patient. 
 
This thesis seeks to address several issues in data analysis of high-dimensional technologies for 
personalized health care. 
  
!
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1.1 High-dimensional analysis in medicine 
High-dimensional studies hold great promise in many fields such as the physical, chemical 
and health sciences [1, 2]. Advances in techniques such as DNA microarrays, infrared (IR) 
spectroscopy, liquid chromatography – mass spectrometry (LC-MS), and nuclear magnetic 
resonance (NMR) spectroscopy have enabled the rapid acquisition of a huge amount of 
molecular data in a sample in a single experiment [3, 4]. Subsequent application of powerful 
data analysis techniques allows for “data driven” research where measurements are 
performed to generate hypotheses rather than to confirm them [3]. 
 
High-dimensional techniques are becoming increasingly popular in medical applications 
[4-9]. Due to the advent of the so-called omics sciences it is now possible to study the 
molecular complexity of biological systems in unprecedented detail and at different levels 
ranging from the complete genome to profiles of metabolites [10]. The omics sciences have 
greatly improved our understanding of health and disease. For example, by means of data 
driven omics research many molecular profiles have been observed that correlate with 
specific biological processes and outcomes such as disease, thereby offering new 
information for processes whose mechanisms are yet unclear. Additionally, such signatures 
(biomarkers) can potentially be used as objective markers for e.g. diagnosis of a specific 
disease or selection and monitoring of therapy [11-14]. It is expected that the omics 
revolution will lead to significant advances in personalized health care where treatment is 
completely catered towards the unique molecular characteristics of an individual patient [4, 
12, 13]. This is in great contrast to most current treatments that can be very successful for 
some individuals while not for others since they have been designed for the average patient 
with that specific disease. Moreover, the omics sciences have the potential to transform 
medicine from conventional reactive approaches (i.e. symptom-oriented diagnosis and 
treatment of diseases) towards disease prevention and early diagnostics [12]. 
1.1.1 What are the omics sciences?  
Omics techniques are relevant for many clinical disciplines. They offer complementary 
views on human health and disease. The five major ones within the medical sciences are 
genomics, transcriptomics, proteomics, metabolomics, and glycomics [10]. These 
techniques are aimed at the universal detection of genes, mRNA, proteins, metabolites, and 
glycosylation profiles, respectively. The information in the genes is called the genotype. It is 
ultimately responsible for the final composition of a body fluid or tissue sample referred to 
as the biochemical phenotype. The genome offers much information regarding an 
individual’s susceptibility to genetic diseases, and prediction of treatment response for a 
given patient. It may also help to elucidate molecular mechanisms of disease, identify 
 General introduction 
 3 
 
 
potential therapeutic targets, design drugs, etc [5]. However, a specific gene sequence is not 
directly related to a final disease outcome. This is because the genes are first transcribed and 
translated into proteins many of which can act as enzymes in numerous metabolic 
reactions. In addition to the genetic makeup of an individual, several environmental factors 
also influence these processes. This means that it is possible to observe patients with a 
similar genotype, but unique proteome (the complete set of proteins), metabolome (the 
complete set of metabolites), glycome composition, and also different disease outcome [7, 
15]. Often, genomic information alone is not adequate to predict disease onset. This 
motivates the need to augment the information offered by genomics with the other omics 
 
Box 1.1   Glossary  
 
Biomarker 
A biological marker (biomarker) is “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention” 
[14].  
 
High dimensional studies  
Experiments that are characterized by the measurement of a few dozen to many thousands of variables 
(dimensions) per sample. The resulting data from such experiments is often referred to a high-dimensional 
data. Due to the “curse of dimensionality” phenomenon many traditional data analysis methods do not scale 
well to high-dimensional data. 
 
Omics 
The collective name for technologies used to comprehensively study the molecules that make up a biological 
sample such as a cell, tissue, organ, body fluid, or organism. The techniques are primarily aimed at the 
universal detection of genes (genomics), RNA (transcriptomics), proteins (proteomics), metabolites 
(metabolomics), and glycosylation profiles (glycomics) in an untargeted and unbiased manner. Such analysis is 
sometimes referred to as high-dimensional biology.
 
Personalized health care 
In this thesis, personalized health care is synonymous for precision medicine, which refers the use of molecular 
information (biomarkers) to target disease prevention and treatment to the needs of the individual patient. 
Outside of this thesis, personalized health care is sometimes viewed as a broader area that also includes 
concepts such as participatory health care, patient involvement, self-monitoring, etc. 
 
Targeted analysis 
A study that focuses on the measurement of a particular and limited set of compounds such as a particular set 
of metabolites. 
 
Untargeted analysis 
The simultaneous unbiased measurement of as many compounds (e.g. metabolites) as possible from a set of 
samples. 
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technologies to obtain information at the functional level of cells and tissues (i.e. the 
proteome, metabolome, and glycome). In concert these will influence the patient’s clinical 
phenotype [5]. 
1.1.2 Metabolomics 
The metabolome is the final downstream product of cellular activity and is thus an 
important driver of the clinical phenotype [16, 17]. It differs greatly between individuals and 
populations [18, 19]. The dynamics of metabolism operates on a timescale of seconds and 
depends on the interplay between genes and environmental factors such as diet, lifestyle 
and gut microbial composition [18]. These are the same factors that cause disease. 
Therefore, metabolomics is expected to become an important aspect of personalized health 
care as a sensitive and powerful method to study health and disease [4, 7, 15, 20, 21]. An 
additional advantage of metabolomics is that many biomarkers can be measured in a 
relatively noninvasive way by analyzing blood or urine samples [22]. Such samples are 
easily obtainable in the clinic. Below, three clinical examples of metabolomics studies are 
presented, which are used throughout this thesis. Note that these are all examples of so-
called untargeted metabolomics studies (see box 1.1). In this thesis novel data analysis 
strategies are developed for such untargeted metabolomics studies. 
Application 1: A nutritional intervention metabolomics study 
Much effort is spent to understand how genetic and environmental factors influence the 
metabolome exactly [15]. This is required for a better understanding of health and disease, 
but also because these factors can act as confounders in clinical studies.  
 
Nutrition can be beneficial but also detrimental for health. However, it is still unclear how 
an individual’s diet relates to a specific health outcome exactly. In recent years, 
investigation of effects of nutrition on health and disease by metabolomics has gained 
significant interest [15]. The goal is to understand what happens to the metabolome with 
changes in diet to elucidate the underlying mechanisms and identify potential biomarkers. 
For example, a possible therapy of metabolic syndrome is to influence the metabolism by 
changing food intake patterns. In this respect it is of interest to understand how specific 
diets influence the metabolism and why some patients respond to a diet (i.e. lose a 
significant amount of weight) and others do not.  
 
In chapter 4 of this thesis the metabolic response and loss of body weight due to four 
isocaloric diets was followed through time in individuals suffering from metabolic 
syndrome [23]. Urine 1H NMR metabolomics was used to assess the metabolome at the 
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Figure 1.1   The metabolic pathway of tyrosine, showing the enzymatic defect present in alkaptonuria 
patients. (a) Tyrosine is metabolized to produce maleylacetoacetic acid in three steps. A defect of the enzyme 
homogentisic acid oxidase causes the build-up of homogentisic acid, and metabolites of homogentistic acid 
that do not occur in healthy individuals. These metabolites cause damage to heart valves, cartilage, and 
precipitate in organs e.g. as kidney stones. (b) High concentrations of homogentisic acid can be observed in 
urine 1H-NMR spectra from affected patients.  
different time points. Significant metabolic differences between responders and non-
responders and between the four diets were identified by means of regularized multivariate 
analysis of variance (rMANOVA; a novel data analysis method introduced in this chapter). 
Application 2: Diagnosis of inborn errors of metabolism 
Metabolomics is becoming an increasingly popular tool for disease diagnosis. Typically, the 
value of a specific biomarker is measured in the patient and it is investigated if this value 
differs significantly from reference values. For example, metabolomics has been used this 
way to diagnose cardiovascular disease, diabetes, cancer, neurological diseases, and inborn 
errors of metabolism (IEM)	  [20,	  24-­‐26].	  
 
IEM comprise a substantial group of rare genetic diseases. An IEM is often a defect in a 
single gene that leads to impaired activity of an enzyme, co-factor, or other relevant protein 
[27]. This often results in a block in a particular metabolic pathway leading to the 
accumulation of a metabolite before the block (e.g. the substrate of an enzyme) and/or a lack 
of one or more metabolites downstream of the block (the product of the enzymatic 
reaction). Alternatively, it can be that the block causes alternative pathways to be used 
resulting in accumulation of unexpected and possibly toxic metabolites. As an example, the 
diagnosis of Alkaptonuria by means of urine 1H NMR metabolomics is shown in figure 1.1. 
The peaks at 3.64 and 6.76 ppm indicate an elevated concentration of homogentisic acid, a 
Chapter 1 
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biomarker for this disease, in the urine of the patient [25]. In chapters 5 and 6 of this thesis, 
novel data analysis methods are introduced that can be used to screen the metabolome of 
patients and automatically identify (patterns of) metabolite concentrations that are not 
expected to occur in healthy individuals. Subsequently, this information can be used for 
disease diagnosis. The methods are used to diagnose different IEM in a number of patients. 
Application 3: Health monitoring by personalized omic profiling 
Recently, metabolomics in combination with other omics technologies was used in a 
pioneering study to monitor a 54-year-old, initially healthy male, at 20 time points over a 
14-months period [28]. The approach was coined integrated personal omic profiling 
(iPOP). During the period of the study the individual suffered from two episodes of viral 
infection. Temporal changes in the personal omics profile (based on measurements of blood 
components) showed strong association with health and disease status; for example, 
changes in metabolite expression levels appeared to be consistent with the emergence of the 
viral infections [4]. Additionally, genomics measurements, performed at the start of the 
study, revealed that the individual was predisposed to type-2 diabetes whose onset was 
observed immediately after one of the viral infections. Due to the early diagnosis offered by 
iPOP, the patient could effectively control and reverse the diabetes phenotype by proactive 
interventions such as a diet change and physical exercise [12].  
 
The iPOP study demonstrated the potential of omics offering a very detailed assessment of 
someone’s health status and closely monitoring disease onset. Temporal iPOP studies may 
become feasible in the near future with decreasing costs of omics experiments. A single 
assessment, however, is already doable and could be used to screen individual patients and 
potentially identify the root cause of disease as we show in chapters 5 and 6 of this thesis. 
The data analysis methodology introduced in these chapters can also be used to 
automatically inspect iPOP data from a temporal assessment. This is discussed in chapter 7.  
1.2 Data analysis challenges in metabolomics 
Due to the complex nature of the metabolome and the high-dimensional analytical 
techniques used to measure it, datasets are extremely large and complex. This is illustrated 
in figure 1.2 where a urine 1H NMR spectrum of a healthy volunteer is shown. The 
complexity of this spectrum is, for example, clearly reflected by the large number of peaks 
that can be observed; the greatly varying peak intensities, which are related to the different 
metabolites in the sample; and the presence of signal that is due to noise. Factors such as 
baseline drift; peak shifts; and dilution differences between samples add further complexity  
 General introduction 
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Figure 1.2   (a) 1H-NMR spectrum of urine from a healthy volunteer and (b) an expansion of a part of this 
spectrum. DMA = dimethylamine; TMAO = trimethylamine N-oxide.  
to the data. The complexity increases even further when other techniques such as LC-QTOF 
are used where more than 10000 peaks can be measured for each sample. Clearly, data 
analysis is indispensable for analysis of such large data [24, 29]. Ideally, a data analyst is 
involved in every step of a metabolomics experiment starting with its design (formulation of 
focused research questions, number of samples, sample collection, collection moments, 
study design, etc.), subsequent pre-processing of the measured data to remove unwanted 
artifacts, (multivariate) statistical modeling to extract the biological information, and 
statistical and biological validation of the results. 
 
Analysis of metabolomics data is not straightforward. Currently the development of novel 
metabolomics technologies greatly outpaces our ability to properly analyze the acquired 
data. This is in a large part due to the large number of variables that are measured in a single 
experiment. Here we present three examples of data analysis challenges that are relevant for 
Chapter 1 
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this thesis. Note that many of these challenges are general challenges that also apply to data 
from other high-dimensional technologies such as proteomics or glycomics. 
 
1. Data pre-processing is a crucial step to remove unwanted variation from the data 
such that subsequent analysis can focus on the relevant biological information in 
the data (e.g. the biomarker). For example, peak shifts in NMR spectra and 
chromatograms are usually corrected for by alignment or warping methods. Often 
it is not directly clear which method will perform best (in some relevant sense) for 
a specific data set and several settings and methods have to be investigated. 
However, many methods are computationally expensive when applied to data with 
a large number of variables. Therefore, this is not a viable approach for 
metabolomics. Guidelines for efficient data pre-processing have to be developed, 
ideally as a standard operation procedure. 
 
2. Analysis of metabolomics data heavily relies on statistical modeling, for example, 
to detect metabolic differences between a group of healthy controls and a group of 
patients in a biomarker discovery experiment. Often, however, the number of 
samples in a data set is much smaller than the number of variables and many more 
or less standard statistical methods become extremely unreliable. One way to 
circumvent these issues is to impose some structure to the model with the aim to 
reduce variance at the cost of some bias. This is known as regularization [2, 30-33]. 
Dimension reduction by principal component analysis (PCA) (or a similar 
method related to explained variance) is a popular regularization approach in 
metabolomics. However, dimension reduction by PCA may not work out well, e.g. 
when group separation is only visible in the last (discarded) principal components. 
Clearly, other regularization approaches for analysis of metabolomics data have to 
be used in some applications. 
 
3. Data analysis for personalized health care requires statistical modeling beyond 
population-based approaches. Metabolomics studies used to compare groups of 
samples to each other (e.g. patients with a specific disease and controls). However, 
for a number of reasons this may be impractical in a clinical setting. For example, 
in the case of diagnosis of rare diseases typically too few samples from diseased 
patients are available for a useful comparison. The population-based approach is 
also not useful for health monitoring (see application 3), because (1) it ignores the 
potential longitudinal aspect of such studies, and (2) the health status of an 
individual should be assessed in an unbiased way instead of focusing on one 
specific disease. Additionally, by definition, population-based models are designed 
 General introduction 
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to be the best for the average population, but not necessarily for specific 
individuals. As mentioned above, individuals are genetically diverse and may have 
different exposures and response characteristics to disease [34]. These individual 
responses are likely to overlap in large population models [4]. 
 
It is clear that the new techniques require that we compare an n = 1 patient sample 
to a group of controls. With this paradigm shift something can be said about the 
individual patient. Ideally, a data analysis method that can screen the metabolome 
of individual patients and automatically identify abnormal (patterns of) metabolite 
concentrations would be extremely useful. 
 
The three aforementioned examples demonstrate that further development of data analysis 
approaches is crucial to unlock the clinical potential of metabolomics (and other high-
dimensional technologies) for personalized health care. For this purpose it is extremely 
interesting to consider novel approaches that have been proposed in fields outside of 
metabolomics. With respect to data pre-processing (challenge 1) the current and emerging 
approaches described in literature should be carefully evaluated on benchmark data. Based 
on these findings more efficient pre-processing guidelines can hopefully be developed. 
Statistical modeling of high-dimensional data for disease diagnosis, biomarker discovery, 
etc. (challenge 2) may benefit from the novel regularization approaches that have been 
developed in fields such as statistics, statistical learning, and machine learning [30, 32]. 
These developments bring interesting new perspectives and deserve more attention from 
the metabolomics community than they have received so far. In many situations these 
methods offer more powerful ways of regularization compared to dimension reduction with 
PCA. Finally, statistical modeling for personalized health care (challenge 3) may benefit 
from ideas that have been developed in the field of industrial process monitoring. Here, the 
goal is to automatically determine whether or not a process is in control (Normal Operating 
Conditions); if not, a known or unknown rare event has occurred that may affect product 
quality. This is essentially the same goal as monitoring the health status of an individual for 
early diagnosis of (rare) diseases.  
1.3 Scope and outline of this thesis 
This thesis addresses several challenges in pre-processing and statistical modeling of data 
generated by high-dimensional technologies (see box 1.2). The focus is on several topics in 
personalized health care, namely biomarker discovery, disease diagnosis, and health 
monitoring.  
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In Chapter 2 current strategies and guidelines for selection of the optimal pre-processing 
method are critically evaluated. It is shown that breaking with current trends in pre-
processing is necessary: all selection approaches have serious drawbacks and are unreliable. 
Throughout the chapter Fourier transform-infrared (FT-IR) data, originating from a food-
authentication study, is used to demonstrate the behavior of the approaches. This type of 
data set is well understood and therefore serves as a perfect benchmark. Metabolomics data 
is often more complicated, but conclusions drawn in the chapter definitely generalize to 
metabolomics data. 
 
In Chapter 3 modern regularization approaches for statistical modeling of high 
dimensional data are reviewed. It is shown that the multivariate techniques in this thesis are 
all related to the Mahalanobis distance and therefore to each other. Because of this, 
regularization is discussed in the context of this distance. However, many of the approaches 
described in this chapter are general and can also be used for other regularization of other 
methods. Chapter 3 provides the basis for the studies presented in chapters 4 – 6. 
 
In chapter 4 analysis of metabolomics data with an underlying experimental design is 
explored. Such data is often obtained in biomarker discovery experiments. Multivariate 
analysis of variance (MANOVA) is a traditional method for analysis of such data. However, 
it cannot be applied to high-dimensional data. ANOVA simultaneous component analysis 
(ASCA) is a recently proposed alternative to MANOVA for analysis of such data. We show 
that ASCA implicitly assumes that the variables in the data are uncorrelated. This unrealistic 
assumption reduces the power of the method and hampers interpretation. An improved 
model is proposed that is essentially a weighted average of the ASCA and MANOVA 
 
Box 1.2   Aims of this thesis 
 
Data pre-processing 
• Evaluation of current approaches for selection of an optimal method for pre-processing of a high-
dimensional data set as a first step towards development of stable and effective guidelines. 
 
Statistical modeling 
• Development of novel regularized models for personalized healthcare that are in principle 
generally applicable to high-dimensional data sets originating from e.g. metabolomics, glycomics, 
or proteomics experiments. 
• Improve e.g. biomarker discovery by development of a multivariate method for analysis of data 
with an underlying experimental design. 
• Development of a multivariate model for the comparison of an n = 1 patient sample to data of a 
group of controls, e.g. for diagnosis of rare diseases or health monitoring. 
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models. This is achieved by combining MANOVA with a modern regularized estimator of 
the covariance matrix. The new method is used to analyze data from an untargeted 
metabolomics nutritional intervention study. 
 
In chapters 5 and 6 novel statistical approaches for identification of the disease biomarker 
in individual patients are introduced. For this purpose, ideas from industrial process 
monitoring are adapted to the clinical setting. The resulting methods can be used for 
analysis of temporal data (health monitoring) or a single assessment (e.g. to diagnose rare 
diseases). The latter approach is used in these chapters to diagnose several IEM. In chapter 
5 one of the most commonly used models for industrial process monitoring is transformed 
to the metabolomics setting. This model uses dimension reduction via PCA for 
regularization. As a consequence, the technique is computationally inexpensive, but reliable 
identification of the disease biomarker is not guaranteed in all situations. Therefore, a novel 
method is developed in chapter 6. More specifically, model estimation is combined with 
variable selection instead of dimension reduction. A so-called ℓ𝓁!-norm constraint is used 
for this purpose. Because of this, a fast algorithm can be used to solve the problem. 
Additionally, the solution can be graphically depicted and provides and intuitive way for a 
clinical practitioner to combine expert knowledge with the output of the model. Note that 
this constrained approach to variable selection has barely been used in metabolomics so far. 
It is shown that the resulting method can often identify the	   individual biomarker more 
reliably compared to the method developed in chapter 5 at the cost of computational 
complexity.	  
 
In chapter 7 the main findings of the research presented in this thesis are summarized. 
Next, various perspectives for further research are presented. Of all interesting avenues for 
further research, this chapter mainly focuses on application of the proposed data analysis 
methods to longitudinal metabolomics studies such as biomarker discovery and health 
monitoring. 
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2 
BREAKING WITH TRENDS IN PRE-
PROCESSING? 
Data pre-processing is an essential part of chemometric data analysis, which aims to remove 
unwanted variation (such as instrumental artefacts) and thereby focusing on the variation of 
interest. The choice of an optimal pre-processing method or combination of methods may 
strongly influence the analysis results, but is far from straightforward, since it depends on 
the characteristics of the dataset and on the goal of data analysis. This chapter is devoted to 
the selection procedure of appropriate pre-processing strategies. We show that breaking 
with current trends in pre-processing is essential, as all selection approaches have serious 
drawbacks and cannot be properly used. 
This chapter has been adapted from:!Engel, J.#, Gerretzen, J.#, Szymańska, E., Jansen, J. J., 
Downey, G., Blanchet, L., & Buydens, L. M. C. (2013). Breaking with trends in pre-
processing?. TrAC Trends in Analytical Chemistry, 50, 96-106. 
# These authors contributed equally to this study. 
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2.1 Introduction 
Due to recent developments in analytical chemistry, increasing amounts of complex 
analytical chemical data are being produced and employed in many different application 
areas, ranging from metabolomics to industrial process monitoring and quality control [1, 
2]. Such comprehensive data requires that increasingly more time and effort is invested in 
data analysis and interpretation, to extract the information of interest. Pre-processing is an 
important first step of data analysis (see figure 2.1) in which raw data is transformed to 
“cleaned” data, from which unwanted variation such as instrumental and experimental 
artefacts have been removed, so that this cleaned data is better suited to the data analysis 
goals [3, 4]. If not performed in the right way, pre-processing can also introduce unwanted 
variation. Proper pre-processing is thus a critical step that directly influences the successful 
outcome of all following steps in the pipeline and therefore the success of the entire 
experiment. 
 
Pre-processing methods are mainly used to adjust the variability of each measured variable 
and their relationships (e.g. by normalisation, scaling) to better comply with the data 
analysis goal. Moreover, they deal with challenging and detrimental data characteristics, 
such as missing values and “data artefacts”, which may be highly specific to the analytical 
chemical techniques used, such as baseline shifts in spectroscopy and peak shifts in 
chromatographic or NMR data [5-7]. The emerging use of hyphenated techniques, 
combinations of techniques (data fusion) and combining data collected in different time 
periods/analysis batches (batch-to-batch effects) or different laboratories (inter-laboratory 
comparisons) make these data artefacts an increasingly challenging issue [8]. 
 
The choice of an optimal pre-processing method or combination of methods depends on 
many different properties of the data and on the goal of data analysis. This choice requires 
very careful thought: when dealing with large data sets, the effects of each numerical data 
pre-processing step are not transparent. However, conclusions drawn should be robust to 
the type of data pre-processing that was applied [9].  
 
Many different pre-processing methods have been developed [10-13]. It is still largely 
impossible to robustly predict whether a certain pre-processing method brings the data 
analysis goal closer. There are no clear-cut guidelines when to use or avoid certain pre-
processing methods.  
 
This chapter critically evaluates current approaches to selection of pre-processing. First, 
several common data artefacts for a variety of different analytical techniques are described,  
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Figure 2.1   An overview of the pipeline for design, performance and analysis of experiments. 
This chapter critically evaluates current approaches to selection of pre-processing. First, 
several common data artefacts for a variety of different analytical techniques are described, 
as well as the pre-processing methods available to reduce or remove these artefacts. Second, 
the approaches used to determine an optimal pre-processing method or strategy are 
discussed. A critical comparison between these three approaches is illustrated by the pre-
processing of a mid-infrared (FTIR) data set with almost 5000 sensible combinations of pre-
processing methods. Finally, we provide an outlook to the near future on where selection of 
pre-processing strategies should head next. 
2.2 Data artefacts and pre-processing  
Pre-processing data generally consists of multiple steps, each one correcting for a particular 
artefact. Several individual pre-processing “methods”, each relevant to a specific artefact, 
will need to be applied consecutively in a pre-processing “strategy” to counter all artefacts  
Experimental design 
Instrument setup and 
experiments 
Raw data 
Data pre-processing 
Cleaned data 
Data analysis 
Interpretation of results 
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Figure 2.2   Schematic representation of a complete pre-processing strategy for IR data. Steps can be skipped 
or added and the order of steps can be changed, based on the data set at hand and the data analysis goal. 
present in the data. Figure 2.2 shows a typical example of such a pre-processing strategy for 
the IR data used below for illustration. This section gives an overview of the data artefacts 
that are most commonly encountered in chemical data and frequently-used pre-processing 
methods that are available to correct for these artefacts. 
 
The order in which the pre-processing methods are applied in the strategy may be specific 
to the data characteristics and the data analysis goal. Note that figure 2.2 presents only one 
out of many possible strategies: changing the order of the pre-processing steps may change 
the final results. Other steps often considered as pre-processing steps are outlier detection, 
feature selection, signal deconvolution and dealing with missing values.  However, these 
steps are so entangled with the subsequent data analysis steps in figure 2.1 that they are not 
discussed further here.  
 
It is our aim to provide a broad overview of data artefacts and analytical techniques, 
although not every artefact for each possible analytical technique will be discussed. 
However, the artefacts discussed in the following sections are mostly relevant to multiple 
analytical techniques. Also, some artefacts related to the sample composition instead of to 
the analytical technique are described. Reviews that describe artefacts and pre-processing 
methods for one particular analytical technique have been published elsewhere [4, 14-18]. 
Table 2.1 presents an overview of the most common artefacts for a set of different analytical 
techniques. Note that very different underlying physical phenomena—relevant to different 
analytical techniques—may cause very similar artefacts that may therefore be solved by the 
same pre-processing method. 
 
Many dedicated software tools, such as MATLAB, R, The Unscrambler or SIMCA [19], can 
be used for data pre-processing. Some pre-processing methods are accessible via 
(commercially available) toolboxes or extensions of this software. Software supplied with 
analytical instruments often also contains some basic pre-processing functions. However, 
many researchers seem to use in-house written routines. 
 
 
Raw data 
Step 1: 
Baseline 
correction 
Step 2: 
Scatter 
correction 
Step 3:   Noise removal  
Step 4: 
Scaling 
Cleaned
 data 
Possible pre-processing strategy 
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Table 2.1   Overview of data artefacts for the most common analytical data types. A cross (X) indicates that the 
artefact is present for an analytical data type. 
Artefact 
Spectroscopy 
(UV/IRa/Raman) 
NMR 
Chromato-
graphy 
Electro-
phoresis 
Mass-
spectrometry 
Fluorescence 
       
Baseline X X X X X X 
Misalignment  X X X X X 
Scatter X      
Noise X X X X X X 
       
a IR includes both NIR and mid-IR data 
2.2.1 Noise 
Noise is common to almost any analytical technique and the underlying background differs 
per analytical technique. The principle of removing noise is commonly based on smoothing 
of a signal via, for example, the Savitzky-Golay algorithm or by using wavelets [20, 21]. The 
Savitzky-Golay algorithm is based on fitting polynomials to many small data windows (one 
polynomial per window). The wavelet approach relates to a Fourier-like transformation of 
the input signal where noise is removed by filtering the high frequency parts of the 
transformed signal  – more details can be found in [21]. Other types of noise, like structured 
(i.e. non-white) technical noise, are not considered further here. 
2.2.2 Baseline offset and slope 
Baseline effects lead to signals having a vertical offset or a slope. Just as with noise, the 
underlying background for a baseline offset or slope differs per analytical technique. Figure 
2.3 shows a baseline offset and a baseline slope for an artificial IR spectrum. Commonly, a 
baseline is corrected by estimation of the baseline and subsequent subtraction of the 
estimate from the measured spectrum.  
 
Common methods for estimating a baseline are “detrending” [10] or estimation via 
“Asymmetric Least Squares Smoothing” (AsLS, [22]). In detrending, one fits a polynomial 
of a fixed degree to the spectrum and subsequently subtracts this polynomial from the 
spectrum. In AsLS, a smoother is combined with asymmetric weighting of deviations from 
the smoothed signal (i.e. peaks) to estimate the baseline. 
 
Baseline effects can also be corrected by taking a derivative of the input signal. A first order 
derivative will eliminate a constant baseline (offset) and a second order derivative will also 
eliminate a baseline slope. Since derivatization can reduce the signal-to-noise ratio, the  
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Figure 2.3   Examples of different artefacts in spectroscopic data. The solid line represents an original (artificial) 
IR spectrum. The others are modified versions of this original spectrum (dashed line: offset; dotted line: slope; 
dash-dotted line: scatter effect).  
Savitzky-Golay algorithm described in section 2.2.1 is frequently used for this purpose, by 
calculating the derivatives of the fitted polynomials. 
2.2.3 Light scatter 
Scatter effects (see figure 2.3) are common to all analytical techniques that involve the use of 
light, such as IR or UV spectroscopy. Light scattering occurs because the size of the particles 
in the sample has at least one dimension that is roughly the same magnitude as the spectro-
scopic wavelengths. In most cases, scatter effects are corrected by comparing signal intensi-
ties to a reference signal. Here, the assumption is made that most systematic differences 
between reference and the spectrum to correct are due to scattering. The size of the scatter 
effect is described by a constant multiplied by the intensity of the spectrum. All spectra are 
corrected for scattering by dividing them by their estimated scatter constant. 
 
Many pre-processing methods can correct for light scatter effects. For example, Standard 
Normal Variate (SNV, [10]) and RNV (Robust Normal Variate, [23]) are methods that sub-
tract the spectrum mean (or median for RNV) from each spectral variable and subsequently 
divide that value by the (robust) standard deviation of the spectrum (i.e. the estimated 
scatter constant). Alternatively, Multiplicative Signal Correction (MSC, [24]) tries to 
estimate the coefficient describing the scattering by regressing the spectrum to correct on to 
a reference. The close relationship between MSC and SNV is elaborated on elsewhere [25]. 
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2.2.4 Temporal and spectral misalignment 
Environmental fluctuations in the sample, laboratory and the analytical technology can 
influence the expression of the same measured sample in the spectral dimension (e.g., NMR 
chemical shift, due to pH changes) or in the temporal dimension (e.g., chromatographic 
time shifts). 
 
These differences are commonly solved by applying “alignment” methods (also known as 
“warping” methods) to the data [26, 27]. Most alignment methods stretch or compress each 
signal to match a certain reference signal in the best possible way. Some methods, like 
Parametric Time Warping (PTW, [22]), aim for a global alignment model, such that the 
stretching (or compression) can be described by one so-called warping function (i.e. the full 
signal is warped at once). Such alignment is deemed most suitable for chromatographic 
data. 
 
Other methods, like Correlation Optimised Warping (COW, [12]) and icoshift [28], apply 
local alignment. These methods split the signal into different segments and optimal align-
ment should be reached by stretching or compressing the individual segments to match the 
segments of the reference best. Local alignment is particularly relevant for the pre-pro-
cessing of NMR spectra where each peak may shift in both (spectral) directions. 
Additionally, the amount of shifting can vary between peaks.  
 
icoshift was originally proposed for NMR data, but has been successfully applied for 
chromatographic misalignment as well [29], clearly showing that the same pre-processing 
methods may benefit analytical artefacts with very different physical backgrounds. 
 
Alignment methods suffer from two limitations. The first one is purely technical: the algo-
rithms are relatively slow, making parameter optimisation a difficult task. Moreover, these 
time-intensive calculations limit their applicability to large-scale datasets, such as those 
encountered in metabolomics. Second, other analytical artefacts present in the data, such as 
baseline effects, scatter effects or high noise levels considerably hamper the performance of 
most alignment methods. However, several methods that tackle these other artefacts may 
rely on properly aligned data, again indicating that the choice of an optimal pre-processing 
strategy is not straightforward (figure 2.2). 
 
An alternative approach for correcting (small) misalignments is binning, also known as 
bucketing, which is routinely applied to NMR data [17]. In binning, the signal is split into 
many segments (called bins). The integral of the signal, or, alternatively, the maximum 
intensity in each bin is used as a replacement for the original signal, thereby reducing the 
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effect of small misalignment [17]. An additional advantage of binning is reduction of data 
size, which may facilitate data analysis by reducing computation time. Consequently, the 
resolution of the spectra is reduced. Important in binning is placing the bin boundaries to 
avoid splitting a peak among multiple bins, so sophisticated binning methods that take into 
account the position of peaks in an NMR spectrum have been devised. An example can be 
found in [30].  
 
Note that misalignment in data does not necessarily have to be corrected prior to data 
analysis. For example, PARAFAC2 can implicitly deal with misalignment in one data mode 
(e.g. in the chromatographic mode of LC-MS data) [31]. 
2.2.5 Normalization, scaling and element-wise transformations 
The previously described artefacts are all related to the analytical techniques used to pro-
duce the data. However, artefacts can also be directly related to the sample under study.  
 
A good example can be found in NMR spectra of urine [32], in which the area of an NMR 
peak is directly related to the concentration of a compound in the sample. However, urine 
samples are generally arbitrarily diluted, which makes the compound concentrations 
inappropriate measures for its composition—specifically considering the data-analysis goal 
of most NMR urine studies. These uninteresting dilution differences therefore need to be 
removed from the data by pre-processing. “Normalization” does this by estimating the 
“dilution factor” by which each sample has to be corrected—e.g., by expressing the intensity 
of each signal relative to the creatinine signal, a normally-occurring metabolite which is 
assumed to be excreted at a stable rate. Another normalisation method corrects by 
equalising the integral of each spectrum, although this can introduce spurious correlations 
among different chemical shifts [33]. Also differences in chromatographic peak heights—of 
the same analyte—may be circumvented by normalisation [34]. 
 
Even if all artefacts are removed from the data, it may not be the case that all measured 
variables contain information that is important for the scientific question at hand. 
Moreover, important variables can be masked by the variability of many unimportant 
variables, specifically—but by far not exclusively—when variables are expressed on different 
scales. Scaling is used to equalise the a priori potential of each variable to contribute to the 
eventual model. Which type of scaling should be applied partly depends on the model that 
will be created after pre-processing. For example, PCA describes the largest variation in the 
data, which means that variables with higher variance are likely to dominate the fitted 
model. A commonly-used scaling method to reduce this effect is autoscaling (also known as 
“Unit-Variance” scaling or “standardisation”), where one divides all measured values for a 
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variable by the standard deviation of these values, after having centred the variable to its 
mean. However, unimportant variables that only contain noise—and therefore have low 
standard deviation—become very important upon autoscaling. Other well-known scaling 
methods include Pareto scaling, level scaling and VAST scaling [3], which each aim to 
equalise the contribution of different variables by assigning different weights to each 
variable. 
 
An alternative to scaling can be found in element-wise transformations of the original data. 
These transformations are different from scaling because they modify individual elements of 
the data matrix rather than entire variables. Examples of such transformations include the 
power and log transformation, which simply take the square root or log of each individual 
data element, respectively. Transformations implicitly correct for heteroscedastic noise [3]. 
Specific transformations may also reduce the importance of large values (in the case of 
power and log transformations), bringing about a “pseudo-scaling” effect [3]. Finally, “rank 
transformations” replace the original values by their ranks, and that dramatically reduces 
the influence of outliers, but also hampers interpretation of the information in the fitted 
model. 
2.2.6 Supervised pre-processing methods 
A somewhat different class of pre-processing methods is found in “orthogonal signal 
corrections”, of which (Direct) Orthogonal Signal Correction [(D)OSC] is the most 
common  [11, 35]. This type of pre-processing assumes that all variation unrelated to a 
response variable (such as a concentration or class vector) is an artefact and should be 
filtered. An advantage of these methods is that multiple artefacts (e.g., a baseline slope plus 
scatter) can be corrected at once. OSC and DOSC aim to remove all variance in the signals 
unrelated to the response variable(s) based on a Partial Least Squares (PLS)-like 
decomposition. The foregoing implies that these methods can only be applied when a 
response variable is present—i.e. these methods are supervised pre-processing methods. As 
we show in section 2.3, the presence of a response variable does not automatically deem 
these methods useful in a pre-processing strategy.  
2.2.7 Artefacts in coupled techniques 
The pre-processing methods presented in the previous sub-sections were all designed to 
deal with two-way data matrices (samples by variables). However, many commonly-used 
analytical techniques combine multiple individual analytical chemical techniques into 
coupled techniques, which result in far-more complex data. Combinations between 
chromatography and mass spectrometry (MS)–based detection are widely used (GC-MS, 
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LC-MS and CE-MS, where CE stands for Capillary Electrophoresis), but there are also 
combinations with IR detection (GC-IR) and NMR detection (LC-NMR). The same 
artefacts as in the individual techniques also apply to these data.  
 
However, application of the same pre-processing methods to correct for these artefacts is 
not always straightforward: the pre-processing method should explicitly take the multi-way 
data structure into account. For scaling and transformations, this is clarified in [36], where 
it is shown that applying a certain type of scaling subsequently on two different data 
dimensions leads to unwanted side effects. 
 
Some pre-processing methods have been specifically developed for pre-processing multi-
way data. For instance, PTW and COW are adapted for dealing with LC-MS and GC-MS 
allowing alignment of two-dimensional data at the same time [37, 38]. An overview of pre-
processing tools for LC-MS metabolomics data is available [18]; a more detailed description 
of the full data-processing strategy for metabolomics data is also available [39]. Many more 
2D pre-processing methods exist, but it is outside the scope of this chapter to elaborate 
more extensively on this subject.  
2.3 Approaches to select a pre-processing strategy 
Section 2.2 showed that a multitude of methods exist that correct for specific data artefacts. 
Naturally, corrections should only be made for artefacts that are present in the data, to 
avoid the introduction of additional, unwanted artefacts or variation to the data. Avoiding 
this is not always possible, because observing artefacts in the raw data may be extremely 
difficult, specifically when multiple artefacts are present. Artefacts may also be multivariate 
in nature—i.e. visible only on combinations between variables, but not on individual 
variables. Moreover, even artefacts known to be present may require pre-processing 
specifically suited to the dataset (also see sub-section 2.3.1). It is crucial to select the optimal 
pre-processing strategy for the data set at hand, as pre-processing can make or break 
subsequent data analysis [40]. 
 
Despite the importance of the selection of optimal pre-processing strategies, it appears that 
selection approaches are not very common. In many cases, pre-processing strategies are 
selected based on identification of artefacts or on past experience, but this does not 
guarantee proper selection, as highlighted in the previous paragraph. Based on an extensive 
literature study, it appears that three types of pre-processing selection approaches are 
commonly used—if used at all—to choose the optimal pre-processing strategy:  
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1. Trial and error, in which one applies different pre-processing strategies and selects 
the best performing one(s) according to the goal of data analysis;  
2. Visual inspection, where, for each pre-processing strategy of interest, the pre-
processed data is inspected by simply looking at these data and checking if any 
artefacts are still visible;  
3. Assessment of pre-processed data by data quality parameters, which aim at 
quantifying the presence of artefacts in the data. 
The “trial and error” approach is a fit-for-use approach where the model of interest (e.g., a 
calibration model) is applied to the pre-processed data. Subsequently, the results of these 
models are used to assess how the applied pre-processing strategy contributed to the data-
analysis goal. “Visual inspection” and “assessment by data quality parameters” are both 
independent of the data-analysis goal. Visual inspection is the simplest approach and targets 
specific data artefacts. Assessment by quality parameters is based on the decrease or in-
crease of quantitative parameters that assess data quality upon pre-processing. 
 
After a literature review of these three selection approaches, we will critically assess and 
compare all three strategy-selection approaches, based on a spectroscopic data set. All pre-
processing methods included in this study are deemed sensible and physically meaningful 
for the current data set, and therefore have a rightful place in the data pre-processing 
strategy. 
2.3.1 Data and methods 
Throughout this chapter, the properties of the three pre-processing selection approaches are 
illustrated by application to FTIR data originating from a food authentication study. More 
specifically, this study considered the authentication of Rochefort beers [41]. One of the 
goals in this study was to discriminate Rochefort 8° beers from the other Rochefort beers, 
those being Rochefort 6° and 10°.  Specifics regarding sample collection and spectroscopic 
measurements are described by Engel et al. [41]. 
 
The raw FTIR data is displayed in figure 2.4, which clearly shows variation between the 
samples unrelated to their class. This artefact seems to be related to the batch in which the 
samples were measured. To cover possible seasonal variability, the samples were collected in 
September 2008 and January 2009.  
 
Based on visual inspection of the raw data, pre-processing should correct for the variation 
among different sample-measurement batches. However, note that not all artefacts may be 
visible to the naked eye; so all pre-processing methods that correct artefacts in spectro 
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Figure 2.4   (a) Raw FTIR data, where Rochefort 8° beers are indicated with a black line and Rochefort 6° beers 
and Rochefort 10° beers with a grey line. (b) Example of two FTIR spectra of beers from one class, measured in 
different batches. The ‘batch effect’ is clearly visible. 
scopic data (see table 2.1) were selected. Noise reduction, scaling and transformations were 
also included. Table 2.2 lists all pre-processing methods that were considered. Note that in 
total 4914 combinations of methods were investigated.  
 
All pre-processed data sets were used as input to a PLS-LDA classifier to predict the beer 
class [42]. A 10-fold cross-validation was used to determine the optimal number of latent 
variables (LVs) in the PLS model as well as the percentage of correct classification. The 
optimal number of LVs will be referred to as the model complexity and the percentage of 
correct classification for this number of LVs as the classification accuracy. The accuracy 
takes the different number of samples that were present in both classes into account (i.e. it is 
a geometric mean instead of an arithmetic mean). 
2.3.2 Trial and error approaches 
The goal of pre-processing selection via trial and error is to select the best method or 
combination of methods from a set of likely candidates. All pre-processing approaches are 
applied to the data and subsequently the pre-processed data is used as an input to a 
classification or calibration model. This model is used to assess the quality of the pre-pro-
cessing strategy by an internal measure, such as RMSEP or RMSECV [11, 43, 44]. 
 
Commonly, only a small set of candidate pre-processing methods is investigated: combina-
tions of methods, such as a baseline correction followed by scatter correction, are not always 
taken into account. For example, Wold et al. compared no pre-processing of NIR data with 
MSC and OSC [11]. In two separate studies on NIR data, Luypaert et al. investigated no  
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pre-processing, SNV, derivatives and detrending; and no processing, SNV, MSC, 
derivatives, offset correction, detrending and DOSC respectively [45, 46]. In yet another 
study on NIR data, Candolfi et al. selected no pre-processing, offset correction, detrending, 
SNV, SNV + detrending, MSC and derivatives for trial and error [47]. When comparing the 
results of these studies it is evident that no single method is best for pre-processing of NIR 
data. In these four studies, OSC, SNV + derivatisation, DOSC, and SNV performed best, 
respectively. In other words, many different methods are suitable for pre-processing of NIR 
data. However, which method is optimal depends on the data set characteristics and the 
goal of data analysis. This raises the question which methods should be selected for trial and 
error. Obviously, the same holds true for data from other analytical techniques.  
 
To assess this selection approach critically, we applied 4914 pre-processing strategies we 
considered as being “sensible” to a two-class classification problem in FTIR data (see sub-
section 2.3.1 for details). The effect of pre-processing on classification accuracy and 
complexity of the model is shown in figure 2.5. Only 273 out of 4914 strategies resulted in a 
more accurate, less complex model, compared to the model based on the raw data. This 
means that in most cases sensible pre-processing strategies actually increased the model 
complexity or worsened the model accuracy by up to 20%. 
 
Also, it was found that the effect of pre-processing methods depends on other methods 
within the strategy. For example, many combinations that included smoothing improved 
the accuracy and complexity, but an equally large number of combinations did not. 
Therefore, the optimal pre-processing strategy cannot be found by sequentially optimising 
each artefact, but strategies that combine all methods should be considered in this trial and 
error approach. This highlights that the holistic overview on data pre-processing, which the 
trial and error approach provides, may be very computationally intensive.  
 
Search algorithms may considerably reduce this time immensely (e.g., genetic algorithms 
may be used to optimise the pre-processing strategy) [48-50]. However, Jarvis et al. note 
that their optimisation took five days for FTIR data with 850 spectral variables and 360 
samples. Considering that e.g., metabolomics and proteomics platforms provide data with 
numbers of variables that can be magnitudes higher, trial and error strategy selection 
through genetic algorithms is at least not generally applicable for all analytical chemical 
data. 
2.3.3 Visual inspection 
The computational intensity of trial and error approaches can be greatly reduced by assess-
ment of the effect of pre-processing before a model is constructed. This is the goal of visual  
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Figure 2.5   Classification accuracy versus complexity of the model for all pre-processing strategies (see sub-
section 2.3.1). The classification accuracy and complexity for the raw data are given by the large red dot. All 
strategies to the right of the vertical dotted line improve the classification accuracy compared to the raw data; 
all strategies to the right of the vertical dotted line and below the horizontal dotted line improve both the 
classification accuracy and the complexity of the model. 
inspection. Samples should show more spectral overlap after pre-processing in visual 
inspection (i.e. artefacts have been removed) and, if applicable, differences between groups 
of samples should be more pronounced. As noted by Giskeodegard et al., the human eye 
and brain are still unsurpassed as pattern recognition tools [51], so they are invaluable tools 
for assessing the quality of pre-processing. At the same time, these tools are not objective: it 
is, for example, a matter of perception whether differences between groups have become 
more pronounced or not.  
 
Visual inspection of the pre-processed spectral data is often performed after peak alignment 
[51].  However, in our experience judging alignment quality in crowded spectra, such as 
NMR spectra of human urine, remains a challenging task. Visual inspection of spectral data 
is also common practice in other fields. For example, a reduction in variation between NIR 
spectra was observed after SNV pre-processing in ref. [52]. 
 
Visual inspection of pre-processing may be very difficult and rather subjective for subtle 
artefacts, so many reports in the literature do not inspect the data in “spectral mode” but in 
a lower dimensional space [53]. Many methods can be used to reduce the dimension of 
data, but PCA is by far the most popular option used to judge pre-processing quality as it is 
unsupervised and therefore ‘unbiased’ towards the data-analysis goal [54]. In [55], for 
example, PCA was used to determine optimal normalisation and alignment of 
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chromatographic spectra. It was observed that between-class distance increased and within-
class distance decreased after alignment. 
 
However, clustering in a PCA score plot is not always an indication of good pre-processing. 
For example, in a metabolomics study, the influence of various centering, scaling and 
transformation methods on GC-MS data was assessed by PCA [3]. The clear clusters within 
the score plots of range scaled and centered data identified both as viable pre-processing 
methods. However, the corresponding loading plots indicated that only range scaling made 
sense from a biological viewpoint, since the differences between the groups were related to 
many metabolites (as is the biological expectation in the data under study in [3]) instead of 
just a few. This shows that the chemical background of the problem is also essential to 
evaluate the chosen pre-processing strategy. 
 
Unfortunately, even when including loading plots, visual inspection may still lead to 
inconclusive results. Torgrip et al. have shown this for normalisation of urine NMR data 
[32]. In this study, the samples were diluted by known constants. Subsequently, it was 
investigated whether a normalisation method (Histogram Matching, HM) could determine 
these constants more accurately from the data compared to other methods. It was found 
that the lowest error was indeed obtained with HM. However, PCA score plots did not show 
any significant improvement of HM estimation compared to other normalisation methods, 
neither did inspection of the loadings. Based on PCA, the user might have selected another 
normalisation method as best. 
 
Gabrielsson et al. compared the raw data with the pre-processed data matrix via O2PLS 
(Orthogonal2-PLS) [56]. O2PLS separates the variation in two matrices—raw and pre-
processed data in this example—into three contributions: ‘joint’ variation shared between 
raw and pre-processed data and variation unique to either raw or pre-processed data. The 
scores and loadings of the orthogonal variation can be used to assess the pre-processing 
quality—even whether it introduced artefacts into the raw data. However insightful and 
robust, visual inspection of such a model for each pre-processing strategy is simply not 
feasible for so many candidate pre-processing strategies, a drawback of course shared by all 
visual inspection approaches described here. 
 
The risk of pre-processing selection via PCA is illustrated for the FTIR example discussed in 
sub-section 2.3.1. We have selected three different pre-processing strategies for visual 
inspection, which are all highlighted in panel a in figure 2.6. These three strategies include 
no pre-processing (i.e. classification of the meancentered data, panel b), the most accurate 
strategy (panel c) and a generally poorer-performing strategy (panel d). For all three  
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Figure 2.6   Visual comparison of three different pre-processing strategies. (a) The accuracy and complexity of 
the corresponding model for three selected strategies. (b) The score plot of the raw data (red dot in panel (a)). 
(c) The score plot of the best pre-processing strategy (green dot), and (d) the score plot of a poorer pre-
processing strategy (blue dot). 
strategies, the score plots of PC 1 versus PC 2 are given in their respective panels. The data 
contain two batches and two classes, where separating the classes comprises the data 
analysis goal. Panel b clearly shows that the batch effect is associated to the majority of all 
variation in the data: PC 1—the direction in which the batch effect is visible—explains over 
90% of all variation. However, both classes are also separated reasonably well in the raw 
data. 
 
Panel c shows that the most favourable pre-processing strategy reduces—but does not 
remove—the batch effect. This strategy however does not really seem to improve separation 
between classes, although in a PLS-LDA model it appears to be the most accurate strategy. 
 
The more or less identical between-class separation in panel d suggests a model accuracy 
similar to that in panel c. Additionally, panel d shows how this strategy completely removes 
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the batch effect from the data. Although visual inspection thus pinpoints the latter strategy 
as most appropriate, it has a 17% lower accuracy than the most accurate strategy in a PLS-
LDA model and an almost 10% lower accuracy than a model of the raw data. This highlights 
a major risk of visual inspection of the data compared to trial and error approaches.  Visual 
inspection necessarily filters all visible data artefacts before data analysis, but this does not 
always lead to optimally accurate models: the batch effect turns out unimportant for the 
classification accuracy and visual inspection led to a focus on an artefact irrelevant to model 
accuracy. 
2.3.4 Quality parameters 
The third approach for pre-processing selection involves the use of quality parameters. 
These parameters aim to provide an objective measure of the quality of the pre-processed 
data. Here, data of a higher quality is defined as data with fewer artefacts. The advantage of 
such methods compared to trial and error approaches is that they do not require 
computation of calibration or classification models, thereby greatly reducing computational 
intensity. Quality parameters offer a robust, objective and sometimes quicker alternative to 
visual inspection. However, pre-processing strategy selection via quality parameters does 
not yet seem to be common practice. 
 
The ‘simplicity value’ was introduced by Skov et al. to assess the quality of chromatographic 
alignment [12], and it has since been extended to assess alignment of NMR spectra [13, 51]. 
To compute the simplicity value, PCA is applied to the pre-processed data. Note that the 
data is not centered unless required by the pre-processing strategy. Next, the variance 
explained by the principal components is assessed. The assumption is that correct pre-
processing will remove variation from the data. Therefore, the first PCs of correctly pre-
processed data will have a higher percentage of explained variance compared to the raw 
data. The simplicity is given as a number between 0 and 1, with higher values indicating 
better pre-processing. Although the simplicity value is mainly applied in assessing the 
quality of alignment, we think that it can be useful in assessing the removal of other 
artefacts as well. 
 
In addition to the simplicity value, the Pearson correlation coefficient can also provide 
useful insights into the way to select the best pre-processing strategy. Wu et al. showed this 
for a peak alignment algorithm called ‘Fuzzy Warping’ on urine NMR spectra [57]. The 
concept behind the correlation is similar to that behind simplicity: removing data artefacts 
will make spectra more similar, hence increasing their correlation. The correlation can also 
be used as a parameter to optimise in alignment, as shown by Skov et al. for their COW 
alignment method [12]. 
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The ‘peak factor’ quality parameter originates from chromatographic alignment [12, 51]. An 
appropriate pre-processing strategy should leave the shape of peaks intact, something not 
taken into account with the simplicity value. Instead, the peak factor studies the normalised 
differences between pre-processed and raw spectra. The smaller the sum of distances, the 
smaller the differences; this indicates better pre-processing. Since this parameter relates to 
peak deformations, which are most common in alignment, this parameter is unsuitable for 
the general purpose of evaluating the quality of pre-processing. For example, methods such 
as derivatization (see section 2.2) clearly alter peak shapes. 
 
Esquerre et al. discuss some quality parameters for pre-processing of hyperspectral NIR 
images; all measures are based on PCA analysis of the pre-processed data [58]. 
Interestingly, they use supervised quality parameters besides the unsupervised methods that 
have been discussed so far, and that may specifically benefit classification problems since, in 
such cases, the pre-processing objective is to decrease spectral overlap between classes. 
More specifically, the separation of the two classes of interest along PC1 is assessed by the 
coefficient of variation (CV). Note that this measure can be used for two-class problems 
only. Also, the classes should be separated along only PC1. As shown in figure 2.6, this is 
not always the case. These issues might be circumvented by using a multivariate coefficient 
of variation measure [59]. This multivariate CV can also be used for multiclass problems 
and can be applied to the data directly, meaning that no PCA step is required. However, in 
our study of the beer data, the multivariate CV parameter did not seem to provide 
interesting information. 
 
Also, Esquerre et al. used the explained variance of PC1 (similar to the simplicity value) and 
the number of outliers as quality parameters. Good pre-processing should be applicable to 
the majority of the data, and therefore not introduce many outliers, so this is an extremely 
interesting quality parameter. However, given the assumption that outliers can already be 
present in the raw data, it is striking that Esquerre et al. used a non-robust PCA algorithm 
to compute the coefficient of variation and simplicity values. 
 
Most likely, no single quality parameter will be able to capture all benefits and drawbacks of 
a specific pre-processing strategy, so Esquerre et al. combined the results of the three quality 
parameters into one “super-parameter”, which was used to judge the pre-processing 
strategies. In their application, this seemed highly beneficial. 
 
As shown in figure 2.7, no single quality parameter was able to detect the correct pre-
processing strategy for the FTIR beer data set either. Here, only the simplicity value and 
correlation are shown, but similar results were found for other quality parameters.  
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Figure 2.7   The relation between simplicity value (a) and correlation (b) of differently pre-processed data and 
the complexity and accuracy of models based on this data. 
Construction of a super-parameter was beyond the scope of this review paper, because not 
much is known on construction of these parameters. Separate studies will be necessary to 
investigate this subject more extensively. However, the work of Esquerre et al. shows the 
great promise of a quantitative super-parameter. 
2.4 Concluding remarks 
Data pre-processing—to remove unwanted artefacts and highlight the variation of 
interest—is crucial to the successful achievement of the data analysis goals, be they e.g., 
exploration, classification, or prediction. Our example shows how extremely difficult it can 
be to determine which method—of the vast number of available pre-processing methods—
can successfully help to achieve these goals. Also, the specific data set characteristics—i.e. 
which artefacts are present among which other properties of the data—are an additional 
factor of considerable importance that cannot be ignored in this choice.  
 
All data set properties dictate the combination of appropriate methods that correct for 
different artefacts. The classification problem presented here led to a more than 20% 
difference in model accuracy between the best and worst pre-processing strategies. All 
strategies were reasonable from a theoretical viewpoint. Sub-optimal pre-processing 
strategies can therefore greatly affect the achievement of the data analysis goals, and that 
makes a robust and quantitative approach to establishing the optimal pre-processing 
strategy of the utmost importance. 
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We have reviewed three widely used approaches (i.e. the current trends in pre-processing) 
for this purpose, and showed that all three have serious drawbacks: they may be time-
consuming beyond practicability or may provide misleading results.  
 
The construction of a quality parameter seems very promising, although approaches based 
on these parameters also provide inconclusive results for our current dataset. The 
quantitative expression of such a parameter is very intuitive, and the information from 
different parameters can also be combined into a super-parameter to quantify the effect of 
pre-processing from different viewpoints simultaneously. These quantitative aspects fit very 
well into the chemometrics paradigm. In different situations, chemometrics has benefitted 
very much from such quantitative expressions. For example, it has derived much of its 
strength from the quantitative power of model validation.  
 
There is an ever-growing body of literature that details and extends such model validation, 
to the point that a solid theoretical framework has emerged. We envisage a similar theory 
for data pre-processing—of course fully integrated with that for model validation and for 
other aspects of chemometrics. This can then be used to establish, or at least predict, the 
data analysis strategy that combines the methods that optimally remove the artefacts from 
the data and thereby highlight the information that is required to achieve any of the possible 
data-analysis goals.  
2.5 Pre-processing in this thesis 
The rest of this thesis is concerned with analysis of urine 1H-NMR metabolomics data. 
Common artefacts in such data include baseline drift, peak shifts between samples e.g. due 
to temperature fluctuations or differences in pH of the samples. Moreover, specific regions 
of the spectrum contain more peaks. These peaks may overlap. Such crowded regions 
contain more information but are generally more difficult to analyze as well. Finally, the 
overall metabolite concentration in urine may vary as a function of the excretion rate and 
specific physiology of each patient. To allow for sample-to-sample comparison all these 
artefacts must be removed by data pre-processing; hence the most important pre-
processing steps are baseline correction, peak alignment, normalization, and binning. 
 
In this thesis, all spectra were baseline corrected using cubic splines in the Bruker NMR 
software. Next, icoshift and COW were considered for peak alignment [12, 28]. Creatinine 
normalization, probabilistic quotient normalization, and histogram matching were used for 
normalization [32, 60]. Equidistant binning, dynamic adaptive binning and adaptive 
intelligent binning were considered to the bucket the data [30, 61]. Similar to the 
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experiment described in sections 2.3.3 and 2.3.4 visual inspection of the data as well as the 
use of data quality parameters was used to select a suitable pre-processing strategy. It was 
observed that icoshift introduced artefacts, e.g. artificial horizontal lines or plateaus, to the 
spectra, especially in crowded regions where a number of peaks overlapped. Therefore, 
COW was preferred for alignment. The optimal setting was based on the peak factor quality 
measure.  Only small differences were observed between various normalization techniques. 
Therefore, histogram matching was selected as the most suitable method because other 
artefacts such as peak misalignments do not influence the results of the method. Adaptive-
intelligent binning resulted in better placements of the bins compared to equidistant 
binning and dynamic adaptive binning. However, all approaches struggled in areas with 
large peak overlap. Therefore, the result of the AI-binning algorithm was manually adjusted 
to minimize the risk that a peak was split in two bins.  
 
The optimized pre-processing strategy was used for data pre-treatment in chapter 4. The 
strategy could also be applied to chapters 5 and 6. These chapters considered the 
comparison of individual patients to a set of controls. Pre-processing of this data was 
challenging because it was unknown how the optimized strategy could influence future 
patient samples; for example, binning or alignment may distort an important peak related to 
a disease that was not present in the training or test data. Therefore, it was decided to use 
the conventional pre-processing strategy involving equidistant binning and normalization 
to creatine in these chapters. This way, it was ensured that the reported results were not 
overly optimistic. It is clear, however, that further development to select a more appropriate 
pre-processing strategy for such data is required.  
  
 Breaking with trends in pre-processing? 
 37 
References 
1. Eriksson, L., et al., Using chemometrics for navigating in the large data sets of genomics, proteomics, and 
metabonomics (gpm). Analytical and Bioanalytical Chemistry, 2004. 380(3): p. 419-429. 
2. Wold, S., A. Berglund, and N. Kettaneh, New and old trends in chemometrics. How to deal with the 
increasing data volumes in R&D&P (research, development and production) - with examples from 
pharmaceutical research and process modeling. Journal of Chemometrics, 2002. 16(8-10): p. 377-386. 
3. van den Berg, R.A., et al., Centering, scaling, and transformations: improving the biological information 
content of metabolomics data. Bmc Genomics, 2006. 7. 
4. Rinnan, A., F. van den Berg, and S.B. Engelsen, Review of the most common pre-processing techniques for 
near-infrared spectra. Trac-Trends in Analytical Chemistry, 2009. 28(10): p. 1201-1222. 
5. Parastar, H., M. Jalali-Heravi, and R. Tauler, Comprehensive two-dimensional gas chromatography (GC x 
GC) retention time shift correction and modeling using bilinear peak alignment, correlation optimized 
shifting and multivariate curve resolution. Chemometrics and Intelligent Laboratory Systems, 2012. 117: 
p. 80-91. 
6. Forshed, J., I. Schuppe-Koistinen, and S.P. Jacobsson, Peak alignment of NMR signals by means of a 
genetic algorithm. Analytica Chimica Acta, 2003. 487(2): p. 189-199. 
7. Ding, T., et al., Far-infrared spectroscopy analysis of linear and cyclic peptides, and lysozyme. Vibrational 
Spectroscopy, 2012. 61: p. 144-150. 
8. Szymanska, E., et al., Evaluation of different warping methods for the analysis of CE profiles of urinary 
nucleosides. Electrophoresis, 2007. 28(16): p. 2861-2873. 
9. Brown, M., et al., A metabolome pipeline: from concept to data to knowledge. Metabolomics, 2005. 1(1): 
p. 39-51. 
10. Barnes, R.J., M.S. Dhanoa, and S.J. Lister, Standard Normal Variate Transformation and De-Trending of 
near-Infrared Diffuse Reflectance Spectra. Applied Spectroscopy, 1989. 43(5): p. 772-777. 
11. Wold, S., et al., Orthogonal signal correction of near-infrared spectra. Chemometrics and Intelligent 
Laboratory Systems, 1998. 44(1-2): p. 175-185. 
12. Skov, T., et al., Automated alignment of chromatographic data. Journal of Chemometrics, 2006. 20(11-
12): p. 484-497. 
13. MacKinnon, N., et al., Variable Reference Alignment: An Improved Peak Alignment Protocol for NMR 
Spectral Data with Large Intersample Variation. Analytical Chemistry, 2012. 84(12): p. 5372-5379. 
14. Cen, H.Y. and Y. He, Theory and application of near infrared reflectance spectroscopy in determination of 
food quality. Trends in Food Science & Technology, 2007. 18(2): p. 72-83. 
15. Zeaiter, M., J.M. Roger, and V. Bellon-Maurel, Robustness of models developed by multivariate 
calibration. Part II: The influence of pre-processing methods. Trac-Trends in Analytical Chemistry, 2005. 
24(5): p. 437-445. 
16. Daszykowski, M., et al., Start-to-end processing of two-dimensional gel electrophoretic images. Journal of 
Chromatography A, 2007. 1158(1–2): p. 306-317. 
17. Smolinska, A., et al., NMR and pattern recognition methods in metabolomics: From data acquisition to 
biomarker discovery: A review. Analytica Chimica Acta, 2012. 750: p. 82-97. 
18. Castillo, S., et al., Algorithms and tools for the preprocessing of LC-MS metabolomics data. Chemometrics 
and Intelligent Laboratory Systems, 2011. 108(1): p. 23-32. 
19. Brereton, R.G., Introduction to multivariate calibration in analytical chemistry. Analyst, 2000. 125(11): 
p. 2125-2154. 
20. Savitzky, A. and M.J.E. Golay, Smoothing + Differentiation of Data by Simplified Least Squares 
Procedures. Analytical Chemistry, 1964. 36(8): p. 1627-&. 
21. Barclay, V.J., R.F. Bonner, and I.P. Hamilton, Application of wavelet transforms to experimental spectra: 
Smoothing, denoising, and data set compression. Analytical Chemistry, 1997. 69(1): p. 78-90. 
22. Eilers, P.H.C., Parametric time warping. Analytical Chemistry, 2004. 76(2): p. 404-411. 
23. Guo, Q., W. Wu, and D.L. Massart, The robust normal variate transform for pattern recognition with 
near-infrared data. Analytica Chimica Acta, 1999. 382(1-2): p. 87-103. 
24. Geladi, P., D. Macdougall, and H. Martens, Linearization and Scatter-Correction for near-Infrared 
Reflectance Spectra of Meat. Applied Spectroscopy, 1985. 39(3): p. 491-500. 
25. Fearn, T., et al., On the geometry of SNV and MSC. Chemometrics and Intelligent Laboratory Systems, 
2009. 96(1): p. 22-26. 
Chapter 2 
 38 
26. Torgrip, R.O., E. Alm, and K.M. Åberg, Warping and alignment technologies for inter-sample feature 
correspondence in 1D H-NMR, chromatography-, and capillary electrophoresis-mass spectrometry data. 
Bioanalytical Reviews, 2010. 1(2-4): p. 105-116. 
27. Bloemberg, T.G., et al., Warping Methods for Spectroscopic and Chromatographic Signal Alignment: A 
Tutorial Review. Analytica Chimica Acta, 2013. (in press). 
28. Savorani, F., G. Tomasi, and S.B. Engelsen, icoshift: A versatile tool for the rapid alignment of 1D NMR 
spectra. Journal of Magnetic Resonance, 2010. 202(2): p. 190-202. 
29. Tomasi, G., F. Savorani, and S.B. Engelsen, icoshift: An effective tool for the alignment of 
chromatographic data. Journal of Chromatography A, 2011. 1218(43): p. 7832-7840. 
30. De Meyer, T., et al., NMR-based characterization of metabolic alterations in hypertension using an 
adaptive, intelligent binning algorithm. Analytical Chemistry, 2008. 80(10): p. 3783-3790. 
31. Amigo, J.M., T. Skov, and R. Bro, ChroMATHography: Solving Chromatographic Issues with 
Mathematical Models and Intuitive Graphics. Chemical Reviews (Washington, DC, United States), 2010. 
110(8): p. 4582-4605. 
32. Torgrip, R.J.O., et al., A note on normalization of biofluid 1D H-1-NMR data. Metabolomics, 2008. 4(2): 
p. 114-121. 
33. Aruga, R., Closure of analytical chemical data and multivariate classification. Talanta, 1998. 47(4): p. 
1053-1061. 
34. Kultima, K., et al., Development and Evaluation of Normalization Methods for Label-free Relative 
Quantification of Endogenous Peptides. Molecular & Cellular Proteomics, 2009. 8(10): p. 2285-2295. 
35. Westerhuis, J.A., S. de Jong, and A.K. Smilde, Direct orthogonal signal correction. Chemometrics and 
Intelligent Laboratory Systems, 2001. 56(1): p. 13-25. 
36. Bro, R. and A.K. Smilde, Centering and scaling in component analysis. Journal of Chemometrics, 2003. 
17(1): p. 16-33. 
37. Christin, C., et al., Optimized time alignment algorithm for LC-MS data: Correlation optimized warping 
using component detection algorithm-selected mass chromatograms. Analytical Chemistry, 2008. 80(18): 
p. 7012-7021. 
38. Bloemberg, T.G., et al., Improved parametric time warping for proteomics. Chemometrics and Intelligent 
Laboratory Systems, 2010. 104(1): p. 65-74. 
39. Hendriks, M.M.W.B., et al., Data-processing strategies for metabolomics studies. Trac-Trends in 
Analytical Chemistry, 2011. 30(10): p. 1685-1698. 
40. Famili, F., et al., Data pre-processing and intelligent data analysis. International Journal on Intelligent 
Data Analysis, 1997. 1(1). 
41. Engel, J., et al., Confirmation of brand identity of a Trappist beer by mid-infrared spectroscopy coupled 
with multivariate data analysis. Talanta, 2012. 99: p. 426-432. 
42. Barker, M. and W. Rayens, Partial least squares for discrimination. Journal of Chemometrics, 2003. 
17(3): p. 166-173. 
43. Denoord, O.E., The Influence of Data Preprocessing on the Robustness and Parsimony of Multivariate 
Calibration Models. Chemometrics and Intelligent Laboratory Systems, 1994. 23(1): p. 65-70. 
44. Renard, B.Y., et al., When less can yield more - Computational preprocessing of MS/MS spectra for peptide 
identification. Proteomics, 2009. 9(21): p. 4978-4984. 
45. Luypaert, J., M.H. Zhang, and D.L. Massart, Feasibility study for the use of near infrared spectroscopy in 
the qualitative and quantitative analysis of green tea, Camellia sinensis (L.). Analytica Chimica Acta, 
2003. 478(2): p. 303-312. 
46. Luypaert, J., et al., An evaluation of direct orthogonal signal correction and other preprocessing methods 
for the classification of clinical study lots of a dermatological cream. Journal of Pharmaceutical and 
Biomedical Analysis, 2002. 30(3): p. 453-466. 
47. Candolfi, A., et al., The influence of data pre-processing in the pattern recognition of excipients near-
infrared spectra. Journal of Pharmaceutical and Biomedical Analysis, 1999. 21(1): p. 115-132. 
48. Jarvis, R.M. and R. Goodacre, Genetic algorithm optimization for pre-processing and variable selection of 
spectroscopic data. Bioinformatics, 2005. 21(7): p. 860 - 868. 
49. Bocklitz, T., et al., How to pre-process Raman spectra for reliable and stable models? Analytica Chimica 
Acta, 2011. 704(1-2): p. 47-56. 
50. Laxalde, J., et al., Characterisation of heavy oils using near-infrared spectroscopy: Optimisation of pre-
processing methods and variable selection. Analytica Chimica Acta, 2011. 705(1-2): p. 227-234. 
51. Giskeodegard, G.F., et al., Alignment of high resolution magic angle spinning magnetic resonance spectra 
using warping methods. Analytica Chimica Acta, 2010. 683(1): p. 1-11. 
 Breaking with trends in pre-processing? 
 39 
52. Luypaert, J., et al., The effect of preprocessing methods in reducing interfering variability from near-
infrared measurements of creams. Journal of Pharmaceutical and Biomedical Analysis, 2004. 36(3): p. 
495-503. 
53. Andersson, F.O., R. Kaiser, and S.P. Jacobsson, Data preprocessing by wavelets and genetic algorithms for 
enhanced multivariate analysis of LC peptide mapping. Journal of Pharmaceutical and Biomedical 
Analysis, 2004. 34(3): p. 531-541. 
54. Sanchez, F.C., P.J. Lewi, and D.L. Massart, Effect of Different Preprocessing Methods for Principal 
Component Analysis Applied to the Composition of Mixtures - Detection of Impurities in Hplc-Dad. 
Chemometrics and Intelligent Laboratory Systems, 1994. 25(2): p. 157-177. 
55. Hendriks, M.M.W.B., et al., Preprocessing and exploratory analysis of chromatographic profiles of plant 
extracts. Analytica Chimica Acta, 2005. 545(1): p. 53-64. 
56. Gabrielsson, J., et al., OPLS methodology for analysis of pre-processing effects on spectroscopic data. 
Chemometrics and Intelligent Laboratory Systems, 2006. 84(1-2): p. 153-158. 
57. Wu, W., et al., Peak alignment of urine NMR spectra using fuzzy warping. Journal of Chemical 
Information and Modeling, 2006. 46(2): p. 863-875. 
58. Esquerre, C., et al., Suppressing sample morphology effects in near infrared spectral imaging using 
chemometric data pre-treatments. Chemometrics and Intelligent Laboratory Systems, 2012. 117: p. 129-
137. 
59. Albert, A. and L.X. Zhang, A novel definition of the multivariate coefficient of variation. Biometrical 
Journal, 2010. 52(5): p. 667-675. 
60. Dieterle, F., et al., Probabilistic quotient normalization as robust method to account for dilution of 
complex biological mixtures. Application in 1H NMR metabonomics. Analytical chemistry, 2006. 78(13): 
p. 4281-4290. 
61. Anderson, P.E., et al., Dynamic adaptive binning: an improved quantification technique for NMR 
spectroscopic data. Metabolomics, 2011. 7(2): p. 179-190. 
 

  
3  
REGULARIZATION 
 
High dimensional data poses significant challenges for statistical modeling. Many 
techniques are not applicable to such data, or their results are unreliable. Regularization is a 
common approach to obtain sensible statistical models for high dimensional data.  Most 
approaches try to reduce the variance of the model at the cost of some bias, i.e. by adding 
constraints or penalties to the model.  
 
In this chapter we review general regularization approaches in the context of SPC, LDA, and 
MANOVA. These statistical methods are of main interest in this thesis (see chapter 1). Note 
that the regularization approaches described in this chapter are general and can also be used 
for other chemometric methods.  
 
 The covariance matrix plays an important role in these methods. Therefore, we first discuss 
regularization of this matrix. Next, constraints to achieve variable selection are discussed. 
Applications of these types of regularization in SPC, LDA and MANOVA are provided at 
the end of the chapter. Finally, we place these methods in the context of the regularized 
methods that are developed in chapters 4 – 6 of this thesis. 
  
!
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3.1 Introduction 
Many experiments in physical and biomedical sciences give rise to an ever-increasing 
amount of measurement data, originating from multiple advanced analytical technologies 
[1-4]. Sometimes this is referred to as the data tsunami [5]. The availability of such high 
dimensional data has reshaped statistical thinking and data analysis [1, 3, 4, 6, 7]. One of the 
advantages of massive data is that experiments can be performed to generate hypothesis 
regarding the system under study instead of experiments that aim to prove a hypothesis [8].  
 
In metabolomics, for example, techniques such as NMR and LC-MS are used to measure 
the concentration of a large number of metabolites in an untargeted way in different groups 
of samples. Subsequently, data analysis is used to determine if these groups differ 
significantly and which metabolites are related to the difference. The identified metabolites 
can be further studied in new, possibly targeted, experiments. This approach has proven 
successful in many applications such as to find biomarkers for a specific disease [9-12]. 
 
Although it is nowadays possible to generate a wealth of data per sample, many statistical 
methods that perform well for low dimensional data are facing significant challenges in 
analyzing such high dimensional data [1, 2, 4, 6]. Often these challenges are combined 
under the term “curse of dimensionality” and include amongst others inaccurate parameter 
estimation, noise accumulation, and spurious correlation. More details can be found in [4, 
6, 13]. For example, a result of the curse of dimensionality is that the precision matrix, that 
is, the inverse of the covariance matrix, cannot be computed when the number of samples in 
a data set is lower (n) then the number of variables (p) [14, 15]. Because of this, many 
techniques such as statistical process control (SPC), linear discriminant analysis (LDA), and 
multivariate analysis of variance (MANOVA) are not directly applicable to high 
dimensional data.  
 
Regularization is a common approach to obtain sensible statistical models for high 
dimensional data [6, 14-17].  Regularization essentially means that some structure is 
imposed on the model with the aim to reduce its variance at the cost of some bias. For 
example, Bickel et al showed that the standard LDA model has poor performance when 
applied to high dimensional data[18]. They showed that much better performance was 
obtained when the prior assumption that all variables were uncorrelated was included in the 
model. Clearly this assumption is not always realistic (i.e. in metabolomics) and the 
resulting model was more biased compared to LDA. However, at the same time its variance 
was greatly reduced. Because of this, the model generalized better to new data explaining the 
improved performance.  
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In this chapter we review regularization approaches for SPC, LDA, and MANOVA. These 
statistical methods are of main interest in this thesis (see chapter 1). We describe general 
regularization methods for any of these techniques; most regularization approaches could 
also be used for other chemometric methods. To be able to describe the regularization 
methods in a general fashion we first note that the Mahalanobis distance (MD) plays an 
important role in SPC, LDA, and MANOVA (see section 3.2). Regularization of the three 
methods essentially comes down to regularization of MDs. Additionally; regularization 
methods that have been used for any of these techniques can most likely also be applied to 
the others due to their close connection.  
 
In section 3.2 we study some aspects of the MD in high dimensional data.  Based on these 
considerations we observe two interesting strategies for regularization of the MD, namely 
(1) using a regularized estimate of the covariance matrix (note that this includes dimension 
reduction approaches), or (2) by reducing the number of features in the data set by variable 
selection. These strategies are often used in literature. In section 3.3 the so-called shrinkage 
approach to regularization of the covariance matrix is described. Section 3.4 deals with 
variable selection, mainly focusing on ℓ𝓁!-norm constrained models. In section 3.5 examples 
from the literature on regularization in SPC, LDA, and MANOVA using strategy 1 or 2 are 
presented. At the end of the present chapter we give a brief overview of the regularization 
methods for SPC and MANOVA that are used in later chapters in this thesis for analysis of 
metabolomics data. 
3.2 The role of the Mahalanobis distance in chemometrics 
Many chemometric techniques essentially involve the measurement of distances [6, 19, 20]. 
In this section we show that the squared MD plays an important role in SPC, LDA, and 
MANOVA. Next, we review some properties of the MD in high dimensional data.  
3.2.1 The Mahalanobis distance 
The squared Mahalanobis distance is essentially a measure of the distance between an object 
(𝐱) and a group of samples with multivariate normal distribution 𝑁(𝛍,𝚺) [19]: 
 
 𝑀𝐷! 𝐱 = 𝐱 − 𝛍 𝚺!! 𝐱 − 𝛍 !  (3.1) 
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Figure 3.1   Plot of simulated data (blue stars) for two variables. The ellipses represent equal MDs towards the 
centre of the data points (asterixes). 
where 𝛍 and 𝚺 indicate the mean and covariance matrix of 𝑁(𝛍,𝚺), respectively. Details such 
as equations for 𝛍 and 𝚺 can be found in numerous references such as [6, 19-21]. A general 
discussion of estimation of 𝚺 is presented in section 3.3. The MD can be interpreted as a 
multivariate generalization of measuring how many standard deviations (𝜎) object 𝑥 is away 
from the centre of the group 𝜇, i.e. 𝑥 − 𝜇 !/𝜎!. An example is shown in figure 3.1. The 
ellipses indicate points with equal distance from the group centre. 
 
As will be shown below, many techniques estimate the MD by first finding the linear 
combination of the variables that maximizes the following Rayleigh criterion [20]:  
 
 𝐚 = 𝑎𝑟𝑔𝑚𝑎𝑥𝐚 𝐚 𝐱 − 𝛍 ! 𝐱 − 𝛍 𝐚!𝐚𝚺𝐚! = 𝐱 − 𝛍 𝒂! !𝐚𝚺𝐚!  (3.2) 
 
Geometrically, 𝐚 (commonly referred to as a canonical variate) can be interpreted as the 
direction in the data along which the sample differs most from the centre of the group 
relative to the variance within the group. An example is shown in the first row of figure 3.2. 
It can be shown that the solution to (3.2) equals 𝐚 = 𝐱 − 𝛍 𝚺!! [20]. Due to the definition 
of 𝐚, the squared MD can be computed by considering the scalar projections of the data on 𝐚, i.e. 𝑀𝐷! = 𝐱 − 𝛍 𝒂! !/(𝐚𝚺𝐚!). Often, the coefficients of 𝐚 are studied to determine on 
which variables the sample differed most from the group, where high absolute coefficients 
are assumed to indicate large differences.  
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Figure 3.2   Schematic representation illustrating in two dimensions (regularized) SPC methods. Two 
situations are considered: the outlier (red sample) differs from the controls (green sphere) in the direction of 
(a) the first eigenvector, or (b) the second eigenvector of 𝚺! . The discriminant direction 𝐚!"#  is indicated by a 
dotted line. The first row corresponds to the use of the SPC model defined in equation 3.3 the second row to 
using equation 3.3 with a pseudo-inverse of 𝚺! , and the third row to using equation 3.3 with a shrinkage 
estimator of 𝚺! . For clarity, the estimated control sphere of the standard SPC model (row 1) is indicated by the 
dark green dotted sphere in the regularized models (row 2 and 3). 
Chapter 3 
 46 
Note that equation 3.1 assumes a multivariate normal distribution. Metabolomics data are 
often not normally distributed [22]. For example, a normal distribution allows for negative 
concentrations, which is not very realistic. A log-normal distribution might give a more 
accurate description of the data. However, for the data in this thesis we have not observed 
improved results when analyzing log-transformed data. Therefore, we will assume a 
multivariate Normal distribution in the rest of this chapter. 
3.2.2 Statistical process control 
The aim of statistical process control (SPC) techniques is to determine if a sample (𝐱!) 
differs significantly from a group of control samples (𝐗!) [23, 24]. An example is the 
comparison between a patient and a set of healthy controls as we will consider in chapters 5 
and 6. Note that SPC is closely related to outlier detection techniques [23, 25]. 
 
Often it is assumed that the control group follows a multivariate normal distribution 𝑁(𝛍! ,𝚺!), where 𝛍! and 𝚺! indicate the mean and covariance matrix of the control samples, 
respectively. Typically, the null hypothesis of no significant difference between 𝐱! and 𝐗! is 
rejected if [26]: 
 
 𝑀𝐷! 𝐱! = 𝐱! − 𝛍! 𝚺!!! 𝐱! − 𝛍! ! > 𝑐 (3.3) 
 
This is clearly a squared MD. When the sample estimates for the mean and covariance 
matrix are used, the upper limit 𝑐  is obtained from a scaled F-distribution [23]. 
Geometrically, 3.3 tests whether the sample of interest falls inside the confidence sphere of 
the control samples, i.e. an ellipse in the first row of figure 3.2. Note that expression 3.2 can 
be used to determine on which variables 𝐱! differed from the controls. This information can 
be used in a subsequent step to investigate the cause of the difference. 
3.2.3 Linear discriminant analysis 
The goal of LDA is to compare a sample (𝐱!) to multiple groups or classes and predict to 
which class it belongs, e.g. to predict whether a sample is healthy or diseased [6, 20, 21]. The 
method assumes that the classes are multivariate normal with different means but the same 
covariance matrix. Note that new samples are always assigned to one of the classes specified 
in the model. The maximum likelihood LDA rule assigns 𝐱! to the class 𝑖 that minimizes: 
 
 𝑀𝐷!! 𝐱! = 𝐱! − 𝛍! 𝚺!!! 𝐱! − 𝛍! ! (3.4) 
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where 𝛍! is the mean of the 𝑖th class and 𝚺! is the covariance matrix that describes the 
variation of the samples within each class. Geometrically, LDA assigns a sample to the class 
towards which it has the smallest squared MD. When the number of classes is two the rule 
allocates 𝐱! to the first class when: 
𝐱! − 𝛍 𝐚!"#! > 0 (3.5) 
where 𝐚!"# = 𝛍! − 𝛍! 𝚺!!!  and 𝛍 = !! 𝛍! + 𝛍!  [20]. Note that direction 𝐚!"# is closely 
related to the direction 𝐚 estimated by expression 3.2. However, this direction maximizes 
the difference between the two classes of interest instead of the difference between the 
sample and one group. 
Fishers discriminant rule is closely related to the maximum likelihood LDA rule. They give 
the same solution for when dealing with two classes [20]. In Fishers approach to LDA, 
direction 𝐚!"# is first estimated. Subsequently, allocation of a new sample can be done using 
a distance measure based on the scalar projections of the data onto direction 𝐚!"#!  i.e. using 
expression 3.5. When dealing with more than 2 classes a single direction is not enough to 
correctly predict class membership of a new sample. In this case multiple directions are 
used. These directions are essentially found by maximizing the following expression (with 
the added constraint that the directions are orthogonal to each other) [20]: 
𝐚!"#$ = 𝑎𝑟𝑔𝑚𝑎𝑥𝐚 𝐚!𝐒!𝐚𝐚!𝐒!𝐚 (3.6) 
Matrices 𝐒! and 𝐒! are so-called scatter matrices. They have been traditionally used in 
Fisher LDA and are closely related to covariance matrices1. Actually, the same solution is 
obtained when (3.6) is expressed in terms of covariance matrices. Matrix 𝐒! describes the 
scatter (covariance) between the class centroids and matrix 𝐒! describes the scatter within 
each class. It can be shown that the solutions of (3.6) are the eigenvectors of 𝐒!!!𝐒! 
corresponding to the highest eigenvalues [20]. The first eigenvector (with the highest 
eigenvalue) is the direction along which the classes are most separated from each other; the 
second eigenvector is a direction orthogonal to the first with the second most separation; 
etc. This shows that expression 3.6 can be interpreted as an extension of (3.2) when dealing 
with more groups. Typically 𝑔 − 1 directions are inspected when dealing with 𝑔 groups. 
1 Note that covariance matrices and scatter matrices are closely related. For example here 𝚺! = 𝐒!/(𝑛 − 𝑔), where 𝑛 is the total number of samples in the data and 𝑔 is the number of classes. Note that an estimate of a scatter matrix 
is essentially given by its sample covariance estimate times the degrees of freedom.  
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Allocation of a new sample can be done by projecting the data onto the 𝑔 − 1 directions and 
using a distance measure such as the squared MD in this lower dimensional space.  
3.2.4 Multivariate analysis of variance 
MANOVA is mathematically closely related to Fisher LDA (and the MD). However, the 
method is not used to classify a new sample, but rather to determine if the classes of interest 
differ significantly [20, 27]. Therefore, it is sensible to apply MANOVA before LDA. 
Traditionally, MANOVA has been used to analyze experiments that were carried out 
according to an experimental design, i.e. to test significance of main effects and interactions. 
As an example we consider a one-way MANOVA experiment, i.e. one experimental factor 
was varied at 𝑔 levels such as healthy, disease stage 1, disease stage 2, etc. It is assumed that 
all groups are multivariate normal with different means but the same covariance structure. 
The goal of MANOVA is to assess whether the group means differ significantly, i.e.  
𝐻!:  𝛍! = 𝛍! = ⋯ = 𝛍!  vs.𝐴:  at least one mean is diﬀerent 
MANOVA tests are based on the matrices 𝐒! and 𝐒!. Note that these were defined in 
expression 3.6 for Fisher LDA, i.e. matrix 𝐒!  describes the scatter between the group 
centroids and matrix 𝐒! describes the scatter within the groups. In analogy with ANOVA, a 
ratio is formed between the between-group scatter (𝐒!) and the within-group scatter (𝐒!). 
More specifically, hypothesis tests are based on the matrix:  
𝐑 = 𝐒!!!𝑺! (3.7) 
As described for the case of Fisher LDA above, the 𝑔 − 1 eigenvectors of 𝐑 with the highest 
eigenvalues are the directions in the data along which the distance between the class means 
is the largest compared to the variation within the groups, i.e. they are the solution to (3.6). 
The corresponding eigenvalues are a measure of this distance. The MANOVA significance 
tests (i.e. Wilks lambda) are based on these eigenvalues. It can be shown that the test-
statistic is equal to the MD between the group means when comparing two groups. In other 
words, in this case MANOVA tests if the squared MD between the group centroids is 
significantly greater than 0.  
3.2.5 What goes wrong in high dimensions? 
Traditionally, the MD has been applied to data where the number of variables is limited. The 
behavior of the MD is, however, very different in data with many variables [4, 13, 19]. Often 
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these phenomena are not taken into account during data analysis. Below we present three 
problems that are often observed when the MD is applied to high-dimensional data. The 
first problem is related to estimation of the sample covariance matrix; the other two 
problems are related to application of distance measures in high dimensional data.  
The sample covariance matrix 
The covariance matrix, or more exactly its inverse, is a central aspect of the MD (see, for 
example, equations 3.1 and 3.7) [19, 20]. Here, we describe the properties of the matrix in 
the context of process control (equation 3.3). The same principles apply for the other 
techniques that use the covariance matrix such as LDA and MANOVA.  
The unbiased sample estimate of covariance matrix 𝚺! is given by: 
𝚺! = 1𝑛! − 1 𝐱!,! −   𝐱! ! 𝐱!,! − 𝐱!!!!!! = 1𝑛! − 1𝐗!!𝐗! (3.8) 
where 𝑛! is the number rows in matrix 𝐗! (number of samples), 𝐱!,! is the 𝑖th row in this 
matrix, 𝐱! is the average over the columns of 𝐗! (i.e. an estimator for 𝛍!), and 𝐗! is the data 
matrix centered with  𝐱!  [14, 15, 20].  The advantages of the sample covariance (and 
corresponding precision) estimate are its ease of computation and the property of being 
unbiased. However, when the number of samples is smaller than the number of variables the 
sample covariance estimate cannot be considered a good approximation of the true 
covariance matrix [14, 15]. This is also true for cases where 𝑛! is close to 𝑝 in size. In these 
situations the matrix is potentially estimated with large error. For example, consider the 
eigenvalues of 𝚺! [14]. In figure 3.3, boxplots of the ordered eigenvalues are shown for the 
case where 𝚺! is equal to the identity matrix, i.e. the population eigenvalues are all equal to 
one. The sample eigenvalues were calculated for simulated data where the underlying 
distribution was multivariate normal with 100 variables and various numbers of samples. In 
the figure it can be seen that the largest sample eigenvalues are overestimated while the 
smallest eigenvalues are underestimated. This effect becomes more severe when the ratio 𝑝/𝑛! becomes larger. When the ratio 𝑝/𝑛! is less than one but not negligible, the sample 
estimate is numerically ill-conditioned, i.e. inverting it will amplify estimation error [14]. 
When 𝑝/𝑛!   ≥   1  matrix 𝚺!  loses full rank. This can be seen in figure 3.3 as a growing 
number of eigenvalues become zero. This has several undesirable consequences.  First, 𝚺! is 
not positive definite anymore, second it cannot be inverted as 𝚺! becomes singular [14].  
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Figure 3.3   The sorted eigenvalues of the sample covariance matrix estimated from 100 simulated data sets. 
The population covariance matrix was equal to the identity matrix. The population eigenvalues are indicated 
by the dotted line. The number of variables in the simulation was 10, and the number of samples was (a) 500, 
(b) 20, and (c) 5.  
The bias of the eigenvalues has a negative impact on many techniques, i.e. estimates of 
explained variance in PCA or estimates of within-group variance in SPC, LDA, and 
MANOVA. For example, in the context of SPC, the bias of the eigenvalues means that the 
variance of the control group is wrongly estimated. Because of this, the MD distance 
between the sample and the controls can be overestimated or underestimated. Let’s assume 
that the eigenvalue of the first eigenvector in figure 3.2 is biased upwards and the second 
eigenvalue is biased downwards. This means that the SPC model in the first row in the 
figure will underestimate the MD in situation (a), and overestimate the distance in situation 
(b). Another clear disadvantage of the eigenvalue bias is that the techniques are not 
applicable when the number of samples is smaller than the number of variables since the 
precision matrix, that is, the inverse of the covariance matrix cannot be estimated. 
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Figure 3.4   Normalized Mahalanobis distances between samples and the center of the data for different 
dimensionality of the data [13]. Note that for each dimensionality 1000 samples were drawn from a standard 
multivariate normal distribution. The distances were normalized by dividing them by the square root of the 
dimensionality. In this way the average distances were of comparable size over different dimensionalities. 
The concentration effect 
Figure 3.4 shows another effect when using the MD in high dimensional data: the distances 
between samples and the center of the data converge with increasing dimension [4, 13]. The 
same effect occurs when looking at looking at pairwise distances for any two samples in the 
data set. Due to this so-called concentration effect the contrast between samples diminishes 
as the dimension increases. This can potentially compromise the accuracy of distance-based 
methods. Note that the concentration effect does not necessarily hold when the samples are 
separated in distinct clusters. In such situations it can actually cause increased 
discrimination between the clusters. See Zimek et al for more details [13]. 
Irrelevant variables 
In high dimensional data often only a few variables are related to the problem at hand while 
the others can be considered as irrelevant or noise variables. For example, in untargeted 
metabolomics data often only a few peaks (metabolites) are related to a disease while 
thousands are measured. As shown in figure 3.5, the performance of the MD distance is 
negatively influenced by the presence of irrelevant variables in many applications [13]. The 
effect of the relevant variables is masked by the accumulated noise of the irrelevant ones. 
Note that additive noise on relevant variables can cause similar problems.  
 
Chapter 3 
 52 
 
Figure 3.5   Outlier detection based on the Mahalanobis distance. This figure was generated from simulated 
data that followed a standard normal distribution with 100 variables [13]. The number of control and outlier 
samples was 10000. The outlier samples were drawn from the same distribution as the controls. Subsequently, 
the values of a subset of variables of the outlier samples were set to two. This means that these variables were 
abnormal with respect to the controls. The size of the subset was varied from 1 to 100. Note that the MD 
couldn’t identify outliers with only a few abnormal variables. 
Irrelevant variables can cause additional issues in high-dimensional modeling. First, the 
influence of noisy irrelevant variables often results in overfitted models. In case of LDA, it is 
often observed that all samples within the same class have the same score along the 
discriminant direction 𝐚!"#. This means that the within-group variance is zero along this 
direction and a perfect separation is achieved. However, such models do not generalize well 
to new data indicating overfitting. This is known as the data-piling problem [28]. 
 
Finally, we would like to remark that high dimensionality also brings spurious correlation; 
irrelevant variables may have high sample correlations to the response (e.g. a biological 
outcome such as disease) [3]. Such correlation may lead to false discoveries. For example in 
LDA, the vector 𝐚!"# is often inspected. High absolute coefficients indicate variables that 
are important for classification, i.e. a disease biomarker. Irrelevant variables can receive 
high coefficients due to spurious correlations. Therefore, further validation is crucial to 
identify biomarkers that are biologically relevant. 
3.2.6 Regularization 
The above discussion motivates regularization of the MD to obtain better estimators for 
high dimensional data. As mentioned above, regularization essentially means that some 
structure is imposed on the model with the aim to reduce its variance at the cost of some 
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bias. This results in a more robust model that is less likely to overfit. We observe that in 
literature two common strategies are used to regularize the MD and related techniques. The 
first strategy essentially regularizes the covariance matrix to directly correct for the bias in 
the eigenvalues. The second strategy combines the MD with variable selection to directly 
reduce the effects of irrelevant variables and the high dimensionality of the problem. Note 
that the latter approach also results in a parsimonious model that is hopefully more easily 
interpretable. 
3.3 Regularization of the covariance matrix 
In high dimensional data the sample covariance matrix is not a good estimator of the 
population covariance matrix [14, 15]. A (naïve) strategy to obtain a more efficient 
estimator can be to consider an estimator with a lot of structure imposed. This way the 
resulting estimate contains relatively little error, but can be misspecified and therefore 
severely biased. For example, an independent covariance structure can be used, i.e. all 
covariances are zero. This implies uncorrelated variables, which is unrealistic for 
metabolomics data: metabolites are not independent from each other. Another often-used 
strategy in chemometrics to obtain more efficient covariance estimate is to restrict data 
analysis to the space spanned by the eigenvectors of the covariance matrix that have non-
zero eigenvalues, i.e. a Moore-Penrose inverse of the covariance matrix can be used in 
equation 3.1. However, in such cases relevant information may be discarded. Additionally, 
the bias of the eigenvalues that are retained in the model is not corrected. An example of the 
pseudo inverse in the case of SPC is shown in row 2 of figure 3.2. In this two-dimensional 
model, only the first sample eigenvalue is retained, i.e. all the data is projected onto the first 
PC. Therefore, no difference is observed in panel b. 
 
Many more advanced methods for regularization of the covariance matrix have been 
proposed in the literature [14, 15]. In general these procedures obtain an improved 
covariance estimator by reducing its variance at the cost of some bias. Essentially, these 
approaches can be divided in two categories. Many methods aim to impose special structure 
on the covariance matrix or its inverse such as a sparse structure, thereby reducing the 
variance of the resulting estimator. However, whether such structure does indeed exist 
cannot be verified from the data. Therefore, in some applications, a structure free approach 
can be preferred. Here the eigenvectors of the sample covariance matrix are retained, but 
the eigenvalues are corrected by pulling the highest eigenvalues downwards and the smallest 
ones upwards. Note that these estimators can often be interpreted as a weighted average 
between the sample covariance matrix and a matrix with a lot of structure (often a diagonal 
matrix). An example of the use of such an estimator in the case of SPC is indicated in the 
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third row of figure 3.2. Note that the eigenvalues are indeed adjusted as indicated by the 
different shape of the sphere. 
 
In this chapter we focus on these structure free approaches. They are known as shrinkage 
estimators. In section 3.3.4 we provide a brief overview of estimators that do assume a 
special structure.  
3.3.1 Steinean shrinkage 
Shrinkage of eigenvalues is the oldest approach to regularization of the covariance matrix. 
These methods aim to correct the distorted eigenvalue structure of 𝚺 and were introduced 
by Charles Stein (hence the name Steinean shrinkage) [15, 29].  The term shrinkage refers to 
the fact that these methods essentially pull (shrink) the eigenvalus towards a central value 
thereby correcting their bias. 
 
Consider the spectral composition of the sample covariance matrix given by: 
 
 𝚺 = 𝐏𝚲𝐏! = 𝜆!𝐞!!𝐞!!!!!  (3.9) 
 
where 𝚲 is a diagonal matrix of eigenvalues 𝜆! and 𝐏 is an orthogonal matrix of normalized 
eigenvectors 𝐞! (row vector). This decomposition is familiar from techniques such as PCA, 
where 𝐞! are the principal components and 𝛌! is the explained variance. Steinean shrinkage 
approaches aim to regularize the covariance matrix by applying a function 𝜃(. ) to the 
eigenvalues such that the bias of the eigenvalues is corrected. They are of the following 
general form [14]: 
 
 𝚺 = 𝐏𝜃(𝚲)𝐏! = 𝜃(𝜆!)𝐞!!𝐞!!!!!  (3.10) 
 
Note that these estimators retain the eigenvectors of the sample covariance matrix. 
Therefore, they are rotation invariant: rotating the variables results in the same rotation 
being applied to the covariance matrix estimator. Regularization with rotation equivariance 
is preferable when no a priori information about the structure of the covariance matrix is 
available. Note that although shrinkage estimators retain the sample eigenvectors this does 
not mean that they assume that these eigenvectors are estimated without error. It only 
means that it is unclear how the estimation of the eigenvectors should be improved without 
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imposing a specific structure on the eigenvectors or covariance matrix itself [30]. In these 
cases only the bias in the eigenvalues can be corrected. 
 
A huge body of literature on shrinkage approaches, i.e. functions 𝜃(. ), is available [14, 15]. 
Most of these methods have been obtained by minimizing a so-called loss function. These 
loss functions evaluate the difference between the covariance matrix estimate and the true 
covariance matrix in different ways. Popular loss functions include [14, 15]: 
 
 
𝐿! 𝚺,𝚺 = 𝑡𝑟 𝚺𝚺!! − 𝑙𝑜𝑔 𝚺𝚺!! − 𝑝 𝐿! 𝚺,𝚺 = 𝑝!! 𝚺 − 𝚺 !! (3.11) 
 
Loss 𝐿!  is essentially the Kullbach-Leibler divergence between two multivariate normal 
densities with the same mean and covariance 𝚺 and 𝚺. Loss 𝐿! uses the Frobenius norm 
( . !) to quantify the difference between the true covariance matrix and the estimator.  
3.3.2 Linear shrinkage 
Traditional shrinkage approaches shrink the eigenvalues towards a central value. A popular 
method is the linear shrinker introduced by Ledoit and Wolf [31, 32]. The following 
shrinkage function is applied: 
 
 𝜃 𝜆! !" = 𝛿𝜆 + (1 − 𝛿)𝜆! (3.12) 
 
where 𝜆 indicates the average sample eigenvalue. In figure 3.6a, it can be seen that the 
shrunken eigenvalues are much closer to the population eigenvalues compared to those of 
the sample covariance matrix. As shown in figure 3.6b, the Ledoit Wolf (LW) estimator 
shrinks the sample eigenvalues towards a central value (one in this case) in a linear way. The 
parameter 𝛿 varies between zero and one and determines the amount of shrinkage that is 
applied. When 𝛿 = 1 the sample eigenvalues are used and when 𝛿 = 0 all eigenvalues are set 
to the average eigenvalue. The optimal amount of shrinkage is most likely somewhere in 
between these extremes and can, for example, be determined by cross-validation. Theiler et 
al developed an extremely fast cross-validation procedure for this purpose [33]. However, 
such an approach is relatively computer intensive. Ledoit and Wolf showed that an 
analytical expression for the optimal amount of shrinkage can be obtained by minimizing 
loss 𝐿! with respect to 𝛿 [31, 32].  Schafer and Strimmer argue that in practical problems the 
following solution is obtained [34]: 
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Figure 3.6   Comparison of the sample and LW covariance estimators for simulated data with 10 samples and 
10 variables.  (a) The average eigenvalues of the estimators computed over 100 simulations. The population 
eigenvalues are indicated by the dotted line. (b) The sample eigenvalues against the shrunk eigenvalues for 
one simulation.  
 𝛿 = 𝑉𝑎𝑟 𝚺!" + 𝑉𝑎𝑟(𝚺!!)!!!! 𝚺!"! + 𝚺!! − 𝜆 !!!!!  (3.13) 
 
where 𝛴!"  corresponds to the element in the 𝑖 th row and 𝑗 th column of the sample 
covariance matrix, and 𝑉𝑎𝑟(𝛴!") indicates the estimated variance of that element.  More 
details regarding estimation of the variance of 𝚺 are provided in appendix A of Schafer and 
Strimmer [34]. In practical problems with a limited number of samples, expression 3.13 can 
exceed one and even become negative. In order to avoid such problems the estimated 
shrinkage intensity 𝛿 is truncated to lie between zero and one. Fisher et al provide a more 
accurate estimation of 𝛿  for the case that the data come from a multivariate normal 
distribution [35]. Warton et al showed that the LW shrinkage estimator can also be 
obtained via a penalized likelihood approach [36]. In this case the optimal shrinkage 
parameter can be determined by cross-validation. 
 
Note that the LW shrinkage estimator as in expression (3.12) can also be obtained by taking 
a linear combination between the sample covariance matrix and a scaled identity matrix 
[31]: 
 
 𝚺!" = 𝛿 𝑡𝑟 𝛴𝑝 𝐈 + 1 − 𝛿 𝚺 (3.14) 
 
 Regularization 
 57 
where 𝐈 is the identity matrix of appropriate dimension, and 𝑡𝑟(𝚺)/𝑝 is equal to the average 
sample eigenvalue. Equation 3.14 gives another interpretation of the LW estimator. It is a 
compromise between the sample covariance matrix and the scaled identity matrix (𝑡𝑟(𝛴)/𝑝)𝐈. The sample covariance matrix is unbiased but estimated with high variance, 
while the identity matrix estimator has little variance and possibly high bias. Therefore, one 
can view the LW estimator as a weighted average of a variance and bias term. The weights 
are determined by the data and are chosen to optimize the bias-variance tradeoff. Besides 
the scaled identity matrix in 3.14 other, possibly more realistic, targets can be used as well. 
For example, Schrafer and Strimmer introduced six different targets and their associated 
optimal shrinkage value such as shrinkage towards towards 𝑑𝑖𝑎𝑔(𝚺) [34].  
3.3.3 Nonlinear shrinkage 
Recently, Ledoit and Wolf showed that linear shrinkage works well when 𝑝/𝑛 is large or the 
population eigenvalues are similar in magnitude. However, when the ratio 𝑝/𝑛 is small or 
the population eigenvalues are dispersed (e.g. a few PCs describe most variation in the data), 
linear shrinkage only improves upon the sample covariance matrix slightly [30, 37, 38]. An 
example is shown in figure 3.7a. The poor performance of the LW estimator is due to the 
fact that the same amount of shrinkage is applied to every eigenvalue. For example, if the 
shrinkage intensity is 0.5 every eigenvalue is moved halfway towards the grand mean of all 
sample eigenvalues. As shown in figure 3.7a, application of a nonlinear shrinkage function 
to the sample eigenvalue, where each eigenvalue is shrunk by a different amount, is a great 
route to further improve the shrinkage estimator.  
 
Figure 3.7   Comparison of the sample, linear shrinkage (LW) and nonlinear shrinkage (NERCOME) covariance 
estimators for simulated data with 400 samples and 100 variables. (a) The average eigenvalues of the 
estimators computed over 100 simulations. The population eigenvalues are indicated by the dotted line. (b) 
The sample eigenvalues against the shrunk eigenvalues for one simulation. 
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Recently, Ledoit and Wolf proposed such a nonlinear shrinkage estimator using random 
matrix theory [30, 37, 38]. We will abbreviate this method as NONLIN. The NONLIN 
estimator is based on a generalization of the Marcenko and Pastur equation, which 
describes the relationship between the sample and population eigenvalues. Paul et al provide 
an excellent review on the Marcenko-Pastur equation and more random matrix theory in 
statistics [39]. Ledoit and Wolf used the Marceno and Pastur theory to develop the so-called 
QuEST function (Quantized Eigenvalues Sampling Transform), which is used in the 
NONLIN estimator to correct the bias in each eigenvalue separately [37].  Ledoit and Wolf 
showed that the NONLIN method outperforms the linear LW estimator in many situations 
[30]. Unfortunately, their work is mathematically quite involved and difficult to digest. This 
hampers correct implementation of their approach by applied scientists. Additionally, the 
bias correction of each eigenvalue requires nonconvex optimizations making the method 
computationally quite intensive.   
 
Recently, Lam proposed a non-parametric covariance estimator and showed that the 
eigenvalues of their estimator are asymptotically the same as those of NONLIN [40]. We 
will abbreviate their method as NERCOME, as in Nonparametric Eigenvalue-Regularized 
Covariance Matrix Estimator. The NERCOME method does not require any prior 
knowledge regarding the structure of the covariance matrix or its eigenvalues. The 
NERCOME method is based on splitting the data. The first split is used to estimate the 
eigenvectors of the covariance matrix. The second split is used to estimate to eigenvalues 
given the estimated eigenvectors. This way, the following estimator is obtained:  
 
 𝚺!"#$%&" = 𝐏!𝑑𝑖𝑎𝑔 𝐏!!𝚺!𝐏! 𝐏!! (3.15) 
 
where the columns in matrix 𝐏! contain the eigenvectors estimated from the first split, and 𝚺!  is the sample covariance matrix of the second split. Note that 𝑑𝑖𝑎𝑔 𝐏!!𝚺!𝐏!  is an 
estimate of the eigenvalues based on the eigenvectors of the first split and the covariance 
matrix of the second split. The NERCOME method makes use of the fact that 𝐏! and 𝚺! are 
independent to regularize the eigenvalues. Lam argued that the split used to estimate 𝚺! 
should contain max  (30, !!") samples, and that the other samples should be used to estimate 𝐏! . Additionally, they showed that the estimator in 3.15 can be further improved by 
averaging the covariance estimates over many random splits of the data. Typically, 
averaging over 50 splits is sufficient. These settings were used to generate figure 3.7. Lam et 
al show that the NERCOME estimator is optimal with respect to Frobenius loss (an 
expression similar to 𝐿! is used) when estimating the covariance matrix, and optimal with 
respect to Steins loss (𝐿!) when it is used to estimate the precision matrix. Lam et al 
compared the performance of NERCOME, NONLIN, and the method of principal 
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orthogonal complement thresholding (POET) which is briefly mentioned in section 3.3.4 
[40]. The nonlinear LW and NERCOME methods were compared for simulated data where 
40% of the population eigenvalues were small, 20% had intermediate values and 40% were 
large. In this setting, the three approaches had similar performance. The NERCOME, 
NONLIN, and POET approach were also compared for the case where the covariance 
matrix has an underlying factor structure. It was shown that NERCOME outperforms 
NONLIN and POET in many situations in that case. Since Ledoit and Wolf showed that 
NONLIN outperforms the linear LW method, it is expected that NERCOME does so as 
well. 
 
Recently, two penalized likelihood approaches were proposed that essentially shrink the 
sample eigenvalues in a nonlinear fashion. Below, the resulting shrinkage functions are 
presented. Won et al proposed a condition number regularized (CNR) estimator [41]. The 
condition number is the ratio between the largest and smallest eigenvalue of the estimated 
covariance matrix. The penalty on the condition number results in a the following shrinker: 
 
 𝜃 𝜆! !"# = 𝜏∗,𝜆! ,𝜅!"#𝜏∗, 𝜆! ≤ 𝜏
∗𝜏∗ < 𝜆! < 𝜅!"#𝜏∗  𝜆! ≥ 𝜅!"#𝜏∗  (3.16) 
 
where 𝜏∗ > 0. The value for 𝜏∗ and 𝜅!"# are determined from the data by cross-validation. 
From equation 3.16 it is clear that the CNR estimator truncates the sample eigenvalues 
larger than 𝜅!"#𝜏∗ to 𝜅!"#𝜏∗, and those smaller than 𝜏∗ to 𝜏∗. The CNR estimator gives most 
improvement compared to linear shrinkage when a few eigenvalues are much larger than 
the others. These effects diminish when this is not the case.  
 
Chi et al use a nuclear norm penalty that steers the eigenvalues away from the extremes 0 
and ∞ [42]. This way the so-called Covariance Estimate Regularized by Nuclear Norms 
(CERNN) shrinker is obtained: 
 
 𝜃 𝜆! = −𝑛 + 𝑛! + 4𝜏𝛼 𝑛𝜆! + 𝜏 1 − 𝛼2𝜏𝛼  (3.17) 
 
The parameter 𝜏 is determined by cross-validation where 𝛼 are chosen as follows: 
 
 𝛼 = 1 + 1𝑝 𝑡𝑟 𝚺 ! !! (3.18) 
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The parameter 𝜏 essentially determines the amount of shrinkage that is applied while 𝛼 
defines a prior where the eigenvalues are shrunk towards. By means of expression 3.18 the 
eigenvalues are shrunk towards the grand mean of the sample eigenvalues. Compared to the 
CNR method, the CERNN method shrinks extreme eigenvalues in a similar manner but less 
drastically and shrinks intermediate eigenvalues similarly to linear estimators such as the 
LW estimator. Chi et al compare the linear LW, CNR and CERNN estimators with respect 
to loss 𝐿! and a quadratic loss function [42]. They show that CNR performs best when only 
very few population eigenvalues have a large value. When a larger fraction of population 
eigenvalues is large the CERNN method performs best. Ledoit and Wolf also observed that 
NONLIN outperforms CNR and LW in this situation. However, the NONLIN and CERNN 
methods have not been compared so far. 
 
The properties of the estimators discussed above are summarized in table 3.1. Note that only 
a rough discrimination between the properties of the methods is provided in the table. This 
is due to the fact that the comparison studies in literature focus on different loss functions 
and only compare a few methods in a limited number of scenarios. The methods presented 
in this section comprise only a small set of all the shrinkage approaches that have been 
proposed in literature. We chose these methods to demonstrate different approaches and 
because we think they are interesting and can be easily implemented. Many more 
approaches have been developed. We would like to point the interested reader to a 
fascinating paper by Dohono et al who proposed nonlinear shrinkers for 26 different loss 
functions for spiked covariance matrices, i.e. a covariance matrix with only a few large  
eigenvalues [43]. Many additional methods are referenced in this paper. Additional 
references can also be found in [14, 15]. 
Table 3.1   An overview of the properties of five eigenvalue shrinkage approaches. Note that three different 
eigenvalue structures of the population covariance matrix are considered. In a bulk structure all eigenvalues 
are similar in size. In a spiked structure a few eigenvalues are larger than the others. A block structure indicates 
that blocks of eigenvalues of similar size can be detected, i.e. one block with low values, a block with 
intermediate values, and a block with high values.  
  Eigenvalue structure  
Method Shrinkage-type Bulk Spiked Block Computational complexity 
      
LW Linear Good Poor Poor Low 
NONLIN Nonlinear Good Unknown Good High 
NERCOME Nonlinear Good Unknown Good Medium 
CNR Nonlinear Poor Good Poor Medium 
CERNN Nonlinear Good Unknown Good Medium 
      
 
 Regularization 
 61 
3.3.4 Other regularization approaches 
In this chapter we presented several shrinkage approaches for regularization of the 
covariance matrix. As mentioned above, many other regularization approaches have been 
proposed in literature. In contrast to shrinkage of eigenvalues, these approaches impose 
special structure on the covariance matrix. Additionally most (not all) methods are 
computationally more demanding. A brief overview of these other regularization methods is 
presented below. We focus on the main categories of methods, more details can be found in 
numerous references such as [14, 15]. 
Penalized likelihood approaches 
Many regularization approaches can be interpreted as penalized likelihood estimators [14, 
36, 41, 42, 44, 45]. Essentially, these methods estimate the covariance matrix via maximum 
likelihood, but include a penalty to the likelihood function to reduce the variance of the 
estimate. Many of the linear and non-linear shrinkage estimators described above can be 
expressed in the framework of penalized likelihood. However, penalization offers a wider 
range of regularization options besides shrinkage. In recent years there has been a great deal 
of interest in estimation of sparse covariance or precision matrices (i.e. many elements in 
the estimate are zero). Such a structure of the precision matrix is of interest since a zero 
indicates conditional independence between the variables in this case. A sparse structure is 
often enforced by using a so-called ℓ𝓁!-norm penalty, i.e. the sum of the absolute values of 
the elements of the estimate has to be lower than a constant [44, 45]. As will be shown in 
section 3.4, this penalty has the property that many elements are set exactly to zero. 
Banding, tapering and thresholding estimators 
Banding, tapering and thresholding are another class of methods that assume that the 
covariance matrix is sparse [14, 15, 46, 47]. A big advantage of these methods is their low 
computational complexity. These methods assume that the covariance matrix is 
subdiagonally sparse (banding, tapering) or in its individual elements (thresholding). 
Sparsity is enforced by weighting the diagonals of the matrix or shrinking its individual 
elements to zero. Banding and thresholding estimators are not necessarily positive definite. 
Positive definiteness can be guaranteed for tapering estimators. 
Factor models 
There is a wide literature on assuming a low dimensional structure of the covariance matrix 
[14, 15]. This structure is typically modeled by a factor model. Recently Fan et al introduced 
principal orthogonal complement thresholding (POET) [48]. The method combines a factor 
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model estimator with thresholding estimators. More specifically they described the 
covariance matrix as a sum of two matrices, namely an estimate of covariance based on the 
first 𝑘 principal components and an estimate based on the (𝑝 − 𝑘) residual components. The 
latter estimate was regularized by means of thresholding. Note that the resulting POET 
estimator seems well suited for data that does not completely correspond to a factor or a 
sparse structure. 
Regularization of the eigenvectors 
There is also considerable interest in estimation of sparse eigenvectors of the covariance 
matrix. This essentially results in a sparse PCA model with easily interpretable loading 
vectors. Algorithms have been obtained by Witten et al and Shen et al, for example [49, 50]. 
Note that the shrinkage approaches discussed in this chapter are also of use in the context of 
PCA to obtain more accurate estimates of the explained variance per PC [37].  
Final remarks 
Many of the methods discussed above can be recast as problems involving linear or 
generalized linear models. An excellent overview of the use of covariance estimation via the 
generalized linear model (GLM) perspective is presented in the following references [14, 
15]. Although difficult to digest these papers are worth looking into since the use of the 
GLM with its well-developed theory may offer new insights for estimation of covariance 
matrices.  
 
Similarly, a Bayesian framework also offers the advantage of regularization in a well-defined 
statistical approach and deserves future attention. A good introduction into this topic is 
presented in the review by Pourahmadi et al [15]. With the advance of markov chain monte 
carlo (MCMC) techniques we expect that this method can also be used for data encountered 
in chemometrics and metabolomics.  
3.4 Variable selection 
The MD is hard to implement when dimensionality is high due to the difficulty of 
estimating the unknown covariance matrix. As mentioned in section 3.2.6, replacing the 
sample covariance estimator by a regularized estimator can regularize the MD. This way the 
bias in the eigenvalues is corrected. In the context of LDA, Bickel et al showed that 
assuming variable independence (i.e. a diagonal covariance matrix) could improve 
classification accuracy when the dimension is large [18]. Fan et al, however, showed that  
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Figure 3.8   Comparison of outlier detection based on the full and sparse Mahalanobis distance for simulated 
data with 50 training samples and 100 variables. The model used here is introduced in chapter 6. It is a 
constrained model that makes vector 𝐚!"#  sparse. (a) The loading that was obtained for a sparse test with 30 
nonzero (selected) variables. (b) The distribution of the distances of the control samples (blue) and the outlier 
or patient (red) that were found for this test. In panels (c) and (d) the same results are shown, but then for a 
test that used all variables. 
even with the independence assumption classification using all variables could be as bad as 
random guessing due to noise accumulation issues [51].  
 
Often only a few variables are related to the problem at hand, i.e. a few metabolites are 
related to a biological outcome. Therefore, variable selection is another powerful approach 
to regularization of the MD [16, 52]. Variable selection directly improves the MD’s by 
excluding irrelevant variables from the analysis. Another advantage of this approach for 
metabolomics is that the resulting model is more easily interpretable. This is useful for 
biomarker discovery. An example in the context of SPC is shown in figure 3.8. Note that 
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most variable selection methods focus on selection of a subset of variables that is useful to 
build a good predictor, i.e. good classification accuracy in LDA [52].  This is not the same as 
finding all variables that are biologically related to the outcome. A subsampling approach 
where the results from many variable selections are combined can often be used to find 
most biologically relevant variables [52, 53]. 
 
Variable selection has a long history in chemometrics and many methods have been 
proposed. See, for example, the following excellent reviews [6, 16, 21, 52]. We present a 
selective overview of methods relevant to this thesis in this section. First, we briefly 
summarize some subset selection approaches. The rest of the section focuses on recent 
developments involving constrained and penalized models. This is an important class of 
variable selection approaches originating from the field of statistics [6, 16, 21]. Interestingly, 
these methods have been much less widely embraced by the metabolomics and 
chemometrics communities. They do, however, deserve more exploration in these fields due 
to their interesting (mathematical) properties [54, 55].  
3.4.1 Subset selection approaches 
Best subset selection is the most exhaustive approach to variable selection. Here, the model 
of interest is fitted to each combination of the 𝑝  variables to identify the subset of 
relevant/important variables. Typically, criteria such Akaike’s information criterion (AIC) 
or the Bayesian information criterion (BIC) are used to identify the best subset [6, 21]. 
Another approach is cross-validation. A wide range of smart search strategies such as 
branch-and-bound, simulated annealing, and genetic algorithms can be used to find the 
best subset [52]. Most search strategies are computationally expensive and not applicable in 
high dimensions. However, some efficient methods have been proposed that inspect only a 
limited number of subsets [6, 16, 21, 52]. Forward selection and backward selection are 
popular approaches [6, 21]. Note however, that these methods give nested models. In that 
sense forward and backward selection might be suboptimal compared to best subset 
selection [6, 21]. For example, the best predicting set with two variables does not necessarily 
include the best univariate predictor. Additionally, backward selection can often not be 
applied when 𝑛   <<   𝑝. 
3.4.2 Constrained/penalized models 
The variable selection methods that were discussed above fit models that contain only a 
subset of the variables. An alternative strategy is to fit a model on all variables, but use a 
technique to constrain or regularize the model parameters. In other words, use constraints 
that shrink the coefficients towards zero. This greatly reduces the variance of the estimator 
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since the model becomes less flexible due to the constraint. Additionally variables are 
implicitly selected as those variables having a nonzero coefficient. Constrained models have 
the following general form [16]: 
 
 𝐿 𝛽 ,    subject  to 𝑃 𝛽!!!!! ≤ 𝜏 (3.19) 
 
where 𝛽 indicate the model coefficients, 𝐿(𝛽) is a loss function (i.e. a least squares objective 
or likelihood function), 𝑃(. ) specifies the constraint, and 𝜏 controls the strength of the 
constraint. The parameter 𝜏 can be optimized in different ways, for example by cross-
validation. For SPC, LDA, and MANOVA the loss function is either formulated from the 
maximum likelihood or the Rayleigh quotient interpretation (see section 3.2). By either 
minimizing or, depending on the loss function, maximizing objective 3.19 we hope to 
simultaneously estimate the coefficients of the variables and shrink them to zero. In other 
words, it is not required to fit a new model at each step as in subset selection methods. For 
example, the SPC example in figure 3.8 was generated penalizing the estimation of 𝐚!"# ; a 
so-called ℓ𝓁!-norm constraint was used (see below). Estimation of 𝐚!"#  is a minimization 
problem where a direction 𝐚 is sought that minimized the variance of the controls, subject 
to that the distance between the “outlier” and the controls is one.  
 
Usually constrained models are specified in Lagrangian or penalized form [56]:  
 
 𝐿 𝛽 + 𝜆 𝑃 𝛽!!!!!  (3.20) 
 
where 𝜆 is a Lagrange multiplier. Note that the constraint is now added to the objective 
function and acts as a penalty to obtain a bias-variance tradeoff. It can be shown that when 
the problem in equation 3.19 is convex (concave), the solution to minimizing (maximizing) 
3.19 and 3.20 is the same [56]. Additionally, this solution is the global optimum when the 
so-called Kurush-Kuhn-Tucker (KKT) conditions are fulfilled [56]. Via the Lagrangian 
form it is possible to determine the solution to equation 3.19 analytically. This way, very fast 
and efficient algorithms to solve constrained models have been developed [57, 58].  
 
Ideally, the ℓ𝓁!-norm is used as a constraint, which is just the number of variables that are 
included in the model [16]. This essentially gives rise to a best subset selection method. The ℓ𝓁!-norm constraint can also be related to model selection criteria such as AIC and BIC [16]. 
Unfortunately, problems with an ℓ𝓁!-norm constraint are very difficult to solve since the  
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Figure 3.9    Geometric interpretation of  (a) ℓ𝓁!-norm constrained and (b) ℓ𝓁!-norm constrained problems.  
constrained problem is not convex. Therefore, a broader class of penalties is often 
considered, namely ℓ𝓁! penalties where 0 ≤ 𝑞 ≤ 2 [6, 16]. Although all these penalties shrink 
the model coefficients, it can be shown that penalties with 𝑞 ≤ 1 have the sparsity property, 
i.e. they perform variable selection. Additionally all penalties with 𝑞 ≥ 1 are convex which 
often allows for an analytical solution. Because of this the  ℓ𝓁!-norm, that is, the sum of the 
absolute values of the coefficients, is a popular constraint since it is the convex constraint 
that is closest in nature to the ℓ𝓁!-norm. In figure 3.9 it is shown why this constraint results 
in variable selection, while, for example, an ℓ𝓁!-norm (the sum of squared coefficients) does 
not. 
 
This figure is a geometric representation of the constrained loss in equation 3.19. The 
unconstrained optimal solution is marked by 𝛃. The red isocontour lines represent regions 
of suboptimal solutions with constant loss. The blue square and circle indicate ℓ𝓁!, and ℓ𝓁! 
constraints, respectively. Note that a solution to 3.19 is found when 𝛃 falls inside the area of 
the constraint. In that case the unconstrained solution is obtained. When this is not the 
case, the solution is found where the constraint and isocontour lines intersect. With an ℓ𝓁!-
norm this will generally not occur on an axis since the constraint has a circular form with 
no edges. The ℓ𝓁!-norm, however, “sticks out” at each of the axis, and so the isocontour lines 
will often intersect with the constraint exactly at an axis. When this occurs the coefficient of 
the other axis (corresponding to a variable in the data set) will be exactly zero. This induces 
variable selection. In this example, variable 2 is selected by the model and variable 1 receives 
a coefficient of zero.  
 
As mentioned above, the strength of the constraint is determined by 𝜏. This parameter 
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Figure 3.10   Coefficients 𝑥 plotted against their constrained (penalized) values 𝑇(𝑥) for different constraints.  
controls the area of the constraint, i.e. the size of the blue square and circle in figure 3.8. By 
making 𝜏 larger, the constraint increases in size. In the most extreme case, the solution 𝛃 
falls inside the region of the constraint and the unconstrained model is obtained. In 
contrast, when 𝜏 is small a very sparse solution is obtained. Note that constrained models 
also have a Bayesian interpretation by which their properties can be explained [6, 59]. 
 
Although ℓ𝓁!-constrained models have the attractive property of variable selection, it is well 
known that they are slightly biased as well [6]. This is because the constraint shrinks all 
coefficients towards zero even if they correspond to relevant variables. To gain more insight 
in this phenomenom we consider the case where the variables are uncorrelated. In this case, 
the solution to the ℓ𝓁!-constrained model often turns out to be a soft-thresholding (ST) of 
the coefficients of the unconstrained model [6, 21]. As shown in figure 3.10, ST shrinks all 
coefficients towards zero independent of their size. An ℓ𝓁! -constrained model often 
compensates for this bias by choosing a slightly less sparse solution [6]. Because of this, 
extremely sparse solutions are not always obtained. Many other penalties have been 
proposed in literature to correct the bias of ℓ𝓁!-constraints [6, 16]. These methods shrink 
large coefficients less severely than smaller ones. Two examples are shown in figure 3.10. 
The adaptive lasso is basically a weighted ℓ𝓁!-norm constraint. This can be obtained by 
application of an ℓ𝓁!-norm constrained model to scaled data. As shown in figure 3.10, the 
resulting penalty indeed penalizes large coefficients less strongly. Often an initial rough fit 
of the data by the model that uses the adaptive lasso is used to determine the weights. 
Another popular penalty is the smoothly clipped absolute deviation (SCAD) [16]. This 
penalty can directly be applied without first fitting a full model and also penalizes high 
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coefficients less strongly. However, the criterion is not convex, which makes computation 
much more difficult. Note that the hard thresholding rule is also included in figure 3.10. 
Best subset selection can be interpreted as hard thresholding (HT; variables are either in or 
out) [6]. HT is generally undesirable for high dimensional data since a small change in the 
data often results in disproportionally large changes in the model that uses HT. Therefore, 
the more continuous constraints such as the ℓ𝓁!-norm are preferred 
3.5 Applications 
The regularization techniques that we discussed above are general and can be applied to 
many chemometrics methods. For example, nonlinear shrinkage can be used to obtain 
better estimates of the explained variance of principal components. An ℓ𝓁!-norm penalty can 
be used to obtain sparse PCs [49, 50]. Examples of regularization in regression, PCA, PLS, 
and SVM can be found in [54, 55, 60].  
 
Below we focus on regularization of the MD in the context of SPC, LDA and MANOVA 
since these are the main techniques that we mainly applied in this thesis. The aim is not to 
give an exhaustive list of all methods that have been proposed in literature, but rather to 
illustrate the regularization approaches discussed in sections 3.3 and 3.4 with a few 
applications.  
3.5.1 Process control / Outlier detection 
Process control techniques are often applied in an industrial setting where samples can be 
readily measured in large quantities [23, 24]. In such cases regularization of the MD is not 
required since 𝑛   >>   𝑝. However, sometimes PCA is used to reduce the dimension of the 
data because only variation in a specific subspace has to be monitored. This can be seen as a 
form of regularization where the squared MD is used the monitor the samples in the space 
of the 𝑘 selected PCs and the Euclidean distance is used to monitor the residual space [23, 
24]. A similar decomposition is used by robust PCA models to detect outliers [25, 61]. Note 
that in robust PCA the principal components are only fitted on the most similar data points 
and therefore their estimator is most likely not influenced by the outliers in the data [61]. 
Although the (robust) PCA-based model is very powerful for process control and 
identification of outlying samples it can sometimes not correctly identify which variables 
cause the outlying behavior. This is due to the so-called smearing effect [62, 63].  
 
The literature on variable selection in SPC is limited. Some initial work is reviewed in [26, 
64, 65]. Recently, Zou et al and Capizzi et al combined the MD with variable selection [64, 
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65]. More specifically they aim to estimate the squared MD in equation 3.3 subject to an ℓ𝓁!-
norm penalty on 𝐱! (the data is assumed to be centred to 𝛍!). Optimization of the strength 
of the penalty is a difficult task since crossvalidation cannot be used here. Additionally, poor 
performance was observed when criteria such as AIC or BIC were used. Therefore, a simple 
standardization of the test statistic was proposed to be able to determine models with 
different amounts of variables [64, 65]. For an industrial application they showed that the 
resulting model had more power compared to tests that were based on all variables in the 
data set. Additionally, these techniques avoid the smearing effect since no dimension 
reduction step is involved. Note that these methods assume that the ”outlying” sample is 
shifted in a few variables with respect to the mean of the controls. Therefore, direct 
penalization of the difference between these vectors is an intuitively sound choice. However, 
as shown in section 3.2.2 it is actually the weighted difference between these vectors, 𝐚!"# , 
that should be inspected for this purpose. Mai et al make a similar argument for the case of 
LDA (see below) [66]. Therefore we propose an SPC method with a penalty on 𝐚!"#  in 
chapter 6.  
3.5.2 Linear discriminant analysis 
It is well known that LDA is not applicable to high-dimensional or highly collinear data [6]. 
A common approach in chemometrics is to apply PCA to the data and perform 
classification in the reduced space. However, it can be that the components that were not 
included in the analysis are in fact related to the response. PLS-DA models are a popular 
alternative for classification [6]. However, interpretation and variable selection in such 
models is also not without its drawbacks [67].  
 
Regularization of the covariance matrix has a long history in LDA. Already in 1995 Hastie 
proposed penalized discriminant analysis [68]. This method regularizes the covariance 
matrix in a similar way to the LW shrinker. The optimal amount of shrinkage was 
determined by cross-validation. Bickel et al considered an LDA model with variable 
independence by assuming that 𝚺! is diagonal [18]. They showed that this model had better 
prediction accuracy in high dimensions then a model that used all variables. Fan et al, 
however, showed that even with such strict regularization, the method does no better then 
random guessing when the dimension of the data is extremely high [51]. Therefore, many 
sparse LDA methods have been proposed. These methods differ in the assumptions made 
on the within-group covariance matrix (diagonal or full structure), the number of groups 
that can be discriminated (2-group or multi-group), and the vector that is penalized 
(difference between means or direction 𝐚!"#). The properties of the different approaches are 
summarized in table 3.2. All methods optimize the strength of the penalty by 
crossvalidation. 
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Table 3.2   Comparison of 8 sparse LDA methods on the basis of three properties, namely the 
estimate/structure of 𝚺!  that is used, the vector that is penalized, and the maximum number of groups that 
can be discriminated by the method. Note that SM indicates penalization of the weighted class means 𝛍!𝚺!∗ !!, 
where 𝚺!∗  is the covariance matrix with the assumed structure and 𝛍!  is the mean of the ith class. DD indicates 
penalization of the discriminant direction 𝒂!"#$. 
Method Covariance structure Penalty Number of groups Ref 
     
NSC Diagonal SM Multi [69] 
PFLDA Diagonal DD Multi [70] 
PFLDA Shrunk  DD Multi [71] 
RDA Shrunk  SM Multi [72] 
SDA Shrunk  DD Multi [73] 
SLDA Sample DD 2 [74] 
LSDA Sample DD 2 [66] 
MLSDA Sample DD Multi [75] 
     
 
The nearest shrunken centroid (NSC) approach assumes that that within-group covariance 
matrix is diagonal [69]. In this approach, the standardized class means (𝛍!𝚺!"#!! ) are shrunk 
using soft thresholding. New samples are assigned to the closest shrunk centroid based on 
the MD using the regularized estimate of the within-group covariance matrix. Note that this 
approach reduces to the regularized LDA approach of Bickel et al when no shrinkage is 
applied [66]. Many experiments have shown that NSC is competitive for high dimensional 
data. 
 
Using sparse estimates for the standardized class means as in NSC does not guarantee that 
the direction 𝐚!"#  is sparse. Therefore, Witten et al proposed penalized Fisher LDA 
(PFLDA) where the direction 𝐚!"#$ is directly penalized [70]. Again, variable independence 
is assumed (diagonal covariance). Note that the PFLDA problem is not convex and 
convergence of the method to the global optimum is not guaranteed. Recently, Gaynanova 
noted that because of this the constrained and penalized solution of PFLDA do not provide 
the same solution and the penalized form typically selects too many variables [76]. 
Gaynanova et al developed a routine to solve the constrained problem [76]. This way, more 
sparse solutions could be obtained compared to the algorithm of Witten et al. 
 
The above-discussed methods assume that all the variables are uncorrelated. This is clearly 
not realistic in many situations. Mai et al also warn that independence rules could select the 
wrong features [66]. They provide some intuitive examples involving a few variables. Guo et 
al proposed regularized discriminant analysis (RDA). This method is closely related to NSC, 
but no variable independence assumptions are made. Again, this method penalizes the 
weighted class means instead of the discriminant direction, and its feature selection 
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properties can be considered somewhat conservative since it often includes a large number 
of variables [77]. Gaynanova et al proposed to use the LW estimator of covariance in the 
PFLDA method [71]. This method directly penalizes the discriminant directions 𝐚!"#$. As 
mentioned above, this approach typically selects too many variables since the problem is not 
convex. Additionally, the algorithm can get stuck in local optima.  
 
Mai et al showed that two-class LDA problems can be rewritten as a regression problem 
[66]. This way, direction 𝐚!"# can be found efficiently using efficient least squares routines 
such as least angle regression. We refer to the method as least squares discriminant analysis 
(LSDA). Wu et al, proposed sparse LDA (SLDA) to penalize 𝐚!"#$. They turn estimation of 𝐚!"#$ via the Rayleigh quotient into a convex minimization problem that can be penalized. 
Again this method is only applicable to two-class problems. An advantage of the technique 
is that the covariance matrix is used during the optimization instead of its inverse. 
Therefore, regularization is not required although the approach appears to be numerically 
more stable when some regularization is used. It is unclear if SLDA could benefit from 
regularization of the covariance matrix using some the more advanced approaches 
discussed in section 3.3. Mai et al showed that LSDA and SLDA are exactly the same [78]. 
Also sparse discriminant analysis (SDA) is the same as LSDA in case of two groups. An 
advantage of this method is that it can also be applied to multi-group problems. SDA 
transforms the LDA problem into an optimal scoring problem (least squares like problem) 
that can be penalized [77]. Gaynanova et al also extended the LSDA method to the 
multigroup case [75, 79]. 
 
Many of the sparse LDA methods discussed above were compared by Clemmensen [77]. In 
general, it was observed that methods that include the correlation between the variables 
outperform the methods that assume a diagonal covariance structure. Additionally, they 
noted that techniques that directly penalize 𝐚!"# are much easier interpretable compared to 
techniques that penalize the weighted class means 𝛍!𝚺!!!. 
3.5.3 Multivariate analysis of variance 
Many methods have been proposed for application of MANOVA to high dimensional data. 
One of the first proposals to deal with high dimensional data was Dempsters non-exact test. 
This method studies the ratio of the trace of the between matrix and the within matrix. This 
way no inverse of the within-group scatter matrix has to be computed. Many variants of the 
method have been proposed [80-82]. 
 
Another traditional approach is to apply PCA to the data and restrict the MANOVA analysis 
to the first few components [83]. However, it can be that the groups are separated along the 
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components that are ignored. Therefore, this test is suboptimal. Langsrud proposed 50/50 
MANOVA. Again, PCA is applied before MANOVA and 𝑘  components are selected. 
However, an additional 50% of the remaining 𝑛 − 𝑘 − 1 components are also included as 
buffer components. This way it is less likely that components that are important to the 
response are ignored.  
 
Srivastava proposed to use a Moore-Penrose inverse of 𝐖 in equation 3.7 [80]. Remember 
from section 3.3 that this may be considered as regularization of the covariance matrix. 
They showed that this method was more powerful than the non-exact tests. However, the 
performance of this approach is very unstable since the eigenvalues of the covariance matrix 
cannot be reliably estimated (see section 3.2.5). Additionally, information related to the 
group differences might be ignored for the same reason as discussed earlier in the context of 
figure 3.2. 
 
In metabolomics, ANOVA simultaneous component analysis (ASCA) is a popular 
alternative to MANOVA for analysis of designed experiments [84-86]. In essence this 
method applies univariate ANOVA tests to each variable in the dataset and uses PCA to 
combine the results of all univariate tests. We will show in chapter 4 that this approach is a 
regularized version of MANOVA where variable independence is assumed. We will use the 
LW shrinker as an intuitive way to bridge the gap between ASCA and MANOVA and place 
both methods in a general framework. 
 
Tsai et al have also considered replacing the estimate of 𝐖 by the LW shrinkage estimate for 
analysis of microarray data [87]. They showed that this resulted in a powerful method 
compared to popular alternatives in the field of gene set analysis. In their paper on 
penalized likelihood estimation of the covariance matrix Warton et al showed that a 
regularized estimate of 𝐖 resulted in a more powerful test compared to when a Moore-
Penrose pseudoinverse is used [36]. 
 
Not many sparse MANOVA methods have been proposed in the literature so far. Univariate 
ANOVAs are often used to determine variable importance in MANOVA tests. This way 
possible correlations in the data are clearly ignored. Recently, Shen at all truncated the data 
to the best m univariate predictors and applied a multivariate test afterwards [88]. 
Throughout the whole procedure it is assumed that the variables are independent. In 
another work, Shen et al proposed a sparse MANOVA test for gene set analysis. For 
comparing two groups they apply soft thresholding to 𝛍! − 𝛍! 𝐖!! to obtain a sparse 
model [89]. The threshold value is chosen automatically based on signal/noise 
considerations. We note that this does not guarantee that the best sparse subset is found this 
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way. For example, it can be that the two variables in the optimal sparse two-dimensional 
subset have low coefficients in the full model.  The MANOVA thresholding mentioned 
above will shrink these variables quickly to zero and ignore them in the rest of the analysis. 
In this respect, MANOVA could clearly benefit from the ideas proposed in the more 
advanced sparse LDA methods. 
3.6 Discussion 
The high dimensional nature of metabolomics data poses specific problems to data analysis. 
In this chapter we showed how more stable SPC, LDA, and MANOVA models can be 
obtained for such data by regularization. This is achieved, either by correcting the bias in the 
eigenvalues of the sample covariance matrix, or by variable selection. Sometimes a 
combination of both methods is used. These approaches have a wide application and are not 
limited to SPC, LDA, or MANOVA. 
 
The methods presented in this chapter are applicable to data with moderate dimension. 
However, for data with truly high dimensions these approaches are computationally too 
demanding. It is of great interest to investigate how to obtain stable models in these difficult 
scenarios. For example, in metabolomics the above-mentioned regularization methods are 
applicable to binned NMR data. However, most methods run into computational issues 
when analyzing even higher dimensional data such as untargeted LC-MS spectra of complex 
matrix samples (untargeted metabolomics). In fields outside of metabolomics, much 
interest has focused on application of a (univariate) variable screening before application of 
multivariate techniques in truly high dimensional data [16]. In this way the variables that 
are most likely irrelevant are discarded and the dimension of the problem is greatly 
reduced. For example, a 𝑡-test can be used to rank the predictive ability of each sample for a 
group of controls and a group of patients. Subsequently, only the variables with the lowest 
p-value are retained for further analysis. This is known as sure independence screening [90]. 
However, such screening does not take the correlations between the variables into account. 
Extensions to take into account possible correlations have been proposed as well [16]. 
 
Dimension reduction is an important class of regularization approaches that is not detailed 
thoroughly in this chapter. In sections 3.3 and 3.5 it is briefly mentioned that PCA can be 
used to regularize the covariance matrix. However, many other dimension reduction 
methods can also be employed. Application of a model in the lower dimensional space is an 
effective type of regularization since fewer parameters have to be estimated. Examples of 
dimension reduction techniques include independent component analysis (ICA), self-
organizing maps (SOM), or even Fisher LDA before application of another classifier [6]. 
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In conclusion, high-dimensional data brings a unique set of challenges for data analysis. 
Many regularization approaches have been developed to obtain more reliable estimators, 
also in the context of SPC, LDA, and MANOVA (see sections 3.3 – 3.5). Many methods 
have been proposed that either regularize the sample covariance matrix, or use variable 
selection. Based on simulations and real data authors claim that such methods have great 
potential in many fields with high-dimensional data such as metabolomics. However, each 
author uses his own data and simulation to compare methods. Clearly, more exhaustive 
simulations and evaluation of the methods on multiple data sets is required to fairly 
compare the approaches. This way, methods can be identified that perform well in a wide 
variety of situations.  
3.7 Regularization in this thesis 
Applications of different types of regularization approaches in fields such as metabolomics 
and glycomics are limited. The approaches discussed in sections 3.3 and 3.4 bring new 
perspectives and deserve more attention from these communities than they have received so 
far.  Chapters 4 – 6 in this thesis deal with regularization of the MD to make it applicable for 
analysis of metabolomics data. We evaluate three types of regularization, either from the 
perspective of SPC or MANOVA.  
 
In chapter 4, we explore the value of regularization in the context of MANOVA. We show 
that ASCA is actually a MANOVA model with the implicit assumption that the within-
group correlations between the variables are zero. This is not a realistic assumption, but, as 
mentioned in this review, can be useful for analysis of high-dimensional data. For data with 
limited dimensionality a better model can be obtained by taking the correlation structure 
into account. We achieve this by combining MANOVA with the LW shrinker. This way, a 
model is obtained that is essentially a weighted average of the ASCA and MANOVA models. 
 
In chapter 5 we introduce the framework of process control for disease diagnosis. This is a 
novel and intuitive approach to disease diagnosis that is, for example, very useful for 
personalized health applications (e.g. diagnosis of (rare) diseases and health monitoring). In 
this chapter the covariance matrix is regularized by PCA. As mentioned in section 3.5, this 
results in a model that can identify patient samples very well, but cannot reliably identify 
the abnormal metabolites in all situations due to the smearing effect.  
 
We propose an alternative SHM model in chapter 6. This is a sparse model that combines 
the MD with variable selection. Unlike other methods that have been proposed in SPC, we 
penalize the discriminant direction 𝐚!"#  directly which should result in more accurate 
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variable selection. Compared to the PCA-based approach an advantage is that the smearing 
effect is avoided. A disadvantage is that the method is computationally more expensive 
compared to the PCA-based approach discussed in chapter 5.  
 
Although each type of regularization presented in chapters 4 - 6 is only presented in the 
context of one specific model/application they can most likely also be applied in the context 
of the other models since all models are related to the MD.  
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4  
REGULARIZED MANOVA (rMANOVA) 
IN UNTARGETED METABOLOMICS 
 
Many advanced metabolomics experiments currently lead to data where a large number of 
response variables were measured while one or several factors were changed. Often the 
number of response variables vastly exceeds the sample size and well-established techniques 
such as multivariate analysis of variance (MANOVA) cannot be used to analyse the data.  
 
ANOVA simultaneous component analysis (ASCA) is an alternative to MANOVA for 
analysis of metabolomics data from an experimental design. In this paper, we show that 
ASCA assumes that none of the metabolites are correlated and that they all have the same 
variance. Because of these assumptions, ASCA may relate the wrong variables to a factor. 
This reduces the power of the method and hampers interpretation.  
 
We propose an improved model that is essentially a weighted average of the ASCA and 
MANOVA models. The optimal weight is determined in a data-driven fashion. Compared 
to ASCA, this method assumes that variables can correlate, leading to a more realistic view 
of the data. Compared to MANOVA, the model is also applicable when the number of 
samples is (much) smaller than the number of variables. These advantages are demonstrated 
by means of simulated and real data examples. The source code of the method is available at 
the following github repository: https://github.com/JasperE/regularized-MANOVA. 
  
This chapter has been adapted from:!Engel, J., Blanchet, L., Bloemen, B., van den Heuvel, 
L. P., Engelke, U. H. F., Wevers, R. A., & Buydens, L. M. C. (2015). Regularized MANOVA 
(rMANOVA) in untargeted metabolomics. Analytica chimica acta, 899, 1-12 (Featured 
article). 
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4.1 Introduction 
Metabolomics experiments are often carried out according to an experimental design 
having factors such as dose, time, age, etc. Usually an untargeted or global approach is used 
in which as many metabolites as possible are measured. The goal of these experiments is to 
relate metabolic responses to the factors of interest and test their significance. For example, 
Salek et al. used an experimental design with disease and gender as factors to determine 
metabolites that are related to type 2 diabetes [1]. Ressom et al. characterized the metabolic 
changes pertaining to hepatocellular carcinoma in patients with liver cirrhosis; their design 
included three factors, namely disease, injection, and experiment [2]. 
 
Due to the complex nature of the metabolome and the analytical techniques used to 
measure it, datasets are extremely large and complex. For example, NMR based untargeted 
body fluid metabolomics datasets contain hundreds of variables (chemical shift values), 
which are related to the concentration of the different metabolites in the sample. Therefore, 
multivariate statistical analysis is indispensable to interpret the acquired data [3]. Lately, it 
has been recognized that standard tools used in metabolomics such as principal component 
analysis (PCA) often do not extract the relevant (biological) information from designed 
experiments [4]. These suboptimal results originate from the fact that PCA analysis is 
unsupervised and focuses on the captured data as a whole, i.e. it does not differentiate 
between the factors and interactions specified by the experimental design. Classification 
methods such as Orthogonal Partial Least Squares Discriminant Analysis (O-PLS-DA) are 
also sometimes used. However, the resulting model can be difficult to interpret in terms of 
the different factors and interactions since each cell in the experimental design is modeled 
as a different class. Note that these classification methods focus on prediction of new 
samples, which is not equal to testing of statistical significance of a factor or interaction. A 
classification method can be useful after the statistical significance of a factor has been 
established. 
 
Analysis of variance (ANOVA) is a cornerstone statistical method for the analysis of data 
from an experimental design [5]. It is a univariate method and therefore it cannot take the 
relationships (covariance) between the different variables or metabolites into account. 
Multivariate analysis of variance (MANOVA) is the multivariate extension of ANOVA [6]. 
This method does take the experimental design, as well as the covariances between the 
metabolites, into account. MANOVA cannot be applied to data where the number of 
samples is (much) smaller than the number of variables because the inverse of the within-
group scatter matrix cannot be computed in this case. Such high dimensional data sets are 
common in metabolomics. ANOVA simultaneous component analysis (ASCA) was 
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presented as an alternative to MANOVA for the analysis metabolomics data from an 
experimental design [7]. This method combines principles from ANOVA with PCA. First, 
ANOVA is used to separate variation in the data into different sub-matrices according to the 
different factors and interactions. Next, the interesting parts are analyzed by PCA in a 
multivariate fashion. The loadings of the PCA model can be used to determine which 
metabolites are related to a particular factor or interaction. ASCA has been successfully used 
in a number of studies such as [7, 8]. Several variants of this approach have been proposed 
in different fields. Examples include Scaled-to-Maximum, Aligned, and Reduced 
Trajectories (SMART) [9]; Principal Response Curves (PRC) [10]; and ANOVA-PCA [11]. 
Recently, some of these variants were described in a general framework [12].  
 
Because PCA is a multivariate technique, it was assumed that ASCA is so as well. The first 
contribution of this chapter is to show that methods based on ANOVA models – such as 
ASCA – do not truly analyse the data in a multivariate way. From the viewpoint of 
MANOVA, ASCA implicitly assumes independence of the variables and equal variance for 
all metabolites. It is known that metabolites may correlate with one another. Therefore, we 
will show that the independence assumption made by ASCA is most likely incorrect, which 
reduces the power of the method to detect significant factors. Moreover, because of the 
assumption of variable independence, ASCA can mark a significant metabolite as 
unimportant and a less important metabolite as important. This greatly hampers the value 
of ASCA for biomarker identification. As a second contribution, we show that the power of 
ASCA to detect significant factors can be increased by a proper scaling of the data in 
combination with a different test statistic. As a third contribution we introduce regularized 
MANOVA (rMANOVA): a method that is essentially a weighted average of ASCA and 
MANOVA. The optimal weight is determined in a data-driven fashion. In this way the 
strengths of both methods are combined: rMANOVA can take the correlation between 
variables into account and is also applicable when the number of variables vastly exceeds the 
sample size. Simulated as well as real metabolomics data sets are used to compare ASCA to 
rMANOVA.  
4.2 Theory 
Consider a metabolomics experiment of 𝑝 metabolites (variables) with a one-way design 
with 𝑘 experimental conditions of sample sizes 𝑛! . We will refer to the set of samples 
measured under the same condition as a group. ASCA, MANOVA, and rMANOVA can be 
used to analyse such data and determine whether the groups differ significantly. Below, the 
theory for all methods is presented. A numerical example is included to demonstrate what 
some of the equations represent. The data used in this example is shown in table 4.1. Note 
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Table 4.1   Artificial data used to explain the ASCA and MANOVA methods. 
  Concentration 
Experiment Sample label Metabolite 1 Metabolite 2 
    
1 -1 1.3 1.3 
2 -1 0.2 1.3 
3 -1 2.4 0.1 
4 +1 1.3 3.0 
5 +1 2.9 2.8 
6 +1 2.8 3.6 
    
 
 
Figure 4.1   Two examples to illustrate the different approaches of ASCA and MANOVA for 𝑘 = 2 and 𝑝 = 2. 
Note that the group means are indicated by the black dots and the spread of the data around these means is 
represented by the ellipses. ASCA and MANOVA estimate the direction along which the groups are most 
separated. These are indicated by PC1 and CV1, respectively. Note that panel (a) corresponds to the case 
where the ASCA and MANOVA model give the same result. In panel (b) the solution found by ASCA is 
suboptimal and differs from that of MANOVA because the spread of the data is not taken into account.  
that this example involves 2 metabolites (𝑝   =   2), one factor with 2 levels (𝑘   =   2), and three 
samples per level (𝑛! = 3). 
4.2.1 ASCA 
The aim of ASCA is (i) to determine the average metabolite concentration for each 
experimental condition, (ii) determine if these averages differ significantly, and (iii) apply 
PCA to the averages to determine which metabolites are affected by a change in the 
experimental conditions. An example of an ASCA model is shown in figure 4.1 for 𝑘 = 2 
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and 𝑝 = 2. Note that the model can easily be extended to more complicated designs with 
more effects and interactions. 
 
Let 𝐱!"  be the vector of metabolite concentrations measured for sample 𝑗 in condition 𝑖. For 
example, 𝐱!" corresponds to the second row or sample in table 4.1. The basis of ASCA is the 
linear model  
 𝐱!" = 𝛍 + 𝐜! + 𝐞!"  (4.1) 
 
Where 𝛍 corresponds to the overall mean, 𝐜!is the average metabolite concentration for the 
i-th condition and 𝐞!" are the residuals. Note that the data is centred by inclusion of 𝛍 in 
equation 4.1. For the data shown in table 4.1, 𝛍 = 1.8  2.0 , 𝐜! = −0.5 − 1.1 , and 𝐜! =0.5  1.1 . The residuals can be found by subtracting 𝛍 and 𝐜! from the data. Combining 
equation 4.1 for all samples and all factors leads to  
 𝐗 = 𝐃𝚵 + 𝐄 (4.2) 
 
where 𝐃 is a design matrix that shows the labeling of the samples in the experimental 
design. The matrix 𝚵 contains the parameters of the model (4.2) and can be estimated via 
least squares 
 𝚵 = 𝐃!𝐃 !!𝐃!𝐗 (4.3) 
 
For the numerical example in table the following matrices are obtained: 
 
𝐃 =
1 −11 −11 −11 11 11 1
, 𝚵 = 1.8 2.00.5 1.1  
 
 
The first column in the design matrix corresponds to the overall mean (𝛍). The second 
column indicates the label of each sample for factor 𝐜. The first and second rows in the 
effects matrix 𝚵 correspond to 𝛍 and 𝐜, respectively. Note that estimates of 𝛍 and 𝐜 can be 
obtained by multiplying the appropriate columns(s) from the design matrix with the 
corresponding rows of 𝚵. The same approach can be used for more complicated designs 
involving multiple factors and interactions. When the data is unbalanced, the calculations 
are slightly more involved. This is detailed further in appendix A. With respect to the 
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balanced example data, by multiplying the column in 𝐃 corresponding to factor 𝐜 (𝐃!) with 
the corresponding row in 𝚵 (𝚵𝒄), estimates for the group averages of factor 𝐜 are obtained:  
 
𝐗𝐜 = 𝐃𝚵𝒄 =
−1−1−1111
∗ 0.5 1.1 =
−0.5 −1.1−0.5 −1.1−0.5 −1.10.5 1.10.5 1.10.5 1.1
 
 
 
Matrix 𝐗! is called a hypothesis matrix. It contains estimates of the relevant group averages 
for a specific factor or interaction as rows. In this case the group averages 𝐜!. ASCA uses the 
hypothesis matrix to determine whether the corresponding factor was significant and which 
metabolites are related to the factor. 
 
As an example, let’s consider the problem of testing the following hypothesis: 
 𝐻:𝐗! = 0  vs  𝐴:𝐗! ≠ 0 (4.4) 
 
The aim of this hypothesis is to determine whether factor 𝐜 is significant (i.e. at least one of 
the group means 𝐜! differs from the other means). The null hypothesis is that there is no 
effect. To test whether the null hypothesis can be rejected, ASCA uses the sums-of-squares 
(SSQ) of the hypothesis matrix as a test statistic [13]. Note that under the null hypothesis 
(i.e. no significant effect), the group averages are expected to be zero since the data was 
centred. In this case small SSQ-values are expected. Large differences between the means 
(the rows in 𝐗!), and therefore a large SSQ, are expected when an effect is significant. The 
distribution of the test statistic under the null hypothesis is determined by a permutation 
test. We will demonstrate below that alternative statistics such as Wilks’ Lambda provide a 
more powerful test. 
 
If the group means are found to be significantly different, PCA is applied to the hypothesis 
matrix (e.g. 𝐗!). The 𝑘 − 1 PCs are linear combinations of the mean centred variables along 
which the distance between the group means is the largest (see figure 4.1). In this figure 
ASCA actually only “sees” the 2 group averages and neglects the spread of the samples 
around these averages represented by the ellipses. Their (standardized) loadings can be used 
to determine which metabolites were affected most by the hypothesis: high absolute values 
of the coefficients indicate great importance.  
 
We will show in section 4.2.3 that the ASCA model can be severely biased due to the fact 
that the spread of the samples around the group means is ignored. Because of this ASCA 
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may ascribe the wrong variables to a group difference. In some cases, a significant 
difference between the groups is not even detected. In this discussion it is useful to be able 
to show the connection between ASCA and MANOVA. An essential remark in this respect 
is that the PCs of 𝐗! (up to a scaling factor) are actually the same as the eigenvectors of the 
so-called matrix of the sum of squares and products due to the hypothesis, or, simply 
“between” matrix. The between matrix can be easily calculated from the hypothesis matrix. 
For example, for factor 𝐜 it is given by  
 𝐁 = 𝐗!!𝐗! = 𝐃!𝚵! !(𝐃!𝚵!) (4.5) 
 
A numerical example of this matrix is presented in the next section on MANOVA. 
 
As mentioned earlier, the expressions for the hypothesis matrix, and therefore 𝐁 as well, 
only apply for experiments with a balanced design. For unbalanced cases, so-called sums-of-
squares corrections have to be carried out to estimate the between matrix correctly. 
Appendix A contains more details on this point. 
4.2.2 MANOVA 
MANOVA is based on the same linear model (equations 4.1 and 4.2) as ASCA [6, 14]. The 
method assumes independency between the observations. The groups of each of the 𝑘 
experimental conditions are assumed to be multivariate normal with equal covariance 
matrices. In ANOVA the test statistic is based on a comparison of the between and within-
group variance for a specific variable. In MANOVA this is not a sufficient measure since the 
covariance between the variables has to be taken into account. Therefore, the between-group 
and within-group dispersion matrices are used. The between-group dispersion matrix 𝐁 we 
defined already in the equation 4.5. It represents the scatter of the group averages of a 
specific factor. The within-group dispersion matrix 𝐖 is the residual sum of squares and 
products, or “within” matrix.  
 𝐖 = 𝐗 − 𝐃𝚵 !(𝐗 − 𝐃𝚵) = 𝐄!𝐄 (4.6) 
 
The matrix 𝐖 is a measure of the scatter of the samples within a group around their group 
mean as represented in figure 4.1 by the ellipses. In analogy with ANOVA, a ratio is formed 
between the between-group dispersion and the within-group dispersion to determine 
whether and effect is significant. More specifically, hypothesis tests in MANOVA are based 
on the matrix  
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𝐉 =𝐖!!𝐁 (4.7) 
 
For the example in table 4.1, the matrices B, W, and 𝐉 are equal to: 
 𝑩 = 1.6 3.53.5 7.5 ,𝐖 = 4.0 −1.2−1.2 1.3 , 𝐉 = 1.5 3.34.0 8.7   
 
Note that these matrices have dimension 2  𝑥  2  since the example only involves two 
metabolites. 
 
The 𝑘 − 1 eigenvectors of 𝐉 are linear combinations of the mean-centred variables along 
which the distance between the group means is the largest compared to the variation within 
the groups. An example is presented in figure 4.1 for 𝑘 = 2 and 𝑝 = 2. Large absolute 
coefficients of the (standardized) eigenvectors indicate metabolites that change significantly 
in concentration when the experimental conditions are changed. 
 
MANOVA hypothesis tests are based on the eigenvalues (𝜆!𝑱) of matrix 𝐉. These eigenvalues 
are a measure of the ratio of the between group dispersion and the within-group dispersion 
along the direction of the eigenvectors. There are four MANOVA test for significance: 
Wilks’ Lambda, Pillai’s trace, Hotellings trace and Roys greatest root [6]. These four test 
statistics do not always agree and their power is different under various conditions. In this 
work we use Wilks’ Lambda (Λ) which is one of the more popular test statistics 
 Λ = 1/(1 + 𝜆!𝑱)!  (4.8) 
 
where the product runs from 𝑗 = 1 to 𝑗 = min  (𝑘 − 1, 𝑝). Large differences between the 
experimental conditions result in large eigenvalues of 𝐉 and therefore a smaller value of 
Wilks lambda. The null distribution of Wilks’ Lambda is often approximated by an F-
distribution. 
 
When the number of metabolites is larger than the number of samples (𝑛), the inverse of 
matrix 𝐖 cannot be computed and MANOVA breaks down. Essentially, the estimate of 𝐖 
(and therefore the MANOVA model) is unreliable since it suffers from high variance. 
Unfortunately, this is often the case in metabolomics experiments. Even when 𝑝 is close to 𝑛, 𝐖 becomes unstable in the sense that small perturbations in measurements can lead to 
disproportionately large fluctuations in its elements. 
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4.2.3 Comparing ASCA and MANOVA 
The similarities and dissimilarities between the ASCA and MANOVA model are evident 
when considering identification of important metabolites by the methods. As mentioned 
above, both techniques estimate eigenvectors for this purpose, where high absolute 
coefficients indicate important metabolites. However, these eigenvectors are estimated from 
different matrices. MANOVA uses eigenvectors of 𝐉 =𝐖!!𝐁, while ASCA uses eigenvectors 
of 𝐁. From the viewpoint of MANOVA, ASCA assumes that the within matrix 𝐖 is equal to 
the identity matrix 𝐈. This assumption has important consequences. It implies that the 
concentrations of metabolites are uncorrelated to each other and that the variance of all 
metabolite concentrations equals a constant. This can easily be seen when comparing two 
groups of samples with means 𝐜! and 𝐜!.  
 
By definition, the direction along which these groups are most separated is given by (𝐜! − 𝐜!)𝐖!!. Note that this is an eigenvector of 𝐉 =𝐖!!𝐁; the MANOVA model finds an 
estimate for this direction. ASCA, however, assumes that 𝐖 = 𝐈. Therefore, the direction 
found by this approach is equal to the difference between the group means 𝐜! − 𝐜!. This 
implies that ASCA determines the metabolite importance in a univariate way ignoring the 
shape of the data cloud around the averages, i.e. the ellipses in figure 4.1: the importance is 
determined by considering each metabolite on its own. The most important metabolite is 
the one along which the groups are most separated. The variances around these averages are 
not taken into account. We will show in a simulation that the ranking can be improved by 
first scaling the data by the within-group variances (the diagonal elements of matrix 𝐖). 
However, in this case the ranking of the metabolites is still univariate: the coefficients of the 
resulting eigenvector are essentially two-sample t-statistics. 
 
It is known that metabolites may correlate with one another. Therefore, the metabolite 
independence assumption made by ASCA is most likely false and its estimate for 𝐖 can be 
severely biased. This has two implications: (i) ASCA has lower power compared to 
MANOVA in many situations, and (ii) ASCA cannot always correctly identify the most 
important metabolites.  
4.2.4 Regularized MANOVA 
MANOVA is not applicable when 𝑛   <<   𝑝  due to high variance of the estimate of 𝐖. ASCA 
is applicable in every situation, but the method is severely biased. Instead of choosing 
between one of these models, we suggest to combine them in the following way: 
 𝐉∗ = 1 − δ 𝐖 + δ𝐓 !!𝐁 (4.9) 
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The matrix 𝐓  indicates a target or prior structure of 𝐖  and will be discussed more 
thoroughly below. We will refer to this model as regularized MANOVA (rMANOVA).  
Regularization is used in many multivariate methods to obtain efficient estimators for high 
dimensional data, i.e. ridge regression. The parameter 𝛿 ∈ [0, 1] and can be used to select a 
trade-off between bias and variance. The ASCA model (𝛿 = 1,T   =   𝐈) is all bias and no 
variance. MANOVA (𝛿 = 0) is all variance and no bias. The optimal value for 𝛿 (𝛿!"#) is 
calculated in a fast and analytic way according to the Ledoit-Wolf theorem [15]. This lemma 
has been employed with great success in many applications such as stock market prediction, 
portfolio optimization, weather forecasting, economic forecasting, and genomics [16-19]. 
 
The optimum 𝛿!"# depends on the target matrix 𝐓. The choice of the target should be guided 
by the expected structure of matrix 𝐖. In this work we will investigate two targets:  
 
• Average variance: 𝐓! = !! 𝑡𝑟 𝐖 𝐈 
• Unique variance: 𝐓! = 𝑑𝑖𝑎𝑔(𝐖) 
Target one assumes the same variance for each metabolite and is very similar to the ASCA 
target that has been discussed so far. The disadvantage of the target used in ASCA (𝐓 = 𝐈) is 
that the variance assumed by this target does not reflect the true variance in the data. The 
term !! 𝑡𝑟 𝐖 = 𝜈 in 𝐓!is an estimate of the average variance in the data. The optimum 𝛿!"# 
for this target is given by Ref. [18]: 
  δ!"#! = 𝑉𝑎𝑟 𝑤!" + 𝑉𝑎𝑟(𝑤!!)!!!! 𝑤!"! + 𝑤!! − 𝜈 !!!!!  (4.10) 
 
where 𝑤!" indicates the 𝑖𝑗th element of 𝐖.  It can be seen that 𝛿!"# is driven by the data, 
expressed in 𝑉𝑎𝑟 𝑤!!  the variance of the 𝑖𝑗th element of 𝐖. The choice of the target should 
be guided by the expected structure of matrix 𝐖. The second target assumes that the 
concentration of each metabolite can have a different variance. The optimal value for 𝛿!!" 
for this target is given by Ref. [18]: 
  δ!"#! = 𝑉𝑎𝑟 𝑤!"!!! 𝑤!"!!!!  (4.11) 
 
Regularization of a MANOVA model with this target has been successfully applied in the 
context of gene set analysis for data with a one-way design [16]. However, the properties of 
the method were explored far less extensively compared to the present paper. Note that 
complete shrinkage to target 𝐓! (δ!"#! = 1) gives the same model as the traditional ASCA 
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model applied to data that was scaled by the “variances” in 𝐓!, i.e. that was scaled by the 
diagonal elements with the within-group scatter matrix 𝐖. As mentioned in section 4.2.3 
the results of this ASCA model are closely connected to those that would be obtained by t-
tests. Other targets than 𝐓!  and 𝐓!  can also be used, i.e. targets that incorporate prior 
knowledge from metabolic pathways. In this study targets 𝐓! and 𝐓! were selected because 
they demonstrate the connection between ASCA and rMANOVA. Additionally, these 
targets only require a few parameters to estimate. Therefore they have low variance. Because 
of this, the regularization in equation 4.9 offers a bias-variance trade-off.  
 
Similar to MANOVA, eigenvalues of 𝐉∗ are used to calculate the Wilks’ Lambda statistic (Λ∗) 
and test for significant differences between the groups. Unfortunately, the distribution of Λ∗ 
under the null hypothesis is unknown. A permutation test can be used to estimate this 
distribution from the data. In this work we use a sequential permutation test [20, 21]. 
Sequential tests give similar results as conventional tests, but are computationally less 
demanding because permutation is stopped when there seems to be little evidence against 
the null hypothesis. In this study the rows of data matrix 𝐗 are shuffled in each permutation. 
Alternative permutation strategies for ANOVA are discussed in [22, 23]. When an effect is 
significant the eigenvectors of 𝐉∗ can be used to determine the important metabolites. Often 
it is useful to standardize the coefficients of the eigenvectors. We will refer to the 
standardized eigenvectors as discriminant functions (𝐃𝐅). We will use this term for 
eigenvectors found by ASCA, MANOVA and rMANOVA. 
4.3 Methods 
We used two simulation designs and real data to compare ASCA, MANOVA and 
rMANOVA. 
4.3.1 Simulation design 1 
The first simulation was carried out to highlight the implications of the metabolite 
independence assumption of ASCA. Data corresponding to a one-way design with two 
levels was simulated. The data contained five metabolites with variances [1,1,3,1,1]. The 
group averages were 𝛍! = 0,0,0,0,0  and 𝛍! = [0,2,10,0,0] . The covariance between the 
metabolites was zero, except for the covariance between metabolites 1 and 2, which was set 
to 0.9. For each group, 500 samples were drawn from a multivariate normal distribution.  
The simulated concentrations of the five metabolites are shown in figure 4.2a. The samples 
corresponding to the first group are color coded in red, and those belonging to the second 
group are color-coded in blue. It is clear from the figure that the groups are not separated  
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Figure 4.2   (a) Scatterplot of simulated metabolite concentrations for two experimental conditions or groups 
(red and blue) as defined in simulation 1. (b) The importance of the metabolites to separate these groups as 
determined by 5 methods. Note that the “oracle” indicates the standardized weights that are expected 
theoretically. The unstandardized weights are given by !!! ! !!!!!!!.  
along metabolites 4 and 5. The groups are separated along metabolite 3 since the difference 
between the group averages !! and !! is 10 along this metabolite. However, the within-
group variance is 3 and therefore the separation is still quite poor. The groups are clearly 
different, however, on the first two metabolites. This difference is related to the correlation 
between the metabolites and can only be observed when the metabolites are studied 
together, i.e. by a truly multivariate method. From a univariate perspective, the groups are 
not separated along metabolite 1 and somewhat separated along metabolite two. Based on 
these considerations, analysis of the data should mark metabolites 1 and 2 as most 
important.  
4.3.2 Simulation design 2 
The power of ASCA and rMANOVA tests was compared by simulation design 2. A balanced 
one-way design with ! ! ! experimental conditions was considered. In each simulation the 
number of metabolites (!) was set to 100 and the number of samples in each experimental 
condition !! was 20. Note that ! indicates the !th experimental condition. The samples were 
drawn from multivariate normal distributions !!!! !!!.  
 
The covariance matrix ! was equal for each condition. The variance of each metabolite – the 
diagonal elements of the covariance matrix (!) – was drawn from the uniform distribution 
!!!!!!!"!. Next, these variances were combined with a specific correlation matrix ! to form 
the covariance matrix ! . It is difficult to simulate correlation structures that closely 
resemble the complex structures of metabolomics data. Therefore, we studied a number of 
“simple” structures to be able to systematically explore the properties of!"#$!%&'()*'!
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Figure 4.3   A graphical representation of (a) the common correlation, (b) the block diagonal, (c) the Toeplitz, 
and (d) the sparse correlation structures with ! ! !!! that were used in simulation 2. Structures (a-c) are equal 
to an independent structure when ! ! !. This is shown in panel e. 
method. Note that the simulated data contains some aspects of real metabolomics data such 
as correlations between variables, grouping of variables, and! +%%$,$-./"! /0+1$! -.%+.2,$13!
We applied rMANOVA to real NMR metabolomics data to study its performance for more 
complicated correlation patterns (see section 4.3.3.).  
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The following four correlation structures between the metabolites were considered in the 
simulation study:  
 
1. R1 Common correlation: all variables were correlated to each other with value 𝜌   
2. R2 Block-diagonal: variables were correlated to each other with value 𝜌 within 
blocks. The different blocks were uncorrelated. Twenty blocks were defined; each 
block contained 5 subsequent variables. The first five variables corresponded to 
the first block, the next five to the second block, etc. 
3. R3 Toeplitz structure: variables close to each other were more highly correlated 
compared to variables that were far apart. The distance between variables with 
indices 𝑝1 and 𝑝2 was defined as 𝑝1 − 𝑝2 . For example, the distance between the 
first and fourth variable in the data is equal to three. The correlation between 
metabolites was given by 𝜌 !!!!! . 
4. R4 Sparse structure: the word sparse here indicates that many variables were 
uncorrelated to each other. The correlations between the variables were drawn 
from a uniform distribution 𝑈(0,1). This did not immediately result in a sparse 
matrix. Therefore, 95% of the off-diagonal elements of the matrix were set to zero. 
Subsequently the off-diagonal elements were divided by a constant 𝑐 to ensure that 
the matrix was positive definite. 
The following correlation values were used in structures R1, R2, and R3: 𝜌 ∈ 0, 0.2, 0.4, 0.6, 0.8, 0.95 .  Note that when the correlation was set to zero, an independent 
structure was obtained. A graphical representation of the different covariance structures is 
shown in figure 4.3. 
 
In this simulation it was investigated how well differences between the four experimental 
conditions could be identified when the group means 𝛍! were shifted in different ways. The 
following shifts were considered:  
 
1. S1: The mean of each group was zero for most variables and equal to 𝛾 on five 
variables. For the first group, the first five variables were nonzero, for the second 
group the next five, etc. 
2. S2: As S1, but only the first and the last group were shifted by – 𝛾 and 𝛾, 
respectively. The second and third group had zero mean on all variables. From 
ANOVA power studies it is known that this shift is more difficult to detect 
compared to shift S1.  
3. S3: The groups were shifted along eigenvectors of the covariance matrix 𝚺. The 
first group was shifted along the eigenvector with the highest eigenvalue by 𝛾√(𝜆!!  ) 
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units , where 𝜆!! corresponds to the eigenvalue. The next group along the 
eigenvector with the second highest eigenvalue (𝜆!!) by 𝛾√(𝜆!!  ) units, etc. In other 
words, the groups are shifted along the directions where the variation within the 
groups was the largest.  
4. S4: As S3, but now the groups were shifted along the eigenvectors with the lowest 
eigenvalues. The groups were thus shifted along the directions where the variation 
within the groups was the smallest. 
Note that for shift S1 and S2 the groups differ on a few metabolites. Scenarios S3 and S4 are 
extreme cases where the groups were shifted along the direction of the maximum and 
minimum within-group variance, respectively. The effect size 𝛾 was varied between zero and 
2 in steps of 0.2. Note that 𝛾 = 0 corresponds to the null hypothesis of no significant group 
differences. Each simulation was repeated 1000 times. Each time, a permutation test with 𝑚   =   1000 permutations was used to assess significance. To fairly compare ASCA and 
rMANOVA, both the SSQ and Wilks’ Lambda were used to test the significance in the 
ASCA models. Note that MANOVA could not be applied in this simulation since it involved 
more variables than samples. 
4.3.3 Nutritional intervention study 
In this so-called Lower study, the metabolic response and loss of body fat due to four diets 
was studied in individuals suffering from metabolic syndrome [24]. 313 Subjects were on 
one of four isocaloric diets. Diets used were: (a) sustained protein normal carbohydrate; (b) 
sustained protein low carbohydrate; (c) supra sustained protein normal carbohydrate; and 
(d) supra sustained protein low carbohydrate (percentages protein : carbohydrate : fat 
amounted to: (a) 30 : 35 : 35; (b) 30 : 5 : 65; (c) 60 : 35 : 5 ; (d) 60 : 5 : 35). For each patient, 
urine samples were collected at the start of the study; after 3 months; and after 12 months. 
At the end of the study, each individual was flagged as responder or non-responder based 
on the amount of weight loss. Good responders lost more than 6% of the initial body weight 
while bad responders lost <6% in 3 months. NMR measurements were done on urine 
samples of 64 subjects, being the best and the worst responders in each of the arms of this 
study. 
 
The urine samples were analysed by 1H-NMR spectroscopy according to the protocol 
described in Wevers et al. [25]. Correlation optimized warping, histogram matching, and 
adaptive-intelligent binning were used for alignment, normalization and binning of the 
spectra, respectively [26-28]. Additionally, the bin at 3.16 ppm was removed from the data. 
This resonance, present in multiple samples, is associated to metformin, which is a drug that 
is often used in the treatment of (type II) diabetes patients. Robust PCA analyses of the data 
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showed four clear outlying patients because of high ethanol signal at 1.17 ppm or a high 
unknown peak in the glucose region around 3.53 ppm [29]. Additionally, one patient was a 
type I diabetic. Further analysis excluded the type I diabetic and the outlying patients. The 
final data set contained 59 individuals and 530 bins. 
 
Next, ASCA and rMANOVA were used to study the contrast between the data at the start of 
the study and after three months. Due to the limited amount of samples, the analysis 
focused on the responder (r) and diet (d) effects only. Note that this corresponds to a two-
way design. The following model was fit to the data: 
 𝐱!"#!!!!!!! = 𝛍 + 𝐫! + 𝐝! + 𝐞!"# (4.12) 
 
Here, index 𝑖 indicates the 𝑖-th responder group, index 𝑗 indicates the 𝑗-th diet, and index k 
the 𝑘-th sample. A permutation test with 𝑚   =   1000 permutations was used to determine 
the significance of each effect. In case of significant effects the coefficients of the 
discriminant function were used to identify metabolites related to this effect. 
4.4 Results 
Below, two simulation studies and analysis of real data are used to demonstrate the 
properties of ASCA, MANOVA, and rMANOVA. The first simulation shows the drawback 
of the variable independence assumption made by ASCA and that the method offers a 
different – essentially univariate – view of the data. On the other hand, MANOVA offers a 
truly multivariate view of the data. In the second simulation the power of ASCA and 
rMANOVA is compared under scenarios where MANOVA cannot be applied. Finally, the 
value of rMANOVA compared to ASCA is also demonstrated for analysis of real 
metabolomics data.  
4.4.1 Effect of metabolite dependence: selection of wrong variables by ASCA 
In simulation 1, the concentrations of 5 metabolites and an underlying balanced one-way 
design with 3 levels were simulated as shown in figure 4.2a. As mentioned earlier, analysis 
of the data should mark metabolites 1 and 2 as most important for separation of the groups. 
The perfect separation can only be observed when the correlation between both metabolites 
is taken into account. From a univariate perspective, the groups are not separated along 
metabolite 1 and somewhat separated along metabolite two.  
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In figure 4.2b, the coefficients of the discriminant function found by MANOVA are shown. 
High weights indicate important metabolites. It is clear that the model marks metabolites 1 
and 2 as most important. Actually, the importance values found by MANOVA are very close 
to the theoretical values indicated as “oracle” in the figure. The metabolite importance as 
given by ASCA and two univariate approaches is also shown in figure 4.2b. ASCA does not 
mark metabolites 1 and 2 as most important. As expected, the univariate approaches do 
neither. It is clear, that the results found by ASCA and the univariate approaches are exactly 
the same. When the average variance target (T1) is used, the metabolite importance is 
proportional to the difference of the group means. The difference between the group 
averages is the largest along variable 3 and therefore this metabolite is marked as most 
important. However, this way the variance of the data around these averages is ignored. It 
can be seen in figure 4.2a that the overlap between the two groups is actually quite severe. 
Therefore, a false interpretation of the data is obtained when the variance of each metabolite 
is ignored. When using target 𝐓!, the results are the same as those found by the two-sample 
t-test. In this case the group differences are studied relative to the variance of each 
metabolite. Therefore, metabolite two is marked as most important, followed by metabolite 
3. The correlation between variables 1 and 2 is not observed. 
 
This simulation shows that independence rules can select the wrong variables and 
essentially offer the same view of the data as univariate tests do. As a result, ASCA tests have 
lower power than MANOVA in many situations. Unfortunately, as mentioned above, 
MANOVA is not applicable when the number samples is less than the number of 
metabolites or variables. We propose a weighted average between the ASCA and MANOVA 
models. The resulting regularized MANOVA test aims to use as much information 
regarding between-metabolite correlations as the data allows. Compared to ASCA, this 
strategy deals more efficiently with situations where the number of samples is less than the 
number of variables. 
4.4.2 The power of the tests: rMANOVA has more power in most situations 
The power of the ASCA and rMANOVA tests was compared by simulation design 2. As 
mentioned in the methods section, the tests were compared over a wide range of correlation 
structures (R1-R4) and four different shifts of the group means. The patterns observed in 
the power simulations were similar across different correlation structures. Therefore, we 
mainly discuss the results for common correlation structure R1. All other results are 
provided in appendix B.  
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Figure 4.4   The power of the ASCA and rMANOVA tests as a function of the effect size (!) in the case of the 
common correlation structure and shift direction S1, i.e. the groups differ on a few metabolites. Panels a-c 
correspond to ! ! !! !!!!!!"#!!!!, respectively.  Note that in panel c the ASCA model that uses the SSQ test has 
poor performance, even when the effect size is large. 
Figure 4.4 illustrates the empirical powers for different effect sizes !  and different 
correlations ! when the groups are shifted according to structure S1, i.e. the groups differ 
on a few metabolites. The power is defined as the percentage of simulations in which the 
method marked the groups as significantly different. For all methods, the type I errors are 
reasonably close to the chosen significance level of 5%, which can be observed when ! ! !. 
It can be seen that rMANOVA clearly has the highest power to detect differences between 
the groups (! ! !). The largest different between the methods was observed for ! ! !!! as 
shown in panel c. In this case the ASCA tests had low power even when the effect was large. 
Only in cases of zero correlation (panel a) do the methods have similar power: here the 
independence assumption made by ASCA is correct. Note that for all tests the power 
increases with the effect size. If ! is large enough, the ASCA test can also detect a difference 
between the groups. In this case, prior !! has the greatest power since it takes the variance  
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Figure 4.5   The power of the ASCA and rMANOVA tests as a function of the effect size (!) in the case of the 
common correlation structure with ! ! !!!. Panels a-d correspond to shifts S1-S4, respectively. Note that for 
shift S1 and S2 the groups differ on a few metabolites. Scenarios S3 and S4 are extreme cases where the 
groups were shifted along the direction of the maximum and minimum within-group variance, respectively. 
in the concentration of all metabolites into account. Note that the power of the SSQ test is 
considerably lower compared to the other tests, which are based on Wilks’ Lambda. 
 
The power under different shifts S1-S4 with ! ! !!! is shown in figure 4.5. Note that for 
shift S1 and S2 the groups differ on a few metabolites. Scenarios S3 and S4 are extreme 
cases where the groups were shifted along the direction of the maximum and minimum 
within-group variance, respectively. As expected, the power of the tests to detect shift S2 
was lower compared to shift S1 since the group means were more similar. Similar to S1, 
however, rMANOVA clearly had the best power. ASCA had the greatest power when the 
groups are shifted in the direction of the maximum within-group variance (S3), as can be 
expected. For case S4, only a high power is achieved with rMANOVA using a unique 
variance target !!. In this case, target !! (average variance) overestimates the variance in 
these directions.  
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Table 4.2   Standardized AUC of the size power curves for three ASCA and two rMANOVA tests for shift 
direction S1. The best performing test is indicated in boldface. Note that rMANOVA with a unique variance 
prior performed best in most cases. 
   ASCA  rMANOVA  
Correlation 
structure 
Correlation SSQ 
Average 
variance (T1) 
Unique 
variance (T2) 
Average 
variance (T1) 
Unique variance 
(T2) 
       
R1 Common 
correlation 
(Figure 4.3a) 
0.00 0.42 0.45 0.58 0.46 0.57 
0.20 0.19 0.26 0.39 0.41 0.44 
0.40 0.11 0.19 0.30 0.50 0.56 
0.60 0.08 0.17 0.28 0.59 0.62 
0.80 0.06 0.16 0.26 0.68 0.71 
0.95 0.07 0.19 0.28 0.80 0.83 
R2 Block 
Diagonal 
(Figure 4.3b) 
0.00 0.40 0.46 0.57 0.45 0.57 
0.20 0.41 0.41 0.55 0.40 0.53 
0.40 0.38 0.35 0.48 0.36 0.46 
0.60 0.32 0.32 0.45 0.30 0.41 
0.80 0.26 0.28 0.41 0.31 0.42 
0.95 0.21 0.25 0.35 0.34 0.48 
R3 Toeplitz 
(Figure 4.3c) 
0.00 0.39 0.44 0.57 0.46 0.57 
0.20 0.38 0.44 0.56 0.46 0.57 
0.40 0.38 0.41 0.52 0.42 0.52 
0.60 0.31 0.34 0.49 0.41 0.50 
0.80 0.23 0.25 0.38 0.48 0.57 
0.95 0.09 0.17 0.27 0.69 0.75 
R4 Sparse 
(Figure 4.3d) 
- 0.39 0.41 0.53 0.43 0.53 
      
  
In table 4.2, the AUC of the size power curves of shift S1 is shown for all methods and all 
correlation structures. Similar tables for shifts S2-4 are available in supplementary material 
B. In all tables, the best performing method (the highest AUC) is highlighted in boldface. 
Again, unique variance (𝐓!) seems to outperform the SSQ and 𝐓! tests which assume equal 
variance for all metabolites. Additionally, rMANOVA has the highest power for shift S1, S2 
and S4. For the sparse covariance structure (R4) shrinkage did not greatly improve the 
power. This lack of difference is due to properties of our simulation: the sparse covariance 
structure was very close to diagonal to satisfy the semi-positive definite constraint (see 
figure 4.3). 
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Table 4.3   The significance of factors responder and diet given by the ASCA and rMANOVA tests. The 
parameter 𝛿 indicates the amount of shrinkage towards the target. Note that 𝐓! and 𝐓! indicate an average 
variance and a unique variance prior, respectively. 
Model p-value responder p-value diet 𝛿 
    
ASCA SSQ 0.57 0.38 1 
ASCA T1 0.57 0.67 1 
ASCA T2 0.08 0.04 1 
rMANOVA T1 0.04 0.02 0.27 
rMANOVA T2 0.01 0.00 0.48 
 
4.4.3 Real data 
Metabolic syndrome is an important risk factor for developing diabetes or cardiovascular 
disease amongst others. A possible therapy is to influence the metabolism by changing food 
intake patterns. In this study, the metabolic response and loss of body fat due to four diets 
was studied in individuals suffering from metabolic syndrome. The main aim was to assess 
differences in metabolic response between responders and non-responders to the diet, 
where a responder was defined as an individual who lost more than the average amount of 
weight during the study. 
 
In table 4.3, the results of the different models are shown. It can be seen that rMANOVA 
uses some correlation information in the model since 𝛿 < 1. The ASCA tests cannot use this 
information. This is reflected in the p-values observed for the methods. The regularized 
methods (rMANOVA) mark both factors as significant, while ASCA does not. ASCA in 
combination with 𝐓! does give p-values below a significance limit of 10%. However, when a 
limit of 5% is employed only the diet factor is marked as significant. In figure 4.6, the 
density of the samples projected onto the discriminant function for the response factor is 
shown. It is clear that rMANOVA separates the two groups much clearer compared to 
ASCA.  
 
Since the main aim of the study was to assess the metabolic differences between responder 
and non-responder the absolute coefficients of the responder discriminant function were 
inspected to identify important metabolites. Unfortunately, the function was rather noisy 
and important metabolites could not easily be identified. As a first tentative approach, the 
25 largest absolute coefficients of the discriminant function were used to identify important 
metabolites. The important metabolites included beta-hydroxybutyric acid (1.22/1.24 ppm), 
acetone (2.22 ppm), and acetoacetic acid (2.30 ppm), collectively referred to as the ketone 
bodies. These ketone bodies are related to the breakdown of fatty acids for energy supply. 
This process is known to be triggered during caloric restriction and during starvation.  
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Figure 4.6   Density plots of the data projected onto the discriminant functions found by ASCA with targets (a) 
average variance (𝐓!) and (b) unique variance (𝐓!) and rMANOVA with targets (c) 𝐓! and (d) 𝐓!. 
Responders are consuming their fat reserve more than non-responders leading to an 
increased amount of ketone bodies. The obvious next step in the analysis is to determine the 
important metabolites more carefully, possibly leading to new biological knowledge. This 
might involve a variable selection procedure such as sure independence screening, or direct 
sparse estimation of the discriminant functions. Such analyses, although interesting in their 
own right, are beyond the scope of this article. 
4.5 Discussion 
All test statistics that were proposed in this study are based on Wilks’Lambda and had 
higher power compared to the current ASCA SSQ statistic. Additionally, rMANOVA had 
higher power compared to ASCA. In general, the power of the tests seems to increase in the 
order SSQ < ASCA 𝐓! < ASCA 𝐓! < rMANOVA 𝐓! < rMANOVA 𝐓!. The lower performance 
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of the first three tests comes from the fact that the structure underlying the metabolite 
concentrations (i.e. a metabolic pathway) is ignored. However, the tests based on an 
independence rule had greater power when the groups were shifted in the direction of the 
maximum within-group variance. In practice, however, a metabolomics experiment is 
carried out according to an experimental design because the effect of interest is expected to 
be subtle. Therefore the groups are most likely not shifted in the direction of maximum 
variance. Additionally, such a case can most likely also be detected by regular PCA analysis 
of the data. Cole et al. studied how the power of MANOVA can both increase and decrease 
as a function of within-group correlations among the dependent variables [30]. They 
revealed that (a) power increases as correlations between dependent variables with effect 
sizes in the same direction move from near 1 to -1; (b) power increases as the correlation 
between variables with very different effect sizes becomes more positive or negative; and (c) 
power increases as correlations between dependent variables with small effect sizes shift 
from positive to negative. In light of these findings and our simulation results, we expect 
rMANOVA to be a very competitive alternative to ASCA in most situations. 
 
In practical applications, the assumption of symmetric and equal covariance made by the 
methods may not hold. For example, distributions of metabolite concentrations can often be 
better approximated by a log-normal distribution. This can be addressed using a log-
transformed version of the data. The metabolite intercorrelations in a group of diseased 
subjects can be very different from those in a group of healthy controls. In MANOVA 
literature, it is well known that Wilks’ lambda is not the most robust statistics against such 
violations from the model assumptions [6]. It would be of interest to explore the relative 
merits of ASCA and rMANOVA; especially in situations where the assumptions made by the 
model are violated. Other approaches such as non-parametric MANOVA, Dempster’s non-
exact test, Srivastava’s test, and the Chen-Qin test could also be of interest in this respect 
[31-33]. Note that these approaches do not automatically generate discriminant functions 
and their results are most likely less easy to interpret compared to the approach suggested in 
the present paper. 
 
Often the assumption that errors are identically and independently distributed is violated as 
well; when analysing longitudinal data, for example. It would be interesting to use a mixed-
effect model in such cases. However, it is not directly evident how the relationship between 
time and all the metabolites should be specified. Other possibilities include the study of 
contrasts (as in this paper), summary statistics, or using a repeated measurements 
MANOVA strategy [34]. 
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4.6 Conclusion 
In metabolomics research, it has become increasingly popular to analyse data with an 
underlying experimental design. In this work, we have discussed this analysis problem in 
the context of ASCA and MANOVA. We propose the regularized MANOVA model, which 
is a weighted average of the ASCA and MANOVA models. This way, correlations can be 
included and the model can be applied in situations when MANOVA cannot, for example 
the analysis of high dimensional metabolomics data. Numerical examples have 
demonstrated that the rMANOVA method has higher power compared to ASCA under a 
wide range of scenarios and offers a more realistic view of the data. Here, rMANOVA was 
introduced for analysis of metabolomics data, but the method can be applied for analysis of 
any high-dimensional data set with an underlying experimental design.  
 
This work also brings additional insight into the ASCA method. We have shown that ASCA 
assumes that the metabolite concentrations are independent, and therefore the method 
offers a similar view of the data as univariate techniques do. Additionally, it was shown that 
the SSQ-statistic used to test significance in ASCA has low power. The power of ASCA can 
be improved by using the Wilks’Lambda test and by a suitable scaling of the data. However, 
the improved ASCA test is still suboptimal in many cases.  
 
The rMANOVA source code is available from the first author upon request, and also at the 
following github repository: https://github.com/JasperE/regularized-MANOVA. 
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Appendices 
A. Sums-of-squares corrections for unbalanced data 
Consider data with an underlying design with two main effects. In this case the following 
model is suitable:  
 x!"# = µμ + α! + β! + e!"# 
 
However, there is no reason why factor α should be fitted before factor β or the other way 
around. The following model is also suitable:  
 x!"# = µμ + β! + α! + e!"# 
 
Actually, when analysing balanced data the sequence in which the main effects enter the 
model doesn’t matter. Their contributions to the fit will be the same. Unfortunately, this is 
not the case when analysing unbalanced data. In this case the upper two models cannot be 
used for the same purpose. In the first model, the contribution of factor α is estimated 
before all other effects. Therefore, the estimated effect of α, say X!, can be interpreted as the 
contribution of factor α while ignoring main effect β. In the second model, X!'  can be 
interpreted as the contribution of factor α given factor β (X ! ! ). Clearly, careful thought 
should be paid to which model is analysed for unbalanced data.  
 
Studying effects given the other main effects is also referred to as type-II sums of squares 
correction in ANOVA. In this example, such a correction can be achieved by comparing the 
residual sums of squares of a full model that contained all effects (W!,!) to that of a reduced 
model that did not contain the factor of interest (W!). The corrected sums of squares are 
given by B ! ! = W!,!-­‐W!. Studying effects given the other main effects and interactions is 
known as type-III sums of squares.  
  
Chapter 4 
 108 
B.  The AUC of the size power curves of shifts S2-4. 
Table B.1.   Standardized AUC of the size power curves for three ASCA and two rMANOVA tests for shift S2. The 
best performing test is indicated in boldface. Note that rMANOVA with a unique variance prior performed best 
in most cases. 
   ASCA  rMANOVA  
Correlation 
structure 
Correlation SSQ 
Average 
variance (T1) 
Unique 
variance (T2) 
Average 
variance (T1) 
Unique variance 
(T2) 
       
R1 Common 
correlation 
(Figure 4.3a) 
0.00 0.21 0.23 0.40 0.26 0.39 
0.20 0.11 0.12 0.19 0.21 0.22 
0.40 0.06 0.10 0.14 0.27 0.34 
0.60 0.08 0.10 0.14 0.39 0.42 
0.80 0.06 0.09 0.12 0.50 0.55 
0.95 0.07 0010 0.14 0.70 0.73 
R2 Block 
Diagonal 
(Figure 4.3b) 
0.00 0.21 0.25 0.37 0.24 0.37 
0.20 0.18 0.21 0.36 0.21 0.34 
0.40 0.16 0.17 0.28 0.19 0.27 
0.60 0.16 0.16 0.25 0.15 0.22 
0.80 0.12 0.15 0.23 0.17 0.26 
0.95 0.16 0.14 0.18 0.17 0.28 
R3 Toeplitz 
(Figure 4.3c) 
0.00 0.24 0.24 0.38 0.26 0.38 
0.20 0.25 0.25 0.38 0.24 0.36 
0.40 0.22 0.23 0.32 0.22 0.32 
0.60 0.17 0.17 0.28 0.21 0.29 
0.80 0.14 0.12 0.19 0.23 0.33 
0.95 0.07 0.10 0.13 0.48 0.57 
R4 Sparse 
(Figure 4.3d) 
- 0.20 0.20 0.33 0.26 0.33 
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Table B.2.   Standardized AUC of the size power curves for three ASCA and two rMANOVA tests for shift S3. The 
best performing test is indicated in boldface. Note that ASCA performed best in many cases. 
   ASCA  rMANOVA  
Correlation 
structure 
Correlation SSQ 
Average 
variance (T1) 
Unique 
variance (T2) 
Average 
variance (T1) 
Unique variance 
(T2) 
       
R1 Common 
correlation 
(Figure 4.3a) 
0.00 0.65 0.67 0.59 0.66 0.59 
0.20 0.72 0.71 0.70 0.56 0.47 
0.40 0.70 0.72 0.70 0.54 0.50 
0.60 0.70 0.71 0.71 0.53 0.47 
0.80 0.69 0.69 0.68 0.48 0.43 
0.95 0.69 0.69 0.68 0.45 0.36 
R2 Block 
Diagonal 
(Figure 4.3b) 
0.00 0.67 0.69 0.59 0.66 0.59 
0.20 0.72 0.71 0.67 0.69 0.66 
0.40 0.72 0.73 0.69 0.69 0.67 
0.60 0.73 0.75 0.71 0.68 0.67 
0.80 0.75 0.75 0.72 0.69 0.69 
0.95 0.75 0.76 0.72 0.68 0.70 
R3 Toeplitz 
(Figure 4.3c) 
0.00 0.67 0.67 0.60 0.67 0.60 
0.20 0.69 0.70 0.64 0.68 0.63 
0.40 0.73 0.73 0.68 0.69 0.67 
0.60 0.76 0.75 0.74 0.70 0.69 
0.80 0.77 0.78 0.77 0.69 0.70 
0.95 0.65 0.67 0.59 0.66 0.59 
R4 Sparse 
(Figure 4.3d) 
- 0.72 0.71 0.70 0.56 0.47 
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Table B.3.   Standardized AUC of the size power curves for three ASCA and two rMANOVA tests for shift S4. The 
best performing test is indicated in boldface. Note that rMANOVA with a unique variance prior performance 
best. 
   ASCA  rMANOVA  
Correlation 
structure 
Correlation SSQ 
Average 
variance (T1) 
Unique 
variance (T2) 
Average 
variance (T1) 
Unique variance 
(T2) 
       
R1 Common 
correlation 
(Figure 4.3a) 
0.00 0.10 0.13 0.59 0.16 0.59 
0.20 0.07 0.07 0.36 0.16 0.41 
0.40 0.05 0.06 0.19 0.18 0.47 
0.60 0.06 0.06 0.13 0.20 0.43 
0.80 0.05 0.05 0.07 0.16 0.39 
0.95 0.05 0.05 0.05 0.10 0.3 
R2 Block 
Diagonal 
(Figure 4.3b) 
0.00 0.10 0.15 0.59 0.15 0.59 
0.20 0.13 0.10 0.55 0.15 0.56 
0.40 0.08 0.07 0.41 0.15 0.49 
0.60 0.06 0.07 0.27 0.11 0.42 
0.80 0.05 0.07 0.12 0.11 0.39 
0.95 0.05 0.06 0.05 0.06 0.16 
R3 Toeplitz 
(Figure 4.3c) 
0.00 0.12 0.13 0.59 0.16 0.59 
0.20 0.13 0.12 0.56 0.15 0.56 
0.40 0.09 0.10 0.44 0.13 0.48 
0.60 0.08 0.07 0.26 0.12 0.40 
0.80 0.06 0.05 0.09 0.09 0.33 
0.95 0.05 0.06 0.06 0.07 0.26 
R4 Sparse 
(Figure 4.3d) 
- 0.06 0.07 0.31 0.08 0.32 
      
 
  

  
5  
TOWARDS THE DISEASE BIOMARKER IN AN 
INDIVIDUAL PATIENT USING STATISTICAL 
HEALTH MONITORING 
 
In metabolomics, identification of complex diseases is often based on application of 
(multivariate) statistical techniques to the data. Commonly, each disease requires its own 
specific diagnostic model, separating healthy and diseased individuals, which is not very 
practical in a diagnostic setting. Additionally, for orphan diseases such models cannot be 
constructed due to a lack of available data. An alternative approach adapted from industrial 
process control is proposed in this chapter: statistical health monitoring (SHM).  
 
In SHM the metabolic profile of an individual is compared to that of healthy people in a 
multivariate manner. Abnormal metabolite concentrations, or abnormal patterns of 
concentrations, are indicated by the method. Subsequently, this biomarker can be used for 
diagnosis. A tremendous advantage here is that only data of healthy people is required to 
construct the model. The method is applicable in current – population based - clinical 
practice as well as in personalized health applications. 
 
In this study, SHM was successfully applied for diagnosis of several orphan diseases as well 
as detection of metabotypic abnormalities related to diet and drug intake.  
  
This chapter has been adapted from:!Engel, J., Blanchet, L., Engelke, U. F., Wevers, R. A., 
& Buydens, L. M. C. (2014). Towards the Disease Biomarker in an Individual Patient 
Using Statistical Health Monitoring. PloS one, 9(4). 
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5.1 Introduction 
Metabolomics is becoming increasingly important in a whole range of healthcare-related 
fields such as disease prevention, diagnosis and intervention, and studies of the impact of 
diet and nutrition on various forms of illness [1-3]. In such studies, the metabolic phenotype 
or metabotype of individuals is studied. The metabotype is a characteristic metabolite profile 
that depends on the interplay between genes and environmental factors such as diet, 
lifestyle, gut microbial composition, and – in patients – medication. This profile varies 
greatly between individuals and populations. Therefore, metabotyping has applications in 
population-based and personalized medicine [1, 4]. For example, various (subtle) 
abnormalities in the metabotype have been related to cancer states, diabetes, cardiovascular 
diseases, neurological diseases and inborn errors of metabolism (IEM) [1, 3, 5, 6].  
 
 Commonly, the metabotype of an individual is measured from easily accessible biofluids 
such as urine or serum, or more seldom from tissue [2]. Typically, untargeted metabolomics 
techniques such as 1H nuclear magnetic resonance (NMR) spectroscopy or mass-
spectrometric methods are used for this purpose [2, 7, 8]. These techniques can measure a 
wide range of metabolites simultaneously and generate a multivariate profile of metabolites 
present in the sample. Due to the complex nature of the metabolome in biofluids 
multivariate data analysis is often required to interpret the acquired data and detect 
metabolic abnormalities. Most studies deal with classification problems such as disease 
diagnosis (healthy versus a specific disease) [3, 9]. During data analysis, such problems are 
commonly tackled as a two-class or a one-class problem.   
 
Two-class classification strategies aim to model the metabolic differences between groups of 
healthy and diseased individuals. These differences are grouped in a metabolic pattern or 
biomarker representing the abnormalities related to the disease. Typically used methods for 
two-class classification are orthogonal projection to latent structure (OPLS) and linear 
discriminant analysis (LDA) [9]. More challenging problems are generally tackled using 
non-linear approaches such as SVM, K-PLS or Random Forests [10, 11]. In contrast, one-
class classification methods focus on the similarities that are encountered within the 
diseased group. This results in a characterization of the expected metabotypes for a specific 
disease (e.g. an average metabotype and expected metabolic variation). Here, the most 
commonly used technique is SIMCA [9]. For both classification strategies, a diagnosis is 
made by matching the metabotype of a patient against the result of the model, being this 
biomarker or expected metabotype.  
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Both strategies focus on groups of patients with one specific disease. This might be 
impractical in a clinical setting for three reasons. First, it is not realistic to construct a 
statistically reliable model for rare or orphan diseases. Such diseases are defined in the 
United States as any disease that affects fewer than 200000 individuals, and in the European 
Community as any disease that affects fewer than 5 in 10000 individuals [12]. Some rare 
diseases have less than a dozen known cases. In other words, the number of potential 
patients to base the model on is too low. Secondly, even if orphan diseases are ignored, each 
disease requires its own specific model. Thirdly, unknown metabolic perturbations, for 
instance caused by unknown diseases, may not be detected or falsely interpreted.  
 
Interestingly, similar problems are encountered when monitoring industrial processes. 
Analogous to disease diagnosis one wants to know whether or not the process is in-control 
(healthy); if not, a known or unknown rare event (a disease) has occurred that may affect 
product quality.  So-called statistical process control (SPC) techniques have been developed 
to detect all of these events as early as possible [13]. Due to the success of SPC, we propose 
here to adapt these strategies and apply the method on metabolome profiles of body fluids 
with the aim of diagnosing the disease of a patient. This provides a new tool for diagnostic 
support: statistical health monitoring (SHM).  
 
In SHM, the so-called normal operating conditions (NOC) of healthy people are defined. 
NOC is a term that is often used in SPCA. In this case it basically means that a one-class 
classifier is used to model the expected metabotypes of healthy individuals. The NOC 
should therefore represent the average metabotype of a population and the inherent 
(normal) variation present in this population e.g. due to difference in life style. Next, the 
metabotype of a patient is compared to NOC. Deviations from NOC such as abnormal 
metabolite concentrations or abnormal patterns of concentrations are indicated by the 
method. Subsequently, this information – a (disease) biomarker for this individual patient – 
can be used for diagnosis. The fact that only data of healthy people is required to construct 
the SHM model is a tremendous advantage of this approach. Because of this, SHM is not 
disease specific and can be used for diagnosis of rare diseases. 
 
As a case study we applied SHM for diagnosis of a family of orphan diseases, namely inborn 
errors of metabolism. IEM comprise a substantial group of rare genetic diseases that can be 
diagnosed by NMR spectroscopy in combination with visual inspection of the data [5]. 
Because of the complex structure of the spectra this can be quite a challenge. Moreover, 
such an approach is extremely time-consuming and quite subjective. The proposed SHM 
approach may make the diagnosis of IEM easier and objective. Additionally, it will be 
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shown that, depending on how the NOC are defined; SHM can also detect metabolic 
abnormalities related to diet and medication. 
 
The next section will outline the concept of SHM and mathematic background. In the 
remaining sections the properties of SHM are discussed based on application of SHM to the 
case study example involving IEM. 
5.2 Theory  
In SHM the metabotype of an individual is compared to that of healthy people in a 
multivariate manner. Abnormal metabolite concentrations, or abnormal patterns of 
concentrations, are indicated by the method. This is achieved in two steps. In this first step 
– detection of abnormal metabotypes – the metabotype of an individual is matched against 
NOC and marked as normal or possibly abnormal. The abnormal metabolites are identified 
in a second step.  
5.2.1 Detection of abnormal metabotypes 
The first step in SHM is to select samples that represent the NOC of healthy humans well. 
From now on we will refer to these samples as normal or NOC samples. The choice of NOC 
samples should reflect the goal of the SHM analysis. For example, if the goal is purely to 
detect abnormalities related to disease, the NOC set can include healthy individuals who 
recently took medication. However, if one also wants to detect abnormal metabolites related 
to drugs, these individuals should not be included. Additionally, the demographics of the 
NOC samples and the expected patients should be as similar as possible. For example, if a 
patient has a completely different lifestyle compared to the NOC samples, many metabolites 
may falsely be marked as abnormal. However, if the demographics are too loosely specified, 
the limit of detection of the SHM model will be negatively affected. We will further 
elaborate on this important aspect in the discussion section.  
 
The NOC samples are stored in data table (𝐗!). Each row in 𝐗! contains the metabotype 
information from one healthy individual. Each column corresponds to a measured feature, 
e.g. a chemical shift value in an NMR spectrum. The data is centred to zero mean before 
starting the statistical analysis. Often it is also useful to scale the data – e.g. to unit variance – 
to ensure that each feature has equal chance to influence the model.  
 
Principal component analysis (PCA) is used to describe the NOC data [13]: 
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 𝐗! = 𝐓!𝐏!! + 𝐄! (5.1) 
 
Here, 𝐓!𝐏!! is the part of the model that describes the structural metabolic variation between 
the NOC samples, while matrix 𝐄! only contains residuals or non-structural variation. 𝐓! 
describes the systematic metabolic differences or variation between the NOC samples. The 
columns in 𝐏!, or factors, are the actual model. The factors are descriptors that indicate in 
which measured features the systematic differences occur. A property of the factors is that 
they are ordered by importance: the first “explains” most variation, followed by the second, 
etc. At some point the remaining factors only describe noise. These factors are not included 
in the model.  
 
To determine whether someone is possibly diseased, the metabotype information from this 
individual (𝐱!"#) is evaluated using the constructed model:  
 
 𝐱!"# = 𝐭!"#𝐏!! + 𝐞!"# (5.2) 
 
Note that 𝐭!"#𝐏!! describes which part of the individual’s metabotype is in accordance with 
the metabotypes that are expected for NOC samples2. If an individual is similar to the 
normal samples, this prediction should capture his/her complete metabotype. In this case, 
the error 𝐞!"# should be small and fall in the range of the error of the NOC samples. 
Therefore, abnormal metabotypes can be detected by inspection of the size of 𝐞!"#. In 
industrial process control, the so-called Q-statistic is used for this purpose [13]: 
 
 𝑄 = 𝐞!"# ! (5.3) 
 
A sample with a high 𝑄-value corresponds to a metabotype that either contains abnormal 
metabolite(s) or abnormal metabolite concentrations that break the normal between-
metabolites correlation pattern.  The metabotype of an individual is marked as abnormal if 
the value for 𝑄 exceeds the significance limit given by 𝑄! [14]:  
 
 𝑄 > 𝑄! 𝑧! 2𝜙!ℎ!!𝜙! + 𝜙!ℎ!(ℎ! − 1)𝜙!!
!!!
 (5.4) 
 
where the parameters of the approximation are defined as: 
                                                                  
2	  (Additional comment) Here, it is assumed that a disease will break the normal metabolite correlations, for 
example, by causing a block in a metabolic pathway. In the possibly unlikely scenario that correlations are not 
broken, but e.g. only the average concentration of certain metabolites are affected, patients may have abnormal 
values in 𝐭!"#𝐏!!  and not in 𝐞!"#  and Hotellings T2-statistic should also be used for detection (see appendix A). 
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 ℎ! = 1 − 2𝜙!𝜙!3𝜙!!  (5.5) 
 
 𝜙! = 𝑡𝑟 𝚲! ,      𝑖  =1,2,3 (5.6) 
 𝚲 is the covariance matrix of 𝐄!, and 𝑧! is the standardized normal variable with (1 − 𝛼) 
confidence limit, having the same sign as ℎ! [14].   
 
To summarize, for a measured metabotype (𝐱!"#) the PCA model (𝐭!"#𝐏!!) is used to 
predict what this metabotype would look like if the individual was an NOC sample. The 
larger the difference between predicted and measured metabotype (𝐞!"#) the more likely 
the metabotype is to be abnormal. The size of this difference is expressed via the 𝑄-statistic. 
An example of SHM when monitoring 2 metabolites is presented in appendix A.  
 
5.2.2 Identification of abnormal metabolites 
The second step in SHM is to detect the abnormal metabolites that caused the deviation 
from NOC. A clinical practitioner can use this information for example for disease 
diagnosis, possibly via a database search.  
 
Since the 𝑄-statistic should detect all deviations from NOC, the contribution of measured 
features to this statistic should be investigated. For this purpose, the value for 𝑄  is 
decomposed into per feature contributions. Here, we used partial decomposition [15]:  
 
 𝑄 = 𝐞!"# ! = 𝐱!"# 𝐈 − 𝐏!𝐏!! 𝐱!"#! = 
(5.7) 
 𝐱!"# 𝐈 − 𝐏!𝐏!! 𝛏!𝛏!!𝐱!"#! = 𝑞!!!!!
!
!!!  
 
where 𝐈 is the identity matrix and 𝛏!  is the 𝑖th column of the identity matrix. Index 𝑖 and 𝐾 
indicate a specific feature and the total number of measured features, respectively. The 
contribution of the measured value in feature 𝑖  to 𝑄  equals 𝑞! . High values indicate 
abnormal behaviour of this particular feature. However, the contribution of each feature in 
the NOC data should be taken into account as well: a large contribution of a feature 
becomes less meaningful if such contribution values were also observed for the NOC 
samples. Therefore, all contributions were studied relatively to the variance of the NOC 
residuals 𝐄! [15]:  
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 𝑟𝑞! = 𝑞!𝛬!,! (5.8) 
 
Where 𝛬!,!  indicates the element in the 𝑖th row and column of 𝚲. The set of relative 
contributions for all features will be referred to as a personal health profile or personal 
biomarker. 
5.3 Methods 
5.3.1 Data 
To assess the value of SHM for disease diagnosis, a set of urine samples of 193 healthy 
children and a set of 24 patients was measured using proton NMR spectroscopy. Eighteen 
patients were known to suffer from one of seven different IEM. For the other six patients, no 
IEM was diagnosed, but their metabotypes contained commonly prescribed drugs such as 
depakine and sabril. More details regarding the healthy and patient samples are specified in 
tables 5.1 and 5.2, respectively. Note that a subject had to be between 4 ‒ 12 years old to 
participate in this study and be of Dutch ancestry. An equal amount of males and females 
were selected. No other selection criteria such as lifestyle and diet were imposed.  
Table 5.1   Abnormal compounds present in urine 1D 1H-NMR spectra from the healthy individuals. The 
metabolites were identified by comparison of the abnormal resonances to a database of NMR spectra of model 
compounds [5]. In cases where the overlap of resonances in the 1D spectrum was quite severe, 2D COSY NMR 
experiments were used to provide additional information and confirm that the metabolite identification based 
on the 1D spectrum was correct. 
Compound CS (ppm); multiplicity Origin 
   
Acesulfame 2.11d; 5.67q Artificial sweetener 
Acetaminophen 2.15s; 6.90d; 7.25d Paracetamol 
A-glucuronide* 2.16s; 5.12d; 7.13d; 7.34d Paracetamol 
A-L-cysteinyl* 2.15s; 6.99d; 7.51d Paracetamol 
A-N-acetyl-L-cysteinyl* 1.84s; 2.14s; 6.93d; 7.42d Paracetamol 
A-Sulphate* 2.17s; 7.45d; 7.31d Paracetamol 
Cyclamate 1.53 – 2.06m Artificial sweetener 
Mannitol 3.6-3.8v Sweetener 
N-Methylhydantoin 2.92s; 4.08s Bacteria 
TMA-oxide 3.54s Fish meal 
   
*Spectrum not completed interpreted; s=singlet; d=doublet; t=triplet; q=quartet; m=multiplet; v=various multipets 
A = Acetaminophen; TMA = Trimethylamine 
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Table 5.2   Abnormal compounds present in urine 1D 1H-NMR spectra from the patients. The metabolites were 
identified by comparison of the abnormal resonances to a database of NMR spectra of model compounds [5]. 
In cases where the overlap of resonances in the 1D spectrum was quite severe, 2D COSY NMR experiments 
were used to provide additional information and confirm that the metabolite identification based on the 1D 
spectrum was correct. 
Compound CS (ppm); multiplicity Origin 
   
Arginine 1.69m; 1.92m; 3.24q; 3.85t Cystinuria 
4-Amino-5-hexenoic acid 1.94m; 2.08m; 2.46m; 5.47m; 5.80m Medication: Sabril 
Dihydroxycholenic acid 0.67s; 0.80-0.94v 3β-Hydroxy-∆5-C27-steroid 
dehydrogenase deficiency 
Formiminoglutamic acid 2.00-2.22v; 2.47t Formiminotransferase deficiency 
Homogentisic acid 3.64s; 6.78m Alkaptonuria 
Hydantoin-5-propionic acid 2.00-2.22v; 2.51t Formiminotransferase deficiency 
3-Hydroxyisovaleric acid 1.33s; 2.55s Isovaleric aciduria 3MCC-
deficiency 
Isovalerylglycine 0.94d; 2.02m; 2.18d; 3.94d Isovaleric aciduria 
Lysine 1.47m; 1.72m; 1.92m; 3.01t; 3.77t Cystinuria 
3-Methylcrotonylglycine 1.86d; 2.03d; 3.97d; 5.78m 3MCC-deficiency 
2-oxo-1-pyrrolidine acetamide 2.10m; 2.48t; 3.52t; 4.01s Medication: Piracetam 
5-Oxoproline 2.20m; 2.43m; 2.55m; 4.36m 5-Oxoprolinuria 
Taurine 3.27t; 3.43t(wide due to exchange) Unknown; possibly nutrition 
Trihydroxycholenic acid 0.73s; 0.80-0.94v 3β-Hydroxy-∆5-C27-steroid 
dehydrogenase deficiency 
Valproic acid 0.88t; 1.30m; 1.50m; 2.44m Medication: Depakine 
   
*Spectrum not completed interpreted; s=singlet; d=doublet; t=triplet; q=quartet; m=multiplet; v=various multipets 
3MCC=3-Methylcrotonyl CoA carboxylase 
The urine samples were centrifuged before analysis. A volume of 70 µμl of a 20.2 mmol/l 
trimethylsilyl-2,2,3,3-tetradeuteriumpropionic acid (TSP, sodium salt; Aldrich) 2H2O 
solution was added to 700 μl of urine as a chemical shift reference (𝛿 = 0.00) and as a lock 
signal. The pH of the urine was adjusted to 2.50 ± 0.05 with HCl. Finally, 650 µμl of the 
sample was placed into a 5-mm NMR tube (Wilmad Royal Imperial; Wilmad LabGlass, 
USA).  
 
1H NMR spectra were obtained using a Bruker 500MHz spectrometer (pulse angle 90o, 
delay time 4s, number of scans 256, temperature 298K). The water resonance was 
suppressed by gated irradiation centred on the water frequency. Shimming was performed 
automatically on each sample prior to the data acquisition using the TopShim method from 
Bruker BioSpin. The phase and baseline were corrected manually. 
 
The regions 0.2 ‒ 4.7 ppm and 5.0 ‒ 10.0 ppm were selected for further analysis in Matlab 
7.14 (Mathworks, Natick, Massachusetts, U.S.A.). Next, the urine profiles were normalized 
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to the creatinine signal to correct for dilution effects. Equidistant binning with a bin size of 
0.04 ppm was used to reduce the dimension of the normalized data from 30888 to 246 
variables. Finally, the data was centred to zero mean and scaled to unit variance.   
 
For some samples (see below), 2D COSY NMR spectra were also recorded for extra spectral 
information. The spectra were recorded at 500 MHz using 4k data points in F2 and a 
spectral with of 6002 Hz. For all samples, 256 increments and 16 scans per increment were 
used. The TR was 2s, during which the water resonance was presaturated. Prior to Fourier 
transformation, a since function was applied in both time domains. 
5.3.2 Ethics statement 
The medical ethical committee of the Radboud University Medical Centre in Nijmegen, The 
Netherlands, approved the study protocol. Informed verbal parental consent was obtained 
for all volunteers. At that time consultation of the medical ethical committee of the 
Radboud University Medical Centre in Nijmegen, The Netherlands resulted in the advice to 
ask the collaboration of the parents/caretakers of the children via an information letter 
explicitly stating that their collaboration was on a voluntary basis and that all samples would 
be fully anonymized and that all samples would be destroyed at the latest 5 years after the 
sample collection. 
5.3.3 SHM model construction and validation 
First, the raw NMR spectra of the 193 healthy individuals were extensively screened by an 
experienced clinical practitioner to rule out any abnormal metabolic patterns in these 
samples. Seventeen samples with abnormal patterns related to dietary influences and drug 
intake were identified. These samples were marked as abnormal and used to validate the 
SHM approach since detection of abnormal patterns due to diet and drugs is in principle no 
different from detection of abnormalities related to a disease. Additionally, the set of 24 
patients was used for validation. In all samples, the abnormal metabolites were identified by 
the clinical practitioner by comparison of the abnormal resonances to a database of NMR 
spectra of model compounds [5]. In cases where the overlap of resonances in the 1D spectra 
was quite severe, 2D COSY NMR experiments were used to provide additional information 
and confirm that the metabolite identification based on the 1D spectra was correct. 
 
The SHM model was constructed on the basis of 120 training samples that were selected 
from the remaining set of 176 binned 1H NMR spectra of normal (healthy) individuals by 
the Kennard Stone algorithm [16]. The optimal number of factors in the PCA model was 
determined by a bootstrapping algorithm called NUMFACT [17]. In essence, the PCA 
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factors determined for each resampling were compared for changes. Factors that changed 
significantly from one resampling to the next were probably due to noise and excluded from 
the model. 
 
Validation of identification of abnormal metabolites was performed by applying the left-out 
56 healthy; 17 healthy, but abnormal; and 24 patient samples to the SHM model. An 
imposed significance limit (α) of 5% was used. Note that centring and scaling of the test 
data was based on the feature means and standard deviations of the training data.  
 
All analysis was performed using in-house developed algorithms. Bootstrapping to estimate 
the number of factors in PCA was performed with PLS_Toolbox 6.7.1 [18]. 
5.4 Results 
5.4.1 Inspection of the 1H NMR data: current clinical practice 
The data was first analysed according to current clinical practice, namely by visual 
inspection and by means of PCA score plots. This inspection was required to select the NOC 
samples (healthy individuals) on which the SHM model could be trained.  
 
A clinical expert visually inspected the NMR data of the 193 healthy children and the 24 
patients. Ten exogenous metabolites related to diet or drug intake were observed in the set 
of 193 children. More details are specified in table 5.1. Seventeen samples contained 
metabolites related to bacteria, a fish meal, paracetamol, or cyclamate. The artificial 
sweeteners Acesulfame K and mannitol were present in the metabotype of such a large 
number of healthy individuals that they were not marked as abnormal metabolites.  Fifteen 
abnormal metabolites were observed in the 24 patient samples. These were related to 7 IEM 
(18 patients) as well as medication (6 patients). More details are specified in table 5.2.  
 
In figure 5.1, a PCA score plot of all samples is shown (autoscaled data). The samples were 
coloured according to the observations made by the clinical expert. Clearly, many abnormal 
metabotypes could not be distinguished from healthy samples this way. Alternative 
colourings of the plot indicated no trends related to age, gender or other demographics 
either. 
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Figure 5.1   PCA score plot of the autoscaled data. Note that the points are coloured according to the 
observations made by a clinical expert as healthy; healthy, but exogenous metabolites were present; patients 
diagnosed with IEM; and other patients. 
5.4.2 Statistical health monitoring 
The SHM model was constructed on the basis of 120 healthy metabotypes. The clinical 
expert had not detected any of the exogenous metabolites listed in table 5.1 in these samples, 
except for the articial sweeteners Acesulfame and mannitol. This means that future samples 
that contain exogenous metabolites related to fish, paracetamol intake, etc will be marked as 
abnormal by the model even if they are healthy. This can be undesirable if the sole purpose 
of the SHM model is disease diagnosis. We will further elaborate upon this choice of NOC 
samples in the discussion 
 
Eighty-three percent of the total variation in the NOC data was estimated to be systematic 
by NUMFACT. This variation was modelled by the first 16 factors. Next, the metabotype of 
the validation samples was automatically inspected using the constructed SHM model. As 
shown in figure 5.2, 𝑄-values of the abnormal metabotypes were clearly larger compared to 
the normal metabotypes. Using the imposed significance limit of 5%, all normal and 
abnormal metabotypes were correctly identified. Note that the cut-off point 𝑄!% to mark a 
patient’s metabotype as abnormal was completely based on the training samples (equation 
5.4).  
 
The 17% variance left out of the model must correspond to individual variations, which did 
not necessarily belong to the NOC of the whole group. This unexplained variance partly re- 
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Figure 5.2   𝑄-values obtained by statistical health monitoring for 56 healthy and 42 abnormal metabotypes.  
appeared as 𝑄 contribution. Therefore, metabotypes of normal individuals did not have zero 
contribution for every feature. Statistically speaking, with the chosen significance level 5% 
of the samples that are within NOC are expected to be incorrectly marked as abnormal (i.e. 
3 individuals). In this case all normal individuals were correctly detected which is related to 
size of our test cohort. 
 
For metabotypes marked as abnormal, the abnormal metabolites were identified via the 
relative feature contributions to 𝑄. The set of relative contributions can be considered as a 
personal biomarker for that individual since they highlight how and how much this 
individual is different from NOC. The contribution can be visualized in a so-called 
contribution plot, which is commonly done in industrial process control, or in the original 
NMR spectrum to integrate SHM in current clinical practice. In a contribution plot the 
relative contribution is plotted against the chemical shift value. Three examples are 
presented in figures 5.3a, c, and e. In each figure, high peaks relative to the baseline indicate 
resonances that were abnormal with respect to NOC. An advantage of contribution plots is 
that features with a large contribution are easy to identify, even if they have a low intensity 
in the original NMR spectrum (e.g. the resonances between 9.6 – 9.8 ppm in figures 5.3e 
and 5.3f). In contrast to contribution plots, visualization in the NMR spectrum itself allows 
the user to make combined use of contribution values as well as NMR knowledge such as 
multiplet structure to make a diagnosis. As shown in figures 5.3b, d, and f, the contribution 
values are colour coded in this type of visualization.  
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Figure 5.3   Feature contributions visualized in a contribution plot and the original NMR spectra for three 
abnormal metabotypes. The abnormal metabolites are related to (a, b) high concentrations of taurine, (c, d) 
alkaptonuria, and (e, f) paracetamol comsumption. The arrows indicate the resonance corresponding to the 
middle of a bin. Each bin had a width of 0.04 ppm.  
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The abnormal metabotypes were further inspected using both representations of the relative 
contribution. All IEM, were correctly diagnosed this way. Similarly, all abnormalities 
related to diet and the different types of medication were correctly identified. Most IEM 
were diagnosed via key resonances – biomarkers relating to the specific IEM; not always 
were all relevant biomarker resonances for a specific IEM marked as abnormal. This is 
similar to visual inspection of the data: resonances with a high degree of splitting or overlap 
cannot be discerned from noise in 1D spectra.  
 
In order to illustrate the principles of relative contributions and the procedure to follow to 
establish a potential diagnostic better, we will describe the three examples in figure 5.3 in 
more detail below. The complexity of these examples is progressively rising in terms of 
spectral interpretation meaning that correct identification by SHM is more challenging.  
Case 1 
The first example is considered relatively simple because only two resonances are involved. 
As shown in figure 5.3a, SHM clearly marked two resonances at 3.27 and 3.43 ppm as 
abnormal: the relative contribution was much larger compared to the contribution of other 
resonances. Similar to visual inspection of the data, the metabolite corresponding to these 
abnormal resonances was identified by comparison of the resonances to a database of NMR 
spectra of model compounds. These particular two resonances correspond to taurine 
indicating that the metabotype of this patient contained abnormally high concentrations of 
taurine. This was confirmed by visual inspection of the spectrum by the clinical expert. At 
the moment the cause of the high concentrations of taurine in the metabotype of this patient 
is unknown. Perhaps, the abnormality can be related to diet, e.g. consumption of energy 
drinks.  
Case 2 
The contribution plot of this patient also showed two resonances that were abnormal: a 
singlet at 3.64 ppm and a multiplet at 6.78 ppm (figures 5.3c and 5.3d). However, inspection 
of this plot was more difficult compared to case 1. The multiplet was much easier to detect 
compared to the singlet because the NMR spectra of healthy individuals did not contain 
much signal around 6.78 ppm. Therefore, the relative contributions of this multiplet were 
very large. In contrast, the singlet at 3.64 ppm was positioned in a crowded region of the 
spectra resulting in much lower contribution values. However, compared to the 
contributions at the surrounding chemical shifts, the singlet at 3.64 was still clearly 
abnormal. This shows that inspection of contribution plots should not only focus on the 
absolute value of the contributions, but on their size relative to the contribution that is 
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observed for most chemical shifts. One could say that for each individual the “𝑄 baseline” 
must be used to determine if a particular peak is abnormal or not. The abnormal singlet at 
3.64ppm and the multiplet at 6.78 ppm indicated that the metabotype of this individual 
contained a large concentration of homogentisic acid [5]. Thanks to this, the patient was 
diagnosed with the IEM alkaptonuria. Alkaptonuria is caused by a deficiency of the enzyme 
homogentisic acid oxidase in tyrosine catabolism[5]. This results in high concentrations of 
homogentisic acid in the urine of such a patient.  
Case 3 
As shown in figure 5.3e, eight regions in the NMR spectrum of this individual had 
abnormal contributions. Similar to case 2, the contributions of the relevant resonances 
again differed by orders of magnitude.  
 
Comparison of the abnormal regions to spectra of model compounds clearly indicated that 
the metabolites acetaminophen, acetaminophen-glucuronide, and acetaminophen-sulphate 
were present in high concentrations (see table 5.1). This is caused by consumption of 
paracetamol by this individual.  As shown in table 5.1, this drug can actually be detected in 
urine via abnormal concentrations of five metabolites. A number of these metabolites will 
be visible in the NMR spectrum depending on how the drug was metabolized. In this case 
no high 𝑄-values were observed at resonances 1.84, 6.99, and 7.51 ppm. This indicates that 
the compounds A-N-acetyl-L-cysteinyl and A-L-cysteinyl were either present in very low 
concentration, or that in this particular case paracetamol was not metabolised into these 
metabolites. This was confirmed by visual inspection of the NMR spectrum. Due to the 
large number of resonances involved, identification of paracetamol intake via SHM is 
considered more difficult compared to the previous two cases. Additionally, the intensities 
of the resonances involved are much lower which makes diagnosis even more difficult.   
 
Note that for all individuals who consumed paracetamol, the resonances around 9.8 ppm 
were also marked as abnormal. These resonances have not been described in literature. 
However, by means of a simulated NMR spectrum of paracetamol in the Bruker software we 
ascribe these resonances to NH-groups in the molecule.  
5.5 Discussion 
In this study, SHM was introduced as a valuable tool for diagnosis of a multitude of possible 
(rare) diseases. The method was successfully applied in a case study involving diagnosis of 
several IEM as well as metabolic abnormalities related to drug consumption and diet.  
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First, the metabotype of each individual was marked as normal or abnormal: 100% of the 
“healthy” and 100% of the abnormal metabotypes were correctly identified. Next, it was 
shown that feature contributions can be used to identify the abnormal metabolites. The 
contributions are very easy to calculate without prior knowledge. Prior knowledge, however, 
is required to interpret them and relate the abnormal features to a disease. Therefore, SHM 
should be regarded as a decision support tool for diagnosis.  In case of rare diseases, SHM is 
the only tool available to detect the abnormalities. In case of more common diseases, the 
SHM-based metabotype screening could be followed by more classical targeted approaches 
(e.g. a two-class classifier) to confirm the diagnosis.  
 
The first step of SHM, detection of abnormal metabotypes in a multivariate fashion, is 
functioning in a reliable way. The second step concerns identification of the abnormality. 
This identification relies on a univariate evaluation of the individual contributions of each 
feature or measured signal to 𝑄. These contributions should be studied with some caution 
due to the so-called smearing effect: contributions from abnormal features can propagate to 
other features meaning that fault free features can show increased contribution [15].  This a 
well-known issue in industrial process control that has been greatly discussed in literature 
[13]. The smearing effect is a direct consequence of the fact that an SHM model is 
constructed on the basis of normal metabotypes. Because of this the model is very well able 
to detect when a metabotype is abnormal. However, when the abnormal metabolites are 
identified via the Q-statistic again information from the normal (NOC) individuals has to 
be used (see equation 5.7). The model assumes that the correlations between metabolites in 
the abnormal metabotype are the same as those encountered in the NOC samples. This 
doesn’t have to be the case.  This imperfect assumption may lead to some false positives i.e. 
some metabolites can be marked as abnormal while they are not. Unfortunately, the 
smearing effect cannot be avoided. In this study, the smearing effect was minimized by 
using partial decomposition of the 𝑄-statistic, instead of the commonly used complete 
decomposition method. This ensures that the contribution of an abnormal feature will 
always be greater than the contribution given to the “good” feature [15].  
 
Some works in the process control literature suggest the use of control limits for 
determining the significant feature contributions. However, this should be discouraged 
since the  (biological) unrelated features might also show an increased contribution due to 
the smearing effect [15]. Therefore, we prefer to rely on human expertise by visually 
inspecting the contribution plots.  
 
Selection of NOC samples is a critical step in the construction of an SHM model. The 
proposed method detects deviations from these normal samples. This deviation can be 
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related to disease, but also a healthy sample with a deviation that is not present in the NOC 
set – e.g. the paracetamol example presented in case study 3. When disease diagnosis is the 
goal of the SHM model, examples such as case 3 are false positives. As shown in figure 5.1, 
the patient samples differed more from the NOC samples (the healthy group) compared to 
the group of healthy samples that contained exogenous metabolites. This was the main 
reason why the latter group was not included in NOC: we wanted to investigate if SHM was 
also able to detect these smaller deviations from NOC. This group should be included in 
NOC, however, if the user only wants to detect metabolites related to disease. Therefore, we 
also briefly investigated this disease diagnosis model. A direct consequence of the fact that 
the NOC now contained extra inter-individual variation due to diet and medication was 
that the cut-off value for Q (equation 5.4) was increased. This means that samples will less 
quickly be marked as abnormal, increasing the chance of false negatives. In this case, 
however, all patient samples were still correctly diagnosed. In contrast to the SHM model 
presented in the results section, all samples with metabolites related to medication and 
drugs were now marked as normal. In this feasibility study, the NOC set was a small 
population of healthy children. These samples matched in age and ancestry to the expected 
IEM patients. No restrictions on factors such as lifestyle were imposed to ensure enough 
diversity within the NOC set so that it is representative of future patient samples. However, 
due to the size of our cohort most likely not all possible factors such as all types of 
medication were included in NOC. We expect that a much larger cohort of randomly 
selected NOC samples would contain most of the common diets; types of medication; and 
other factors, thereby avoiding the occurrence of false positives related to this. Additionally, 
if false positives occur later on, the NOC set can be updated with these samples. Note that 
the cohort should match the expected demographics of the patients are closely as possible 
since the larger the biological variation of the NOC samples the more difficult it will be to 
detect a subtle abnormality related to disease. 
 
When working with large cohorts of NOC samples, an interesting research line would be to 
see if sub-populations of normal individuals with completely different characteristics due to 
e.g. environmental factors can be identified. Each sub-population has its own NOC. In such 
a case, a SIMCA-like model structure where a separate SHM model is constructed for each 
population seems more appropriate compared to one general model that was used in the 
present study. Matching new samples only against NOC of the correct sub-group could 
greatly enhance the power of the SHM model for disease diagnosis.  If the subpopulations 
are unknown, perhaps a clustering approach such as mixture modeling can be used to 
define them. 
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Three additional future development lines can be defined for SHM: (1) connection of SHM 
output to a disease database, (2) development of personalized health control, and (3) 
application of SHM in clinical trials. The first research line could be implemented in SHM 
in the form of a database of known disease, which would automatically link the 
abnormalities detected with a list of potential diseases.  
 
The second perspective is to define NOC at an individual level instead of a population or 
sub-group based one. To do so, longitudinal metabotyping experiments should be 
performed. The SHM model would then very precisely describe the NOC metabotype 
profile because no intra-individual differences have to be taken into account. In 
consequence, SHM would be able to detect more subtle abnormalities. An additional 
advantage of longitudinal studies for detection of abnormal metabotypes is that the user can 
accumulate information from a series of measurements. One could check whether 
measurements appear randomly distributed between the control limits or if a structure is 
appearing, signalling the start of a deviation from NOC. Such tests may greatly improve the 
power of SHM for disease detection. Identification of the specific abnormality may be 
improved by studying contributions relative to the last 𝑘 timepoints instead of all NOC 
samples. The abnormal metabotype should be most similar to the last metabotypes that were 
measured before the individual became ill.  
 
In this study, NMR was used to assess the metabotype of each individual because it is a very 
stable technique with a detection limit in the low micromolar range. This technique has 
been used routinely for over 20 years in Radboud University Medical Centre in Nijmegen to 
diagnose IEM. Although NMR is a valuable analytical platform to diagnose IEM, it is not 
necessarily the best technique for other diseases. Other data types such as results of classical 
blood tests or more advanced measurements such as 2D-NMR and LC-MS should be used 
if they are known to provide more relevant information. In principle, SHM can be applied 
to any type of data. For each application it is important to take into account the structure of 
the data and adjust the model accordingly. Here, PCA was used to describe healthy 
metabotypes. Multiway data coming from 2D-NMR or LC-MS could be evaluated using a 
PARAFAC or Tucker3 structure [19]. Because SHM can be applied to any data type, it will 
most likely not only find application in metabolomics, but also in other fields such as 
proteomics or genomics.  
5.6 Conclusion 
Due to the complex nature of metabolomics data, multivariate statistics are required to 
interpret the data. Unfortunately, current multivariate tools can only diagnose diseases in a 
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targeted fashion; a separate model is required for each disease. Additionally, such tools are 
not always applicable to rare or orphan diseases. Abnormal metabotypes can sometimes be 
detected in an untargeted fashion by visual comparison of the data. However, detection of 
subtle abnormalities and abnormal patterns is extremely subjective and time-consuming. 
An alternative approach, SHM, was proposed in this study.  
 
In SHM, the metabotype of an individual is compared to normal (healthy) metabotypes in a 
multivariate manner. Any abnormal patterns are indicated by the method. Subsequently, 
this information can be used for diagnosis. In this study, SHM was successfully applied for 
diagnosis of various metabotypic abnormalities related to diet, drug intake and IEM.  
 
SHM is a general method that is not only applicable to metabolomics data. Additionally, the 
method offers perspectives in the framework of personalized health. 
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Appendices 
A. Schematic depiction of SHM when monitoring two metabolites 
In figure A.1, disease detection is illustrated for a problem where 2 metabolites are 
monitored. Note that in comparison to the main text in this chapter, a second statistic (T2) 
is show here as well. This statistic is often used in statistical process control to monitor the 
values of the scores of the PCA model. In our application this statistic does not offer any 
additional information compared to the Q-statistic. However, this statistic can be useful 
when SHM is applied to other types of data.  
 
Figure A.1 shows a 1-factor (or principal component) PCA model that describes the main 
differences between the NOC samples. Outlier 1 has a low value for the Q-statistic, but a 
high value for the T2-statistic. The metabotype of this individual is explained well by the 
model but is different from the NOC metabotypes in the sense that it is an extreme object 
(it has an extreme score). This means that the sample has extreme metabolite 
concentrations, but the overall between-metabolite correlation pattern is conserved, e.g. due 
to improper correction for dilution effects. Outliers 2 and 3 have a high value for the Q-
statistic. The metabotype of these individuals is not described well by the model because the 
relation between the two metabolite concentrations is very different from NOC. In other 
words, the Q-statistic can detect abnormal correlations between the metabolites. Therefore 
this statistic is the most suitable for disease diagnosis. 
 
 
Figure A.1   Disease detection via statistical health monitoring for a two metabolites problem. The black dots 
indicate NOC samples. The grey dots are outliers. 

  
6  
A NOVEL APPROACH TO DIAGNOSIS AND 
FOLLOW-UP OF INDIVIDUAL PATIENTS BY 
SPARSE MODELING 
 
The –omics technologies are becoming increasingly important in health care and are 
expected to contribute to personalized health care. Statistical health monitoring (SHM) was 
introduced in chapter 5 for analysis of -omics data to automatically identify the disease 
response in an individual patient. This approach could be of use in all sorts of applications 
such as diagnosis of rare diseases, analysis of individual patterns in disease manifestation, 
disease monitoring, or personalized therapy.$$
 
SHM essentially combines estimation of Mahalanobis distances (MD) with principal 
component analysis (PCA). It is well known that the dimension reduction step via PCA can 
hamper reliable identification of the disease response in a patient. Therefore, sparse SHM 
(sSHM) is introduced in this chapter. The method combines estimation of the MD with 
variable selection by inclusion of an !!-norm constraint. 
 
Simulations are used to show that the sSHM model can identify the disease response in an 
individual patient more reliably compared to SHM" Subsequently sSHM is applied to urine 
1H NMR metabolomics data for diagnosis of several orphan diseases. 
  
This chapter has been adapted from:!Engel, J., Blanchet, L., Engelke, U. F. H., Wevers, R. 
A., & Buydens, L. M. C. A Novel Approach to Diagnosis and Follow-up of Individual 
Patients by Sparse Modeling. Submitted. 
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6.1 Introduction 
The advent of the –omics technologies has allowed for analysis of DNA, proteins, 
metabolites and other molecules in a patient at an unprecedented level [1, 2]. Because of 
this, factors that influence health can be studied in great detail allowing for precise 
diagnostics [3]. Omics techniques are becoming increasingly important in health care and 
are expected to contribute to personalized health care. Metabolomics, for example, has been 
used to diagnose cancer states, diabetes, cardiovascular diseases, neurological diseases and 
inborn errors of metabolism (IEM) amongst others [4-8]. Many different types of samples 
can be used in –omics experiments ranging from tissues to body fluids. Sampling is 
becoming increasingly non-invasive focusing on easily obtainable body fluids such as urine 
or analysis of exhaled breath [9, 10]. 
 
Commonly, an –omics experiment involves hundreds to thousands of measured variables 
per patient. Therefore, analysis of the acquired data with (multivariate) statistical 
approaches is a crucial step to diagnose a disease or monitor the healthy state [8, 11]. Often 
classification models are used to classify groups of patients with a specific disease from 
healthy controls. These models focus on populations of patients with a specific disease. This 
might be impractical in a clinical setting for a number of reasons, including: (1) in the case 
of diagnosis of rare diseases typically too few samples are available for a useful comparison 
between patients and controls; (2) a separate model is required for each disease; and (3) 
unknown metabolic perturbations, i.e. caused by an unknown disease, may not be detected 
or falsely interpreted. Additionally, by definition population-based approaches are designed 
to be the best for the average population and not for specific individuals. Individuals are 
genetically diverse and have different exposures and response characteristics to disease [12]. 
These individual responses are hypothesized to overlap in large population models and may 
therefore be very challenging to detect [1]. Clearly, statistical modeling approaches beyond 
population-based models are required to improve analysis of –omics data for (personalized) 
health care. 
 
In chapter 5, statistical health monitoring (SHM) was introduced as an alternative tool for 
disease diagnosis in metabolomics [4]. The method can be used to identify the disease 
response in an individual patient in an untargeted way. This information can be used for 
disease diagnosis, analysis of individual patterns in disease manifestation, disease 
monitoring, personalized therapy, etc.  
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Figure 6.1.   Comparison of a patient (marked red) to a set of controls (marked blue) by the Mahalanobis 
distance. Note that the solid black line corresponds to the 95% confidence sphere, i.e. the NOC. The dotted 
arrow indicates the direction of canonical variate a, which is used to determine on which variables the patient 
differed most from the NOC.  
The basic concept of SHM is shown in figure 6.1. A set of control samples is used to define 
the so-called normal operating conditions (NOC) represented by the black ellipse in the 
figure. The NOC represents the expected characteristics of (a) healthy metabolic 
phenotype(s). The NOC can be defined for the population, or for the individual. When a 
patient sample falls outside the black ellipse it is marked as significantly different. In that 
case a second step is used to determine which pattern of variables in the patient sample is 
abnormal with respect to the NOC. This way, disease responses can be assessed in an 
individual manner. The fact that only data of healthy people is required to construct the 
SHM model is another advantage of this approach. Because of this property, it was possible 
to successfully apply SHM to urine NMR metabolomics data for diagnosis of a number of 
rare diseases, namely IEM [4]. 
 
The SHM model essentially uses the Mahalanobis distance (MD) to compare the patient to 
the NOC (see appendix E) [4]. However, it is well known that the MD cannot be estimated 
reliably when the number of control samples is smaller than the number of variables [13]. 
SHM circumvents these issues by projecting the data to a lower dimensional space using 
principal component analysis (PCA). A major drawback of the PCA step is, however, that it 
allows for interaction between the abnormal variables (i.e. variables on which the patient 
differs from NOC) and the normal variables [14, 15]. Because of this, reliable identification 
of the abnormal variables is challenging (normal variables may appear to be abnormal). This 
is sometimes referred to as the smearing effect and hampers disease diagnosis. Additionally, 
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selection of the correct number of principal components is a crucial step [16]. In our 
experience, standard selection approaches such as screeplots do not provide a clear solution 
for –omics data. 
 
In this chapter we propose an alternative SHM method, that is, sparse SHM (sSHM). The 
key idea consists of combining the MD with a variable selection method instead of a 
dimension reduction method. The main advantage of this approach is that abnormal 
variables are more reliably identified this way as will be shown by simulation. Additionally, 
subtle differences between the patient and NOC can be detected this way while they could 
be masked by the accumulative noise effect of irrelevant variables when no variable selection 
is applied (i.e. when the MD is used). Variable selection in sSHM is achieved by inclusion of 
an ℓ𝓁!-norm constraint during estimation of the MD. A fast algorithm is employed to 
compute the entire solution path of the model, i.e. it finds all solutions with 1,2,⋯,p selected 
variables. This path can be graphically depicted and provides an intuitive way to identify 
those variables on which the patient differs from the NOC, i.e. the disease response of the 
patient. The sSHM method is applicable in cases where the number of control samples is 
smaller than the number of variables, and, unlike SHM, no parameter optimization is 
required.  
 
The next section will outline the concept of sSHM and its mathematical background. In the 
subsequent sections the properties of sSHM are studied based on simulated data. This data 
is also used to compare the model to SHM and an alternative variable selection approach 
originating from the field of industrial process monitoring. Finally, a case study involving a 
real metabolomics data set for diagnosis of IEM is used to demonstrate the value of sSHM 
for disease diagnosis in practice.  
6.2 Theory 
In sSHM an individual patient sample is compared to the NOC in two steps. In the first step 
the patient data is matched against the NOC and marked as normal (healthy) or possibly 
abnormal (possibly ill). When a sample is marked as abnormal a second step is used to 
identify the abnormal variables, i.e. the disease response in this individual. Below, it is first 
described how the Mahalanobis distance can be used to compare a patient to the NOC in 
this way. Next, the sSHM model, which combines the MD-statistic with variable selection, is 
introduced. Due to variable selection more subtle differences between the patient and NOC 
can be detected in the first step. Additionally, the disease response can be better identified 
in the second step. 
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6.2.1 The Mahalanobis distance 
To be able to compare a patient to NOC, a set of healthy control samples (𝐗!) that represent 
the NOC well has to be selected. Note that the choice of control samples defines what kind 
of patterns in the patient sample will be marked as abnormal. For example, if the patient 
data contains signal due to paracetamol intake, but the NOC data does not, this signal will 
be marked as abnormal. More details regarding the choice of NOC samples in the context of 
SHM are provided in chapter 5 [4]. We assume that the distribution of the NOC samples is 
multivariate normal. 
 
First, the patient is compared to the NOC by the squared Mahalanobis distance (𝑀𝐷!) [17]: 
 
 𝑀𝐷! = 𝐱! − 𝛍! 𝚺!! 𝐱! − 𝛍! ! > 𝑐 (6.1) 
	  
where 𝐱!, 𝛍!, and 𝚺 indicate the row vector of patient data, the mean vector of the control 
samples, and covariance matrix of the control samples, respectively. Geometrically, 
expression 6.1 tests whether the patient sample falls inside the confidence sphere of the 
control samples, where the upper limit c is traditionally derived from a scaled F-distribution 
[17]. Note that the sphere defines the NOC: any sample that falls inside the sphere is marked 
as normal. The shape and location of the NOC sphere are defined by 𝛍! and 𝚺. An example 
is shown in figure 6.1.  
 
If a sample falls outside the NOC it is abnormal and must be further inspected. The MD can 
also be used for this step. For this purpose another expression of the MD is used. More 
specifically, it has been shown that the squared Mahalanobis distance is the weighted 
distance between the scalar projections of 𝐱! and 𝛍! onto the vector 𝐚 = 𝐱! − 𝛍! 𝚺!!, i.e. 𝑀𝐷! = 𝐱! − 𝛍! 𝐚! !/𝑣𝑎𝑟(𝐗!𝐚!) [18]. Vector a is a canonical variate (CV) known from 
techniques such as Fisher LDA and MANOVA. The CV is indicated by the dotted line in 
figure 6.1. It is a linear combination of the variables that maximizes the difference between 𝐱! and 𝛍! relative to the variance of the controls [18]. Therefore, the coefficients of a can be 
studied to determine on which variables the patient sample differed most from NOC, where 
large absolute coefficients indicate abnormal variables. The abnormal variables are 
interpreted as the individual disease response of the patient. A clinical practitioner can use 
this information for example for disease diagnosis. 
 
Typically, only a few of the measured variables are related to a disease. However, all 
measured variables are taken into account by 𝑀𝐷!. As shown in appendix A the effect 
caused by the disease in a few variables may be masked by the normal variation in the other 
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variables. This can result in a considerable loss in power and hampers identification of the 
abnormal variables when inspecting direction a, especially when the effect is small. 
Additionally, equation 6.1 cannot be applied when the number of control samples is smaller 
than the number of variables because the inverse of 𝚺 cannot be computed. Because of this, a 
data-driven approach is introduced in this work to only take the most abnormal variables 
into account when comparing a patient to the NOC. This increases the power of the 𝑀𝐷!-
test and improves identification of the abnormal variables. 
6.2.2 Sparse Statistical Health Monitoring 
The defining feature of our approach is that we first estimate the canonical variate a before 
the MD is computed. Additionally, we regularize estimation of direction a with an ℓ𝓁!-norm 
constraint. This constraint is well known from techniques such as the LASSO and the elastic 
net [19]. It has the sparsity property in the sense that it will force some coefficients in a to be 
exactly zero indicating variables on which the patient was similar to the NOC. The MD is 
calculated using this sparse estimate to determine if the patient differs significantly from the 
NOC. In this sense the ℓ𝓁!-norm constraint introduces a variable selection step since only 
the variables with a nonzero coefficient in a contribute to the estimate of the MD. Sparse 
estimation of a is very useful to identify the abnormal variables in a sample. 
Sparse estimation of canonical vector a 
To be able to combine estimation of canonical variate a with a constraint, we first note that 
a can be estimated by maximizing the Rayleigh quotient 𝐚 𝐝!𝐝 𝐚! / 𝐚𝚺𝐚! , where 𝐝 = 𝐱! − 𝛍!. Wu et al showed that maximizing the Rayleigh coefficient is equal to the 
following expression [20]: 
 
 𝐚 = 𝑎𝑟𝑔𝑚𝑖𝑛𝐚 𝐚𝚺𝐚!     𝑠. 𝑡. (𝐱! − 𝛍!)𝐚! = 1 (6.2) 
 
Note that the inverse of 𝚺 doesn’t have to be estimated this way. However, the solution to a 
uses all variables and shares most of the problems as the normal MD. Therefore, an ℓ𝓁!-norm 
constraint is placed on the direction a to obtain a sparse solution, i.e. incorporate variable 
selection: 
 
 𝐚 = 𝑎𝑟𝑔𝑚𝑖𝑛𝐚 𝐚𝚺𝐚!     𝑠. 𝑡. (𝐱! − 𝛍!)𝐚! = 1, 𝑎! ≤ 𝜆!!!!  (6.3) 
 
where 𝑎! indicates the i-th coefficient of a, and 𝜆 is a fixed constant. The value of 𝜆 controls 
the amount of variables that are included in the model; when 𝜆 is small, most of the 𝑎! will 
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be exactly zero. Expression 6.3 can be solved in different ways. Here we use a fast algorithm 
that was developed by Wu et al to solve a sparse LDA problem [20, 21]. Note that 
expression 6.3 can also be written as a penalized regression problem using a suitable 
weighting of the data. This way, standard algorithms for sparse regression such as the 
LASSO or elastic net can be used to estimate a. 
 
Using a regularized estimate of 𝚺 could provide some further improvement; also it stabilizes 
the algorithm used to solve expression 6.3. In this work we regularize 𝚺 by adding the value 𝛿 ∗ log  (𝑝)/𝑛  to its diagonal elements, where 𝛿  is a small constant such as 2 or 4, p 
corresponds to the number of variables in the data and n to the number of training samples 
in matrix 𝐗!  [20]. More advanced methods are available such as linear or non-linear 
shrinkage methods [22]. However, these methods are computationally more demanding; 
additionally in this work we don’t want to entangle estimating covariance matrices with 
variable selection. 
Comparison of a patient to the NOC 
In sSHM, the dissimilarity between the patient and the NOC is evaluated by the squared 
MD using a sparse estimate of a: 
 
 𝑀𝐷!! = 𝐱! − 𝛍! 𝐚!!! !/𝑣𝑎𝑟(𝐗!𝐚!!! ) (6.4) 
	  
where 𝑀𝐷!! indicates a sparse squared Mahalanobis distance based on i selected variables. 
As mentioned above, the power of the method is increased by variable selection. The 
variables are selected in a data-driven fashion by equation 6.3, where 𝐚!!   is its solution with 𝜆 = 𝜆! chosen such that i variables are selected. Typically, a range of constants 𝜆!! < 𝜆!! <⋯ < 𝜆!" exists such that equation 6.3 gives a solution with i nonzero coefficients (i selected 
variables). The value for 𝜆! in (6.4) is always set to the highest constant in this sequence, i.e. 𝜆! = 𝜆!".  
 
For each patient there is an optimal number of selected variables such that a possible 
difference with the NOC can be best observed. This number depends on how much the 
patient differs from the NOC in the abnormal variables with respect to the accumulating 
noise due to normal variation in the other variables (see appendix A). In practice, however, 
this number is unknown. In this work we use two approaches to resolve this issue. The first 
approach was suggested by Wang et al in the context of industrial process monitoring 
where they used domain knowledge to restrict the solution of their sparse model to i 
variables [23]. In the context of sSHM this means that the clinical practitioner must have a 
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rough idea regarding how many variables are affected by e.g. a disease in the patient data. 
Our simulation studies show that often a significant difference from NOC can be detected 
by selecting roughly this expected number of variables. The second approach is to determine 
i from the data by selecting that number of variables for which the largest distance 𝑀𝐷!! is 
observed. However, this is not a straightforward task since distances based on different 
amounts of selected variables are not directly comparable [24]. Therefore, a normalization 
step is used to fairly compare the 𝑀𝐷!!-values: 
	  
 𝑀𝐷!"#! = max!!!⋯!𝑀𝐷!! − 𝐸(𝑀𝐷!!)√𝑉𝑎𝑟(𝑀𝐷!!)  (6.5) 
	  
where 𝐸(𝑀𝐷!!)  and 𝑉𝑎𝑟(𝑀𝐷!!)  are the mean and variance of 𝑀𝐷!!  for control samples, 
respectively. The values for 𝐸(𝑀𝐷!!) and 𝑉𝑎𝑟(𝑀𝐷!!) are estimated from the control data by 
means of leave-one-out cross-validation (LOO-CV). Zou et al and Capizzi et al. also used 
this approach to select the optimal number of variables in their sparse industrial process 
control methods [25, 26].  
 
After selecting a specific number of variables a significance test is required to determine if 
the patient indeed differs from NOC. For this purpose, the upper limit of 𝑀𝐷!! and 𝑀𝐷!"#!  is 
estimated from a generalized extreme value distribution. Note that the significance test does 
not test whether the sample is significantly different from the NOC on the specific variables 
selected by equation 6.3 for that sample. The fact that each sample (control and patient) may 
differ from NOC on completely different variables is taken into account. More details are 
provided in appendix B. 
Identification of abnormal variables 
As described above, the first step of sSHM is to use equation 6.3 to detect a significant 
difference between the patient and the controls. The second step involves interpretation: if a 
sample is found to be significantly different from NOC the subsequent goal is to identify 
most (all) abnormal variables, e.g. the individual disease response. Again, variable selection 
is useful in this respect. In principle, the abnormal variables should be selected first by the 
model and can thereby be identified this way. However, it is unclear how many abnormal 
variables are present in a sample and should therefore be selected. Expression 6.5 seems to 
be useful to automatically select all relevant variables. However, our simulations show that 
this test (that is designed to best observe differences between a patient and NOC) does not 
always reliably identify the abnormal variables (see e.g. figure 6.6a). Similarly, when the 
coefficients of 𝐚!!  for a specific number of selected variables are inspected it can be that too 
many noise variables are included masking the relevant variables (see e.g. figure 6.3a), or 
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that not all relevant variables are selected. Additionally, interpretation of a specific solution 
depends on scaling of the data (e.g. standardized or unstandardized coefficients) although 
the data is typically autoscaled to ensure that the ℓ𝓁!-norm constraint 6.3 affects each 
variable equally. Therefore, we propose to inspect multiple solutions with different numbers 
of selected variables together in the so-called solution path figure to identify most of the 
abnormal variables. Examples will be provided in the results section in figures 6.4 and 6.6.  
 
The solution path offers an intuitive way to see in which order the variables were selected by 
sSHM. Based on this information the variables can be ranked, where it is assumed that the 
most abnormal variables are selected first. The ranking is scale invariant. A clinical 
practitioner can inspect the top ranked variables to determine the patient’s response to e.g. a 
disease, where the number of variables to inspect can be chosen based on practical 
considerations (i.e. it is not feasible to inspect more than 50 variables). Additionally, as soon 
as it is clear that a number of variables corresponding to a specific diagnostic marker have 
been selected, the solution path offers an intuitive way to quickly assess the selection rank of 
other variables that are biologically related to this marker. 
6.3 Methods 
We use simulated and real data to investigate the properties of the sSHM model under 
different structures of the NOC. The simulation study was also used to compare sSHM to 
competitive methods such as SHM with a focus on identification of the abnormal variables 
in a patient. These methods were applied according to the protocols described in the 
original papers [4, 26, 27]. The methods are also briefly explained in appendix E. In the 
main text of this paper, we mainly discuss the comparison between sSHM and SHM in the 
context of reliable identification of abnormal variables.  
6.3.1 Simulation design 
A simulation study was used to compare the SHM and sSHM models. Identification of 
abnormal variables by SHM is reliable when only one variable is abnormal [14, 15]. In this 
simulation, two variables were abnormal. Correct identification by SHM is not guaranteed 
in this case due to variable smearing (see appendix E) [14, 15, 27]. Therefore, this simulation 
design was enough to highlight the main difference between SHM and sSHM. The 
simulation was carried out for different structures of the NOC. Throughout the simulation 
it was assumed that the distribution of healthy controls was multivariate normal 𝑁(𝟎,𝚺). 
The covariance matrix 𝚺 was constructed by multiplication of a predefined correlation 
structure R with variance values drawn from the uniform distribution 𝑈(0.1,16).  
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It is difficult to simulate correlation structures R that closely resemble the complex 
structures of metabolomics data. Therefore, we studied three “simple” structures to be able 
to systematically explore the properties of the sSHM method. Note that the simulated data 
contained some aspects of real metabolomics data such as correlations between variables, 
grouping of variables, and irrelevant noise variables. Additionally, we applied sSHM to real 
NMR metabolomics data to study its performance for more complicated correlations (see 
section 6.3.2 below). The following correlation structures were considered in the simulation 
study: 
 
1. R1 Common correlation: all variables were correlated to each other with value 𝜌   
2. R2 Block-diagonal: blocks of variables were correlated to each other with value 𝜌. 
The different blocks were uncorrelated. Four blocks were defined; each block 
contained 25 variables. The first 25 variables corresponded to the first block, the 
26th to 50th variables to the second block, etc. 
3. R3 Toeplitz structure: variables close to each other were more highly correlated 
compared to variables that were far apart. The distance between variables with 
indices 𝑝1 and 𝑝2 was defined as 𝑝1 − 𝑝2 . For example, the distance between the 
first and fourth variable in the data is equal to three. The correlation between 
variables was given by 𝜌 !!!!! . 
The correlation 𝜌 was set to 0, 0.4, 0.6, and 0.8. The correlation structures are visualized in 
figure 6.2. Note that when the correlation was set to zero an independent covariance 
structure was obtained.  
 
In the simulation the number of variables in the data set was varied between 10 and 100. 
Additionally, the number of control samples that was used to train the sSHM model (i.e. 
used to estimate 𝛍!and 𝚺 in equation 6.3) was 50 or 1000. These samples were drawn from 𝑁(𝟎,𝚺) with a specific covariance matrix as defined above. Next, test samples were 
simulated. These samples were different from NOC on two variables. The amount of 
difference was varied by constant 𝑓, which ranged from 0 to 3 in steps of 0.25. Note that the 
test samples were similar to the controls when f was 0. In this case sSHM should not mark 
them as significantly different from NOC. A thousand samples were simulated for each 
value of 𝑓 as follows to ensure that the canonical vector a was sparse: 
	  
 𝐱! = 𝐱! + 𝑓(𝑒! + 𝑒!)𝚺 (6.6) 
	  
where 𝐱! indicates a row vector that was drawn from 𝑁(𝟎,𝚺), i.e. a control sample. Note that 
half of the samples had a negative sign in 𝑓. The two abnormal variables were defined by  
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Figure 6.2   A graphical representation of (a) the common variance, (b) the block diagonal, and (c) the 
Toeplitz, correlation structures with 𝜌 = 0.6 that were used in the simulation study. Structures (a-c) are equal 
to an independent structure when 𝜌 = 0. This is shown in panel d. 
unit vectors 𝑒! and 𝑒! , where i and j indicated their indices. For each simulated sample, the 
indices 𝑖 and 𝑗 were drawn from a uniform distribution. Prior to construction of the models, 
all simulated samples were autoscaled to the mean and standard deviation of their 
corresponding control samples.  
6.3.2 Diagnosis of inborn errors of metabolism 
To assess the value of sSHM for disease diagnosis, a set of urine samples of 193 healthy 
children and a set of 24 patients was measured using proton NMR spectroscopy. Eighteen 
patients were known to suffer from one of seven different IEM. For the other six patients, no 
IEM was diagnosed, but signals related to commonly prescribed drugs such as depakine and 
paracetamol were found in the NMR spectra. Note that a subject had to be between 4—12 
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years old to participate in the study and be of Dutch ancestry. An equal amount of males 
and females were selected. No other selection criteria such as lifestyle or diet were imposed. 
The study was approved by the medical ethical committee of the Radboud University 
Medical Centre in Nijmegen, The Netherlands. More details regarding the data can be 
found in section 5.3.1 [4]. This section also includes more information regarding the 
measurement and subsequent processing of the NMR data. Briefly, the regions 0.2-4.7 ppm 
and 5.0-10.0 ppm were selected for further analysis. Next, the urine NMR spectra were 
normalized to the creatinine concentration to correct for dilution effects. Equidistant 
binning with a bin size of 0.04 ppm was used to reduce the normalized data from 30888 
measurements to 246 bins. Finally, Pareto scaling was applied to the data for reasons 
justified in section 6.4.3. 
 
Since outliers in the set of controls can heavily influence an sSHM model, the spectra of the 
193 healthy children were inspected using robust PCA. Seventeen samples with abnormal 
patterns related to dietary influences and drug intake were identified. These samples were 
marked as abnormal and used to validate the sSHM model since detection of abnormal 
patterns due to diet and drugs is in principle no different from the detection of 
abnormalities related to disease. The set of 24 patients was also used for this purpose. 
Additionally, another set of 56 samples from the remaining 176 healthy controls was used to 
validate the model. The remaining healthy control samples were used to train the sSHM 
model and define the NOC. Based on their value in equation 6.5, it was observed during 
cross-validation of the 120 training samples that 2 of these samples greatly differed from the 
others. Visual inspection of the data showed that this was due to bad baseline correction and 
water suppression. Therefore, these samples were excluded from further analysis.  
 
As explained in section 6.2.2, the sSHM model improves the Mahalanobis distance in two 
ways. Firstly, a variable selection step is introduced. Secondly, the model is regularized by 
adding 𝛿 ∗ log  (𝑝)/𝑛  to the diagonal elements of covariance matrix 𝚺 . To clearly 
demonstrate the advantage of variable selection by sSHM compared to just the 
regularization of 𝚺, the analysis was repeated 15 times where each time the data was 
concatenated with a block of 100 additional random variables (noise bins). The bins were 
normally distributed with zero mean and a standard deviation chosen such that the 
intensity of the noise bins was roughly equal to the median peak intensity of the control 
samples. 
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6.4 Results	  
6.4.1 Analysis of the simulated samples 
As mentioned in section 6.3.1, the main properties of the sSHM model were studied by 
simulation. A large number of control and patient samples were simulated for different 
structures of the NOC. Below, the analysis of a single simulated sample is described to 
demonstrate the main properties of the method. Additional details of the simulation study 
such as the empirical type I and type II error rates of the sSHM model are presented in 
appendix material C.  
Detection of abnormal samples 
Here, we consider a single simulated sample (f    =   2 in equation 6.6) for the case where the 
correlation matrix of the control samples had a Toeplitz structure with 𝜌 = 0.6 and 50 
training samples were available. The simulated sample was automatically compared to the 
NOC by sSHM. As shown in table 6.1, a significant difference could be observed due to 
variable selection. When using a significance level of 5%, for example, no significant 
difference was observed when all variables were taken into account: the effect of the 
abnormal variables was masked by the “noise” of the other variables. In contrast a clear 
difference was observed when only 2 variables were selected. This was expected since the 
simulated sample contained two abnormal variables. In real applications the number of 
variables that should be selected is unknown. As shown in the table, the simple 
standardization suggested in equation 6.5 ignored enough irrelevant variables such that a 
difference between the patient and the NOC was observed: the observed p-value was similar 
as the p-value found for the solution with 2 selected variables. Similar results were obtained 
for the other simulations (see appendix C).  
Table 6.1   Accuracy of different sSHM tests for health monitoring of a simulated patient sample. 
Number of selected variables p-value 
   
Manual 2 0.00 
 10 0.00 
 25 0.12 
 75 0.12 
 100 0.14 
Automatic 1 0.00 
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Figure 6.3   The canonical vectors of an sSHM model where (a) all variables were selected and (b) 2 variables 
were selected. These results were obtained for analysis of the same simulated patient sample as analysed in 
table 6.1. It was known that two variables were abnormal. These are marked red in the figure. The irrelevant 
(normal) variables are marked blue.  
Identification of abnormal variables 
The observed significant difference between the simulated sample and the NOC suggested 
that the sample should be further investigated to identify which variables were abnormal. 
Figure 6.3a shows the estimates of the coefficients of the canonical vector a that were 
obtained when all variables were selected. The abnormal variables (solid red circle, solid red 
line) could barely be distinguished from the irrelevant variables (blue empty circle, blue 
dotted line). Identification was greatly improved by the variable selection step in sSHM as 
shown in figure 6.3b. In this case the abnormal variables were easily identified since they 
were the only two variables that were selected.  
 
In this simulation it was known that only 2 variables were abnormal. In real applications, 
however, this number is not exactly known and it can be difficult to select the right solution 
to inspect. Therefore, it is preferred to inspect multiple solutions together in the so-called 
solution path figure. The path found for this simulation is shown in figure 6.4. The solution 
path displays the estimated coefficients of a for all possible values of the ℓ𝓁!-norm constraint 
(see equation 6.3). The lines in the figure are the paths of the coefficients shrinking towards 
zero as a function of the constraint. This allows a clinical practitioner to see how specific 
variables behaved as a function of the constraint. Note that the x-axis has been scaled to 
have a maximum value of one3. A value close to 0 means that the 𝑙!-norm constraint was 
large and only a few variables were selected (had nonzero coefficient), while a value of 1  
 
                                                                  
3 The x-axis corresponds to the proportion of shrinkage ( 𝐚 !!/ 𝐚 !!) instead of the size of the 𝑙!-norm constraint. 
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Figure 6.4   Solution path of an sSHM model applied to a simulated patient sample. The known abnormal 
variables are indicated by the solid red lines. The irrelevant (normal) variables are marked by dotted blue lines. 
The vertical dotted line indicates the solution found by automatic variable selection (equation 6.5). 
indicates that all variables were selected. The solutions corresponding to figures 6.3a and 
6.3b can be found at 0.19 and 1, respectively. 
 
Moving from left to right in the solution path figure provides an intuitive way to see at 
which points a variable had a nonzero coefficient, i.e. was selected. In this case, the solution 
path clearly shows that the first two variables that were selected corresponded to the 
abnormal variables in the simulation (red solid lines). This demonstrates that the 
information in the solution path can be used to rank the variables, where it is assumed that 
the abnormal variables are among the first selected ones.  
 
Note that the solution found by automatically variable selection with expression 6.5 selected 
only one of the two relevant variables. Therefore, inspection of the full solution path is 
preferred for identification of abnormal variables.  
6.4.2 Comparison between SHM and sSHM 
The main motivation for the development of sSHM was the unreliable identification of 
abnormal variables by SHM due to variable smearing (see appendix E). Below, the SHM and 
sSHM model are compared with respect to analysis of the simulated data. The analysis of 
the data by SHM was carried out according to the protocol described in section 5.3.3 [4] 
(see appendix E for more details regarding the SHM model). It was observed that SHM and 
sSHM had similar type I and type II error rates with respect to identification of significant  
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Figure 6.5   Correct identification of the abnormal variables in simulated patient samples by sSHM, and SHM as 
a function of the size of the abnormality. 
differences between the simulated samples and the NOC. More details are provided in 
appendix E. Note that a big advantage of sSHM compared to SHM was that no parameter 
optimization was required: it is well known that the number of selected principal 
components can greatly influence the results of an SHM model [16]. 
 
As expected, sSHM greatly outperformed SHM with respect to identification of the 
abnormal variables in the samples. This is shown in figure 6.5 for the case that 50 training 
samples were available to define the NOC. To allow for a fair comparison between the 
different approaches it was assumed that all samples were correctly marked as significantly 
different from NOC. The x-axis in the figure expresses the difference between the NOC and 
the simulated patient as defined by constant 𝑓  in equation 6.6. The y-axis shows the 
percentage of simulated samples in which the abnormal variables were correctly identified. 
Correct identification was achieved by sSHM when the first two selected variables were the 
abnormal ones. Identification of abnormal variables in SHM was achieved by studying the 
so-called contribution values [4]. Correct identification was achieved when the two 
abnormal variables had the highest contribution values. Note that SHM compared the 
patient to the NOC in two subspaces, namely a space spanned by the k selected principal 
components and the orthogonal or residual subspace. The green curve (labeled Hotelling 
T2) in figure 6.5 corresponds to the contribution values found in the subspace spanned by 
the selected PCs and the cyan curve (labeled Q) corresponds to the values found in the 
residual subspace. From figure 6.5 it is clear that for sSHM and SHM the identification rate 
improved when the difference between the patient and the NOC was larger. However, as 
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shown in figure 6.5 the identification rate of SHM remained below 40% for the values of 𝑓 
considered. With sSHM considerable higher identification rates were achieved. 
 
We also performed a comparison of SHM and sSHM to a third technique from the field of 
industrial process monitoring, namely sparse statistical process monitoring (sSPC; see 
appendix E). Similar to sSHM this method combines the MD with variable selection, 
although in a different way. It was found that sSHM outperformed sSPC in most scenarios.  
6.4.3 Diagnosis of inborn errors of metabolism 
Inborn errors of metabolism are a group of rare genetic defects that collectively occur in 
roughly 1 out of every 5000 individuals. Therefore, they are an important group of diseases 
to consider. Unfortunately, standard classification models such as (Partial Least Squares – 
Discriminant Analysis) cannot be used to diagnose these diseases since the number of 
training samples is extremely limited. In chapter 5, SHM was successfully used to analyze 
NMR data and diagnose several IEM [4]. Below, we will use the same data to show the value 
of sSHM in a practical example. As shown in table 6.2, the data did not only contain 
abnormal patient samples related to IEM, but also abnormalities related to diet and 
medication. These abnormalities had already been observed by visual inspection of the data 
and were also used to validate the sSHM approach since detection of abnormal patterns due 
to diet and medication is in principle no different from detection of metabolites related to a 
disease.  
 
First, the data were analyzed after autoscaling. An improvement of roughly 10% in terms of 
the percentage of correctly identified patient samples (the specificity) was observed due to 
variable selection by sSHM. However, subsequent correct identification of the abnormal 
metabolites was hampered by the large influence of baseline signal on the model due to the 
autoscaling. Therefore, it was decided to apply Pareto scaling to the data instead. In this 
case, the abnormal metabolites were better identified (see below). As shown in table 6.3, 
however, the effect of variable selection on the number of correctly identified patient 
samples was less clear in this case. sSHM in combination with a large number of selected 
variable could also be used to identify the abnormal samples. This is attributed to the fact 
the the sSHM model also slightly regularizes the covariance matrix of the training samples 𝚺 
(see section 6.2.2). The original MD (equation 6.1) was not applicable to this data since the 
number of training samples was smaller than the number of variables. To clearly show the 
advantage of the variable selection step for the Pareto scaled data, the analysis was repeated 
15 times. In each repetition the data was concatenated with a block of 100 irrelevant 
variables. As shown in table 3, the percentage of correctly classified samples was improved 
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Table 6.2   An overview of the abnormal samples that were investigated by NMR metabolomics in combination 
with sSHM. Note that the data was also analyzed in [4]. More details regarding the abnormalities can be found 
in this reference. The diagnostic metabolites that were used to diagnose each IEM are included in appendix F. 
Disease (IEM) n Dietary n Medication n Other n 
 	         3β-­‐Hydroxy-­‐Δ-­‐C!"-­‐steroid 
dehydrogenase deficiency 	   1	   Cyclamate (artificial sweetener) 3 Depakine 1 Bacterial contamination 3 
3-Methylcrotonyl CoA 
carboxylase deficiency 
1 Fish 5 Paracetamol 5 
High Taurine signal 
(cause unknown) 
3 
5-Oxoprolinuria 1   Piracetam 2   
Alkaptonuria 1   Sabril 1   
Cystinuria 2       
Formiminotransferase 
deficiency 
2       
Isovaleric aciduria 1       
Table 6.3   Accuracy of different sSHM tests for health monitoring of 56 healthy and 41 abnormal samples for 
analysis. The original data as well as a concatenation of the data with 100 irrelevant bins was analysed. The 
sensitivity and specificity indicate the percentage of correctly classified healthy and abnormal samples, 
respectively. Note that high numbers of variables could be selected due to the regularization of covariance 
matrix 𝚺 that was applied (see section 6.2.2). The reported results for the analysis with 100 irrelevant bins 
correspond to the average of 15 repetitions.  
Number of 
irrelevant bins 
Number of selected bins Accuracy Sensitivity Specificity 
      
0 Manual 2 95.2 100 90.5 
  20 95.2 100 90.5 
  50 95.2 100 88.1 
  100 94.1 100 88.1 
  200 94.1 100 90.5 
 Automatic 1 - 246 95.2 100 90.5 
      
100 Manual 2 95.2 100 90.5 
  20 93.9 99.6 88.1 
  50 93.0 98.8 87.1 
  100 92.8 99.6 86.0 
  200 92.5 99.9 85.0 
 Automatic 1 - 346 94.6 100 89.1 
 
by variable selection in this case. Note that the highest accuracy was obtained when the 
number of variables to select was automatically estimated by equation 6.5. All abnormal 
samples due to an IEM were correctly identified by sSHM. Four other samples were not 
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correctly identified. The abnormality in these samples was related to cyclamate (2x), 
paracetamol, and bacterial contamination.  
 
After a sample had been marked as abnormal, the next step was to identify the abnormal 
metabolites. Again, it was observed that expression 6.5 could not be used in this step as 
indicated in e.g. figure 6.6a. Via inspection of the solution path figures, however, all IEM 
were successfully diagnosed and all dietary and medication abnormalities were successfully 
identified. Two examples are presented in figure 6.6. The solution paths of the other samples 
are shown in appendix F. In these figures the solid red lines indicate the variables 
(resonances in the NMR spectrum) that were known to be related to the IEM and other 
abnormalities in the data. These resonances should be selected first by the model. For clarity 
the relevant features are indicated in the NMR spectrum in panels b and d. In each case the 
variable selection rank (VS) indicates when the variable was selected by the sSHM model, 
where “1” corresponds to the first variable that was selected (the first nonzero coefficient in 
the left of panel a), etc. The IEM and other abnormalities were correctly diagnosed when 
enough of the relevant features had low VS values.  
 
In the solution path of the first example in figure 6a the first four bins that were selected (VS 
1 – 4) corresponded to resonances around 6.76 ppm and 3.64 ppm. This indicates that these 
resonances were abnormal compared to the NOC. The resonances indicate that a high 
amount of homogentisic acid was present in the urine of the patient, which is indicative for 
Alkaptonuria disease. In this case all known resonances (red lines) were selected first by the 
model and the diagnosis was clearly made. The second example is shown in figure 6c. This 
example is considered more difficult since it involved many resonances in many different 
parts of the NMR spectrum. The bins centred around 2.16, 5.14, 7.13, 7.31, 7.45, 9.67 and 
9.78 ppm were clearly marked by the model as abnormal. All these features had VS values 
lower than 20. This suggested that the metabolites acetaminophen, acetaminophen-
glucuronide, and acetaminophen-sulphate were present in high concentrations. This was 
caused by intake of paracetamol by this individual.  
6.5 Discussion 
In this work, sSHM was introduced for rapid screening of patients for many diseases. The 
properties of the method were investigated by simulation. Additionally, sSHM was 
successfully applied to real NMR metabolomics data to diagnose several IEM. The same 
data was previously investigated by the SHM model in chapter 5 [4]. Therefore, sSHM and 
SHM can be compared with respect to this application.  
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Figure 6.6   (a, c) Variable selection paths of sSHM models applied to the NMR data of a urine sample of two 
patients. The relevant diagnostic resonances are indicated by the solid red lines. The vertical dotted line 
indicates the solution of the maximum test (equation 6.5). (b, d) Plot of the NMR spectra highlighting the 
relevant diagnostic resonances and their variable selection rank (VS). The metabolites are markers for (a, b) 
Alkaptonuria disease, and (c, d) intake of paracetamol by the patient.  
The methods had similar power to identify normal and abnormal samples. Compared to 
sSHM, SHM also correctly identified a significant difference between the four samples that 
were misclassified by sSHM. Next, SHM used contribution plots to identify the abnormal 
variables for the samples that were marked as significantly different. The contribution plots 
identified enough key variables as abnormal to make a diagnosis. However, interpretation of 
the plots was less straightforward because of two reasons: (1) the contribution values 
couldn’t be reliably interpreted due to the so-called smearing effect (see appendix E), and 
(2) the contributions of the relevant variables differed by orders of magnitude making it 
difficult to visually inspect the results. In contrast, sSHM does not suffer from the smearing 
effect allowing for much better identification of the abnormal metabolites as shown in 
figure 6.6. This clearly shows that sSHM is a useful alternative to SHM in a clinical setting.  
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In this study it was shown that sSHM ranks the variables from abnormal to normal by 
variable selection. A clinical practitioner can use this information, which is visualized in the 
solution path figure, to diagnose a disease. Currently, however, no clear guidelines on how 
many of the top-ranked variables should be inspected are available. Equation 6.5 could 
clearly not be used for this purpose, nor is this expression based on firm statistical theory. It 
would be interesting to develop another strategy to obtain an upper bound. A possibly 
interesting approach in this respect is offered by stability selection [28]. Essentially, this 
method aggregates the results of multiple variable selection sSHM models that were applied 
to subsamples of the data. An attractive property of this method is that it allows for error 
control on the expected number of falsely selected variables. Additionally, for the LASSO 
model it has been shown that variable selection itself may improve markedly due to stability 
selection. This suggests that more abnormal variables might be among the first selected 
when sSHM is combined with stability selection. 
 
The idea of combining the Mahalanobis distance with variable selection is not new. Several 
other methods have been proposed in the context of industrial process monitoring. These 
methods apply variable selection directly to the difference between the patient and the 
centre of the controls, i.e. 𝐱! − 𝛍!. However, this does not guarantee that the canonical 
variate   𝐚 = 𝐱! − 𝛍! 𝚺!! is sparse. The CV is directly penalized by sSHM. Because of this, 
sSHM is better able to identify abnormal variables in many situations. As mentioned in 
section 6.4.2 and appendix E this was indeed observed in our simulation study. 
 
Similar to SHM, selection of the control samples is critical for practical application of sSHM 
for disease diagnosis. In principle, any metabolic variation that is not included in the NOC 
set will be marked as abnormal by the method. For example, in this study dietary 
abnormalities were not included in the NOC, and because of this some test samples were 
marked as abnormal based on their diet. If this is undesirable we suggest that a much larger 
cohort of control samples is used. If this cohort is randomly selected it should contain most 
common lifestyles and diets. Instead of using a larger cohort of samples, an interesting line 
of future research could also be to define the NOC at an individual level instead of a 
population level. It is expected that the resulting sSHM model would be able to detect more 
subtle abnormalities since no intra-individual differences are included in the NOC.  
 
If the NOC is defined at a population level, it is important that the set does not contain 
outliers, such as people who are ill. Therefore, we propose to screen the control data by a 
robust PCA model before application of sSHM. Any NOC samples that are significantly 
different from the robustly defined NOC are excluded from further analysis. This approach 
was used to inspect the metabolomics data in section as described in section 6.3.2. An 
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alternative strategy to develop a robust method would be to replace 𝛍! and 𝚺 in equation 6.3 
by robust estimators of location and scatter. However, this method is expected to perform 
similarly to the robust PCA approach.  
6.6 Conclusion	  
In this work a new method – sSHM - for identification of disease biomarkers in individual 
patients was proposed. An advantage of this approach is that it can be used for screening of 
patients for a multitude of (rare) diseases. Additionally, the method offers perspectives in 
the framework of personalized health. 
 
The sSHM method combines the Mahalanobis distance with variable selection. This way 
patient samples that are different from the expected healthy metabolic phenotypes (the 
normal operating conditions) can be better identified. Additionally, variable selection allows 
for identification of the abnormal variables when a patient is significantly different from 
NOC. As was shown by simulation and application to a real data set, sSHM can reliably 
identify patient samples and their individual disease biomarkes in many scenarios. The 
method has great advantages compared to SHM model that was proposed in chapter 5, 
especially with respect to identification of the individual disease biomarkes. Additionally, 
no optimization of the number of principal components is required as with SHM. However, 
the sSHM model is computationally more expensive. 
 
sSHM is a general method that is not only applicable to metabolomics data. For example, 
most likely it could be of great value in industrial process control applications as well.  
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Appendices 
A. The effect of noise variables on the Mahalanobis distance 
It can be shown that 𝑀𝐷!  is the optimal single-test statistic when a disease affects all 
variables simultaneously. However, often more structured abnormalities such as shifts in 
only some of the variables are expected, i.e. only a few metabolites are related to the disease. 
In this case all the other variables that were measured can be considered as irrelevant or 
noise. The 𝑀𝐷! is not optimal for such shifts as shown using the simulation presented in 
figure A.1 [24]. The simulated data contained 100 variables and 1000 control samples drawn 
from a standard normal distribution. The patient samples were drawn from the sample 
distribution and subsequently the values of a subset of the variables were set to 2, i.e. they 
differed from the controls on these variables. The number of abnormal variables was varied 
from 1 to 100; 1000 patient samples were simulated in each case. As shown in the figure, the 𝑀𝐷!-statistic can hardly detect patients with small abnormalities in only a subset of the 
measurements. Once the number of abnormal measurements is above 20 (in this example), 
the patients become the highest scoring samples. Zimek et al. highlight that many other 
outlier detection routines suffer from the same problem [24]. This example shows that 
detection of significant differences between a sample and the NOC may be improved by 
variable selection: the accumulating noise in irrelevant variables is reduced by selecting 
most (all) abnormal variables and only a limited number of irrelevant variables. 
 
 
Figure A.1   Outlier detection based on the Mahalanobis distance in simulated data. Note that the MD couldn't 
identify outliers with only a few abnormal variables. 
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B. Significance testing with the sparse Mahalanobis distance 
After selecting a specific number of variables a significance test is required to determine if 
the patient indeed differs from NOC. As mentioned above, an F-distribution is often used 
to determine the upper limit of 𝑀𝐷! when all p variables are taken into account. However, 
this distribution is not applicable since we combine the MD-statistic with variable selection 
in this work. Even for healthy control samples there is a high probability that the sample has 
extreme (outlying) values in a subset of the variables. For example, for p independently 
normally distributed dimensions, the combined probability of an object appearing to be 
normal ( 𝛼 = 5%)  in every single dimension is 0.95! . For 𝑝 = 10  and 𝑝 = 100  the 
probability equals 59.9% and 0.592%, respectively. In other words, every object is extreme 
in at least one dimension in high-dimensional distributions. Because of this, we use extreme 
value theory to determine an upper limit for 𝑀𝐷!! and 𝑀𝐷!"#! .  
Fitting the Generalized Extreme Value distribution. 
The Fisher-Tippet theorem states that the distribution of extreme values can be described by 
the generalized extreme value (GEV) distribution [29]. The GEV has the following 
cumulative distribution function: 
	  
 
𝐹 𝑥 = 𝑒𝑥𝑝 − 1 − 𝜅𝑠 𝑥 − 𝜉 !!       𝜅 ≠ 0 𝐹 𝑥 = 𝑒𝑥𝑝 −exp   − 1𝑠 (𝑥 − 𝜉)       𝜅 = 0 (B.1) 
 
or in inverse form 
	  
 𝑥 𝐹 = 𝜉 + 𝑠𝜅 1 − − ln𝐹 !       𝜅 ≠ 0 𝑥 𝐹 = 𝜉 − 𝑠 ln − ln𝐹       𝜅 = 0 (B.2) 
 
where 𝜅 is a parameter that controls the shape of the distribution, 𝜉 is a location parameter 
and 𝑠 is a scale parameter [29]. Note that 𝑥 refers to the value for 𝑀𝐷!! or 𝑀𝐷!"#!  that was 
found for a specific sample (patient or control). Note that equation B.2 can be used to 
determine the upper limit for the 𝑀𝐷!! or 𝑀𝐷!"#! -statistics defined in equations 6.4 and 6.5 
in the main text. Typically a value of 𝐹 = 0.95 is chosen corresponding to a 5% significance 
level.  
 
In order to use equations B.1 and B.2 the parameters 𝜅, 𝜉, and 𝑠 need to be estimated from 
the training data (a set of control samples). Typically a leave-one-out cross-validation 
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(LOO-CV) procedure is used to determine what values for 𝑀𝐷!! or 𝑀𝐷!"#!  can be expected 
for samples that match the NOC. These values are ordered in ascending order. Maximum 
likelihood can be used to fit a GEV to these cross-validated values [29]. However, in cases 
when the sample size is small this method is known to be suboptimal. In this work we use 
the method of L-moments instead. Below, we present the required equations to be able to 
implement the method. More details can be found in numerous references such as [30].  
 
The parameters of the GEV distribution are easily computed using L-moments via the 
following relationships: 
	  
 
𝜅 = 7.8590𝑐 + 2.9554𝑐!  𝑠 = 𝜅𝑙!/ Γ(1 + 𝜅)(1 − 2!!)  𝜉 = 𝑙! + 𝑠𝜅 Γ 1 + 𝜅 − 1  (B.3) 
 
where 𝑐 = !!!!!!!!! − !" !!" ! , and Γ() is the Gamma function. The values 𝑙!, 𝑙!, and 𝑙! are the first 
three L-moments. The L-moments have a simple interpretation as measures of location, 
dispersion and shape of the data. The first three sample L-moments are given by: 
	  
 
𝑙! = 𝑏!  𝑙! = 2𝑏! − 𝑏!  𝑙! = 6𝑏! − 6𝑏! + 𝑏!   (B.4) 
 
where	  𝑏! 	  is	  the	  so-­‐called	  r-­‐th	  probability	  weighted	  moment	  defined	  by: 
 
 𝑏! = 1𝑟 + 1 𝑗 − 1𝑟!!!!!! 𝑥!/ 𝑛𝑟 + 1    (B.5) 
 
Note that 𝑥!  corresponds to the j-th value in the sequence of ordered and cross-validated 
values of 𝑀𝐷!! or 𝑀𝐷!"#!  of the training samples. 
C. Investigation of the type I and type II errors of sSHM 
A large number of control and patient samples were simulated for different structures of the 
NOC (see section 6.3.1). Either 50 or 1000 healthy control samples were used to define the 
NOC. The other samples were used to study the type I and type II error rates of the 𝑀𝐷!!	  or	  𝑀𝐷!"#! -statistics with respect to detection of significant differences between a sample and 
the NOC. It was observed that the type I and type II errors were similar across all  
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Figure C.1   The power of the sSHM, sSPC, and SHM (T2, Q) tests as a function of the size of the abnormality. 
The sSHM test was used with manual (M) and automatic (A) specification of the number of variables that 
should be selected. Panels a – d correspond to different configurations of the number of training samples and 
variables in the data; n = 50 and p = 10 in panel a; n = 1000 and p = 10 in panel b; n = 50 and p = 100 in panel c; 
and n = 1000 and p = 100 in panel d. 
simulations with different correlation structures of the NOC. As an example we show the 
results that were obtained when the correlation structure corresponded to a Toeplitz matrix 
with 𝜌 = 0.6. 
Investigation of the empirical type I error 
A type I error occurred when a significant difference between a healthy sample and the 
NOC was observed. A sample was marked as significantly different when the value of the 
test statistic (𝑀𝐷!!	  or	  𝑀𝐷!"#! )	  exceeded the cut-off value defined by equation B.2. 
 
The results are shown in figure C.1 for different combinations of number of training 
samples and variables. The x-axis in the figure corresponds to the parameter 𝑓 defined in 
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equation 6.6. When 𝑓   =   0  the simulated samples had the same characteristics as the 
controls, i.e. these samples were healthy and could be used to study the type I error. The 
correct identification rate displayed on the y-axis is defined as the percentage of simulations 
in which the method marked the simulated sample as significantly different. In other words, 
the y-value in the figure at 𝑓   =   0 directly corresponds to the empirical type I error. Note 
that the curves labeled as sSPC, 𝑇!, and 𝑄 in the figure were obtained with other methods 
than sSHM. These curves are discussed in appendix E where sSHM is compared to these 
other methods. Here, we focus on the results of the 𝑀𝐷!! and 𝑀𝐷!"#!  statistics.	  
 
From the figure it is clear that for all tests the type I error was reasonably close to the chosen 
significance limit of 5%. Similar patterns were observed for other significance levels, i.e. 1% 
and 10%. This indicates that the cut-off-point of the test could indeed be estimated from a 
GEV as in equation B.2. The GEV distribution, however, can be heavily skewed. Because of 
this, the fit became less accurate for smaller numbers of training samples. However, the 
estimated cutoff values were still more accurate compared to the values that were directly 
based on the empirical distribution of the test statistic (results not shown). Additionally, the 
resulting inaccuracies in the cut-off value were similar to what was observed for well-
established upper limits of the statistics used in SHM. Therefore, the estimation of the 
cutoff-point by a GEV distribution as used here was deemed acceptable to control the type I 
error rate.  
	  
For regional flood frequency analysis the so-called method of LH-moments is often used to 
estimate high percentile quartiles of GEV distributions when the sample size is small. 
Sometimes this approach results in a more accurate estimator of the cutoff values compared 
to the method of L-moments we used. In these particular simulations this did not seem to 
be the case and therefore the method was not explored further (results not shown). 
Investigation of the type II error 
The results shown in figure C.1 for 𝑓 > 1 were obtained for simulated samples that differed 
from NOC. Large values of 𝑓 correspond to large differences as specified in equation 6.6. 
Because of this, the observed identification rate (power) for these samples could be used to 
study the empirical type II error rate, where the error rate is equal to 1-power. The lowest 
type II error was observed when the test used only 2 variables. This was expected since the 
patient samples were simulated such that only 2 variables were abnormal. Inclusion of 
irrelevant variables (i.e. when more variables were selected) had a negative effect on the type 
II error rate. For example, as shown in figure C.1, the error rate was considerably higher 
when all variables were selected. This effect was clearer when the data contained 100 
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variables instead of 10 and when the number of training samples was smaller. In practice the 
number of abnormal variables is unknown. This makes it challenging to select an 
appropriate number of variables such that a difference between the patient and the NOC 
can be best detected.  
 
As proposed in equation 6.5 in the main text, this number can be estimated from the data. 
The result of the automatic selection approach is the curve labeled A in figure C.1. As shown 
in the figure, the type II error rate of this test was very close to what can be achieved when 
the number of important variables was known a-priori. This can be seen in figure C.1 by 
comparing the curve of the test with 2 selected variables to the curve of the automatic sSHM 
test. In other words, the simple standardization suggested in equation 6.5 is a simple way to 
select a suitable number of variables. It should be realized, however, that the maximum 
sSHM test was designed to negate the negative influence of irrelevant variables. It is not 
guaranteed that all of the relevant variables are selected.  
D. Identification of abnormal variables 
After a sample was marked as significantly different from NOC the next step was to identify 
which variables were abnormal. The simulation study was also used to determine how well 
sSHM could identify the abnormal variables under a wide range of different structures of 
the NOC. Again, similar results were observed for the different structures. As an example 
we show the results that were obtained when the correlation structure corresponded to a 
Toeplitz matrix with 𝜌 = 0.6. 
 
The results are shown in figure D.1. The x-axis in the figure expresses the difference 
between the NOC and the simulated patient as defined by constant 𝑓 in equation 6.6. The y-
axis shows the percentage of simulated samples in which the abnormal variables were 
correctly identified. Correct identification was achieved by sSHM when the first two 
selected variables were the abnormal ones (the simulation was constructed such that 2 
variables were abnormal). Note that to generate the figure it was assumed that all samples 
were correctly marked as significantly different from NOC. From the figure it is clear that 
the correct identification rate improved for larger values of 𝑓. By comparing the top row of 
panels to the bottom row it can be seen that correct identification was not heavily 
influenced by the number of irrelevant variables in the data set. 
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Figure D.1    Correct identification of the abnormal variables by sSHM, sSPC, and SHM as a function of the size 
of the abnormality. Panels a– d correspond to different configurations of the number of training samples and 
variables in the data; n = 50 and p = 10 in panel a; n = 1000 and p = 10 in panel b; n = 50 and p = 100 in panel c; 
and n = 1000 and p = 100 in panel d. 
E. Comparison of sSHM to other methods 
Comparison between sSHM and SHM 
As mentioned in section 6.1, SHM can also be used to compare a patient sample to the 
NOC. In contrast to sSHM, the method combines the MD with dimension reduction 
instead of variable selection. More specifically, principal component analysis (PCA) is used 
to regularize the Mahalanobis distance and compare a sample to the NOC in two different 
subspaces [27]: 
 
 𝑀𝐷! = 𝐱! 𝚺!! 𝐱! ! = 𝐱! 𝐏𝚲!!𝐏! 𝐱! ! + 𝐱! 𝐏𝚲!!𝐏! 𝐱! ! = 𝐓! + 𝐓!"!  (E.1) 
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where the columns in P and the diagonal elements in matrix 𝚲 indicate the k eigenvectors 
(PC) and eigenvalues of 𝚺 that are retained in the model, respectively. The matrices 𝐏 and 𝚲 
indicate the 𝑝 − 𝑘 residual eigenvectors and eigenvalues. The statistic 𝑇! is used to monitor 
the principal component subspace spanned by the k PCs. The residual space is typically 
monitored by the Q-statistic since 𝐓!"!  cannot be applied when the control data has more 
variables than samples.  
 
As shown in figure C.1 SHM and sSHM had similar type I and type II errors with respect to 
detection of significant differences between the NOC and a sample. However, sSHM greatly 
outperformed SHM with respect to identification of the abnormal variables. In SHM the 
values for 𝑇! and Q are decomposed into a sum of terms, each associated with one variable, 
called contributions to identify abnormal variables [14]. Unfortunately, the abnormal 
variables can increase the contribution of variables not influenced by the disease [14, 15]. 
This ‘smearing’ effect quickly leads to ambiguous diagnosis results. As shown in figure D.1 
the correct identification rate of SHM was much poorer than that of sSHM due to the 
smearing effect. This shows that the sSHM model can be used more reliably to identify 
abnormal variables and diagnose as disease.  
Comparison between sSHM and sSPC 
The idea of combining the Mahalanobis distance with variable selection is not new. Several 
other methods have been proposed in the context of industrial process monitoring [25, 26]. 
Wang et al. use a forward-selection algorithm for this purpose [23]. The methods by Zou et 
al. and Capizzi et al. are closer to our approach. They also use an 𝑙!-norm penalty to achieve 
variable selection. Since both approaches are very similar, we focus on the method 
developed by Zou et al. [25]. We will refer to this method as sparse statistical process 
control (sSPC). The defining feature of the sSPC approach is the following optimization 
problem: 
 
 𝛍 = 𝑎𝑟𝑔𝑚𝑖𝑛𝐝 𝐝 − 𝛍 𝚺!! 𝐝 − 𝛍 ! , 𝑠. 𝑡. 𝜇! / 𝑑!!!!! ≤ 𝜏 (E.2) 
 
where 𝐝 = 𝐱! − 𝛍!. Problem E.2 is a generalized least squares problem that can be solved 
using various approaches such as least angle regression (LARS). 
 
The goal of the above test is to determine whether the difference between the patient sample 
and the controls come from a distribution with 𝝁 = 𝟎 (no difference), or a distribution with 𝝁 ≠ 𝟎 indicating that some variables have a different value compared to the average control 
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sample. Although, the direct penalization of 𝝁 might seem like an intuitive sound choice, it 
does not guarantee that the canonical vector 𝐚 = 𝛍𝚺!! is sparse. Note that sparse SHM aims 
to find a sparse estimate of the canonical vector directly. This should result in more accurate 
selection of the variables that can explain the difference between the patient and controls. 
Similar observations have been made when comparing differently penalized sparse LDA 
methods [31]. In other words, identification of abnormal measurements based on sSPC 
might be misleading. 
 
As shown in figure C.1 the sSPC model had a slightly worse type II error rate with respect to 
identification of a significant difference between a sample and the NOC compared to SHM 
and sSHM. Additionally, the correct identification rate of the abnormal variables was 
slightly poorer as shown in figure D.1. Another big disadvantage of sSPC for analysis of –
omics data is that the method is not applicable when the number of control samples is 
smaller than the number of variables. Therefore, no result was obtained when the number of 
training samples was 50 and the number of variables was 100 (panels c in figures C.1 and 
D.1). 
F. Solution paths of the NMR data 
 
Figure F.1   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 3β-­‐Hydroxy-­‐Δ-­‐C!"-­‐steroid	  dehydrogenase	  deficiency	  patient. The solid red lines indicate the centre of the bins 
corresponding to resonances of the diagnostic metabolites dihydroxycholenic	  acid	   (0.67;	  0.80	  –	  0.94;	  1.60	  –	  
1.90	  ppm)	  and	  trihydroxycholenic	  acid	  (0.73;	  0.80	  –	  0.94;	  1.60	  –	  1.90	  ppm). The dotted vertical line in panel (a) 
corresponds to the solution of the maximum test. The VS values in panel (b) correspond to the variable 
selection rank (VS) of the indicated resonances. 
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Figure F.2    (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 3-­‐
Methylcrotonyl	   CoA	   carboxylase	   deficiency	   patient. The solid red lines indicate the centre of the bins 
corresponding to resonances of the diagnostic metabolites 3-­‐methylcrotonylglycine	   (1.86,	   2.03,	   3.97,	   5.78	  
ppm)	  and	  3-­‐hydroxyisovaleric	  acid	   (1.33;	  2.55	  ppm).	  The dotted vertical line in panel (a) corresponds to the 
solution of the maximum test. The VS values in panel (b) correspond to the variable selection rank (VS) of the 
indicated resonances. 
 
Figure F.3    (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 5-­‐
Oxoprolinuria	  patient. The solid red lines indicate the centre of the bins corresponding to resonances of the 
diagnostic metabolite 5-­‐oxoproline	   (2.20,	   2.43,	   2.55,	   4.36,	   7.93	   ppm).	   The dotted vertical line in panel (a) 
corresponds to the solution of the maximum test. The VS values in panel (b) correspond to the variable 
selection rank (VS) of the indicated resonances. 
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Figure F.4    (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample that is 
contaminated by bacteria. The solid red lines indicate the centre of the bins corresponding to resonances of 
the relevant metabolite N-­‐methylhydantoin	  (2.92,	  4.08	  ppm).	  The dotted vertical line in panel (a) corresponds 
to the solution of the maximum test. The VS values in panel (b) correspond to the variable selection rank (VS) 
of the indicated resonances. 
 
Figure F.5   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 
healthy individual who consumed an artificial sweetener. The solid red lines indicate the centre of the bins 
corresponding to resonances of the relevant metabolite cyclamate	  (1.64;	  1.79	  ppm).	  The dotted vertical line in 
panel (a) corresponds to the solution of the maximum test. The VS values in panel (b) correspond to the 
variable selection rank (VS) of the indicated resonances. Note that the bins that were selected first 
corresponded to unknown compounds with multiplets at 1.34 (VS 1, 2) and/or 1.99 (VS 1) ppm. Inspection of 
the NMR data by a clinical expert indeed confirmed that these resonances were abnormal with respect to the 
control samples. 
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Figure F.6   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a	  
Cystinuria	   patient. The solid red lines indicate the centre of the bins corresponding to resonances of the 
relevant metabolites arginine	   (1.69,	   1.92,	   3.24,	   3.85	   ppm)	   and	   lysine	   (1.47,	   1.72,	   1.92,	   3.01,	   3.85	   ppm).	   The 
dotted vertical line in panel (a) corresponds to the solution of the maximum test. The VS values in panel (b) 
correspond to the variable selection rank (VS) of the indicated resonances.  
 
Figure F.7   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a	  
patient	  who	  was	  on	  depakine	  medication. The solid red lines indicate the centre of the bins corresponding to 
resonances of the relevant metabolite valproic	   acid	   (0.88,	   1.30,	   1.50,	   2.44	  ppm).	  The VS values in panel (b) 
correspond to the variable selection rank (VS) of the indicated resonances. Note that one variable was selected 
by the maximum test. The	  strong	  signal	   inbetween	  5	  and	  6	  ppm	  was	   selected	  with	  VS	  4	  and	  5	  and	  might	  be	  
related	  to	  4-­‐Amino-­‐5-­‐hexenoic	  acid.	  This	  might	  be	  due	  to	  sabril	  intake	  by	  the	  patient. 
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Figure F.8   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 
Formiminotransferase deficiency patient. The solid red lines indicate the centre of the bins corresponding to 
resonances of the diagnostic metabolites formiminoglutamic acid (2.00 – 2.22; 2.47 ppm) and hydantoin-5-
propionic acid (2.00 – 2.22; 2.51 ppm). The bin corresponding to the multiplet around 7.80 – 7.92 ppm was the 
second bin (VS 2) selected by the model and is related to one of the diagnostic metabolites (model compound 
not available). The dotted vertical line in panel (a) corresponds to the solution of the maximum test. 
 
Figure F.9   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a 
Isovaleric	  aciduria	  patient. The solid red lines indicate the centre of the bins corresponding to resonances of the 
diagnostic metabolites 3-­‐hydroxyisovaleric	   acid	   (1.33,	   2.55ppm)	   and	   isovalerylglycine	   (0.94,	   2.02,	   2.18,	   3.94	  
ppm).	  The dotted vertical line in panel (a) corresponds to the solution of the maximum test. Large quantities of 
choline, acetylcholine and glucose were observed in the spectrum of the patient. Resonances due to these 
metabolites were first selected by sSHM explaining why many of the resonances related to 3-­‐hydroxyisovaleric	  
acid	  and	  isovalerylglycine	  had	  high	  VS	  values. 
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Figure F.10   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of a	  
patient	  with	  high	  amounts	  of	  taurine	  in	  his	  urine	  (cause	  unknown).. The solid red lines indicate the centre of the 
bins corresponding to resonances of the relevant metabolite taurine	  (3.27,	  3.43	  ppm).	  The VS values in panel 
(b) correspond to the variable selection rank (VS) of the indicated resonances.  
 
Figure F.11   (a) Variable selection path of an sSHM model applied to the (b) NMR data of a urine sample of	  an	  
individual	   who	   just	   consumed	   fish.. The solid red lines indicate the centre of the bins corresponding to 
resonances of the relevant metabolite trimethylamine-­‐oxide	  (3.54	  ppm).	  The VS values in panel (b) correspond 
to the variable selection rank (VS) of the indicated resonances.. 
  
  
  
7  
SUMMARY AND FUTURE PERSPECTIVES 
 
Chemometrics on its way towards personalized health care 
 
Metabolomics has great potential to contribute to a transformation of health care towards 
approaches that are tailor-made for specific individuals instead of being optimal for the 
average patient with a specific disease. This is underpinned by our observation that the 
normal value for a body fluid biomarker in an individual varies within narrow limits well 
within the reference range that clinical chemistry laboratories use to define normality for 
that parameter. This strongly suggests that defining individual reference ranges, thus 
defining a person’s normal operating conditions, holds a great promise. It will allow earlier 
detection of deviations from the healthy state and diagnostics in an earlier phase of disease, 
but also more precise estimates of the patient’s health state when he/she is recovering from a 
diseased state. That would be an important step for precision or personalized health care. 
 
Data analysis is a current bottleneck that prevents such applications. Therefore, novel data 
analysis approaches were proposed in the previous chapters of this thesis. The main findings 
of this research are summarized here. Subsequently, it is shown that extension of the 
developed methodology for analysis of longitudinal data would be extremely interesting. 
Such data allows for assessment of individual responses to a biological perturbation by 
statistical modeling, i.e. truly personalized modeling. 
  
!
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7.1 Summary 
In current clinical practice, most diagnoses and treatment plans have been designed for the 
average patient. Because of this, treatment can be very successful for some individuals, but 
not for others. The rapid development of high-dimensional analytical technologies is 
expected to overcome these limitations. These techniques allow for examination of a patient 
in unprecedented detail at a molecular level. It is expected that this will result in significant 
advances in health care at two levels: (1) a better understanding of biological processes 
whose mechanisms are currently unclear may be obtained, and (2) with improved 
understanding of these processes so-called personalized health care can be applied where 
diagnosis and treatment are completely catered towards the unique molecular 
characteristics of an individual patient. 
 
As described in the general introduction provided in chapter 1 the goal of this thesis was to 
address several challenges in analysis of data generated by high-dimensional technologies for 
personalized health care. Work mainly focused on analysis of untargeted metabolomics data. 
Metabolomics refers to the use of high-dimensional techniques for the global and unbiased 
measurement of metabolites in a sample such as urine or blood. This approach is expected 
to become extremely important for personalized health care because the concentrations of 
these metabolites provide detailed information regarding the patient’s phenotype. However, 
currently our ability to carry out metabolomics experiments greatly outpaces our ability to 
analyze the acquired data. Development of novel data analysis approaches is essential to 
unlock the potential of metabolomics for personalized health care.  
 
Pre-processing is a crucial first step in data analysis to remove unwanted variation such as 
baseline drifts, peak misalignments, etc. These artifacts can completely mask the relevant 
biological information in the data. Based on analysis of a Fourier transform-infrared 
benchmark data set it was shown in chapter 2 how difficult it can be to select an 
appropriate pre-processing strategy for a specific data set. Only a small amount of the 
seemingly viable approaches improved subsequent statistical modeling, while many 
methods actually had a negative impact. Additionally, it was shown that all three widely 
used approaches for pre-processing selection have serious drawbacks; they may be time-
consuming beyond practicability or may provide misleading results. It is clear that more 
efficient pre-processing selection approaches need to be developed. 
 
Statistical modeling, e.g. to compare groups of samples to each other or diagnose a disease, 
is the second data analysis step. As described in chapter 3 metabolomics data poses 
significant challenges for statistical modeling. Many traditional techniques are not 
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applicable, or their results are unreliable. One way to circumvent these issues is to impose 
some structure to the model with the aim to reduce its variance at the cost of some bias. 
This is known as regularization. Chapter 3 reviewed modern regularization methods that 
might be of use to the field of metabolomics. Specific attention was paid to regularized 
estimators of the covariance matrix since this matrix is such an essential element of many 
statistical techniques. Subsequently, the use of 𝑙!  -norm constraints to combine model 
estimation and variable selection was described. The regularization approaches that were 
reviewed in this chapter are widely applicable and formed the basis for the statistical models 
that were developed in chapters 4 - 6. 
 
A first example of regularization was considered in the context of analysis of metabolomics 
experiments that were measured according to an experimental design. Such experiments are 
important for personalized health care to investigate the influence of different factors and 
interactions on metabolism and gain more mechanistic understanding. Multivariate analysis 
of variance (MANOVA) is a traditional method for analysis of data with an underlying 
design. However, it cannot be applied to typical metabolomics experiments in which a large 
number of variables are measured on a few samples. ANOVA simultaneous component 
analysis (ASCA) is a recently proposed alternative to MANOVA for analysis in these cases. 
It was shown in chapter 4 that the ASCA model implicitly assumes that metabolite 
concentrations are independent (uncorrelated) and have the same variance. This unrealistic 
assumption reduces the power of the method and hampers interpretation. Therefore, an 
improved model was proposed that is essentially a weighted average of the ASCA and 
ANOVA model. This was achieved by combining MANOVA with a modern regularized 
estimator of the covariance matrix. By means of simulation it was demonstrated that the 
regularized MANOVA (rMANOVA) model has higher power compared to ASCA under a 
wide range of alternative hypotheses. This was also observed when techniques were applied 
to urine 1H-NMR metabolomics data originating from a nutritional intervention study.  
 
Metabolomics studies used to compare groups of samples to each other (e.g. patient with a 
specific disease and controls). However, as argued in chapters 1, 5 and 6 this might be 
impractical in a clinical setting and a paradigm shift moving beyond such population-based 
approaches is required. In chapter 5 it was shown that ideas from industrial process 
monitoring are extremely useful in this respect. Therefore, statistical health monitoring 
(SHM) was introduced, which adapts data analysis ideas from industrial process 
monitoring to the clinical setting. The SHM model can be used to automatically identify the 
disease response in the individual patient. This is achieved by comparing the measured data 
of an individual patient  (𝑛 = 1) to that of a group of controls. The model indicates 
metabolic differences between the patient and the controls. A tremendous advantage of 
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SHM is that only data of the control group is required to construct the model. Because of 
this, SHM is not disease specific and can e.g. be used for diagnosis of rare diseases. In 
chapter 5 it was shown that several inborn errors of metabolism (IEM) could be diagnosed 
by 1H-NMR metabolomics in combination with the SHM model. Diagnosis of these rare 
diseases by conventional population-based approaches is challenging because	  typically not 
enough samples are available to for a useful comparison between the patient and controls. 
Additionally, a large number of diseases need to be considered. 
 
The SHM model described in chapter 5 used the Mahalanobis distance (MD) in 
combination with regularization via principal component analysis (PCA) to compare the 
patient to the controls. Because of the PCA step, the model is applicable when the number of 
control samples is smaller than the number of variables. A major drawback is, however, that 
it allows for interactions between abnormal variables and normal variables. This is known in 
industrial process monitoring as the smearing effect. Because of this, reliable identification 
of the metabolic differences between patient and controls is challenging. Therefore, a novel 
SHM model was proposed in chapter 6. The key idea consists of regularizing the MD 
estimator by variable selection instead of dimension reduction. Variable selection was 
achieved by inclusion of an ℓ𝓁!-norm constraint during estimation of the MD. By means of 
simulation it was shown that the resulting sparse SHM model could better identify the 
differences between patient and controls. The model was also successfully applied to 1H-
NMR metabolomics data for diagnosis of several IEM. 
 
In conclusion, high-dimensional technologies pose many problems for data analysis. The 
main contributions of this thesis consist of a careful evaluation of current data pre-
processing strategies and the development of three novel statistical models for analysis of 
metabolomics data for personalized health care. The new models were successfully applied 
to urine 1H-NMR metabolomics data to assess the metabolic response of patients suffering 
from metabolic syndrome to four diets, and to inspect the health status of individual 
patients and diagnose several rare diseases. These results show that the developed 
methodology holds great promise in personalized health care. Follow-up studies are, 
however, required to further validate these results and to study the value of the developed 
methodology in other applications.  
7.2 Future perspectives 
Due the emergence of increasingly large data sets in science we expect that the methodology 
proposed in this thesis is widely applicable. Within the context of personalized health care 
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the application of the developed methodology for longitudinal studies seems especially 
interesting. Such studies are of interest because often it is not possible to predict a-priori 
which time point best captures a specific biological effect and at least several time-points 
need to be captured. Additionally, time is an important factor to understand biological 
processes. Finally, data with a longitudinal design potentially allows for separate assessment 
of individual responses to a biological perturbation by statistical modeling. In other words, 
models that are truly personalized can be applied.  
7.2.1 Data pre-processing 
Data pre-processing is an important aspect of any metabolomics experiment, including 
experiments with a longitudinal design. As mentioned above, selection of an appropriate 
pre-processing strategy is not an easy task and guidelines need to be developed. When the 
choice of a method cannot be driven by analytical and biological knowledge (e.g. centering 
and scaling the data to a specific time point), the use of data quality parameters to judge the 
quality of the pre-processed data seems a useful tool to select the optimal methods. Some of 
these parameters were evaluated in chapter 2. However, it is not expected that a single 
parameter can capture all aspects of data quality. Therefore, it should be investigated which 
parameters have to be combined and in what way this has to be done. The sum of ranking 
differences (SRD) method seems interesting in this respect [1, 2]. The method can be used 
for data with repeated observations (longitudinal data) [3, 4]. SRD was developed to rank 
different models (pre-processing approaches) based on multiple merits (data quality 
parameters) and automatically select the best model or collection of models if so desired. 
Because SRD combines multiple merits in a natural way, decisions on how to combine and 
weight the different merits are avoided. SRD was recently used in this way to find the 
optimal shrinkage parameter in a regression model [4]. Ideally, the use of data quality 
parameters for pre-processing selection should be integrated with current practice in 
metabolomics such as the use of quality control (QC) samples that are measured 
throughout the experiment [5]. For example, quality measures can be derived from the QC 
samples such as the % relative standard deviation of each metabolite feature. Hopefully, 
application of this approach to pre-processing will reveal trends regarding suitable and 
robust approaches for specific data types and applications. Based on this, more specific 
guidelines can hopefully be developed to improve consistency between different studies, 
different laboratories, etc.  
7.2.2 Statistical modeling: biomarker discovery. 
Many metabolomics experiments to detect biomarkers have a longitudinal design. This way 
processes such as disease resilience and disease progression can be studied. Also, 
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longitudinal data allows for assessment of individual differences, e.g. is the temporal 
metabolic response to a perturbation the same for all individuals involved in the study? Such 
information is essential to further improve our understanding of health and disease and 
application of personalized health care. 
 
Currently, the number of methods to analyze data with a longitudinal design is very limited 
and often the dynamic nature of the experiment is not taken into account [6]. The 
rMANOVA model developed in chapter 4 seems a useful technique to study the effect of 
time, the perturbation, and their interaction. This model, however, is only applicable to 
cross-sectional data. By definition analysis of such data only provides information regarding 
the average response to a perturbation and no individual differences can be assessed. 
Individual differences are captured by longitudinal studies, but such data cannot be 
analyzed directly by rMANOVA since (1) the intra-individual correlations due to time are 
not taken into account, and (2) no individual time curves are fitted [7, 8]. In univariate 
statistics these problems are resolved by including so-called random effects to the model [7, 
8]. This way, individual trajectories are incorporated in the model in a formal way such that 
questions about individual behavior may be considered. However, application of random 
effects for high dimensional data introduces challenges regarding the complex correlation 
structures between the repeatedly measured samples. It is not directly evident how the 
relationship between time and all the metabolites should be specified in such a model and 
most likely some form of regularization is required. Recently, Schelldorfer et al showed that 
regularization by an 𝑙!-norm penalty was very useful in this respect [9]. They considered the 
case of a high dimensional design matrix. An et al have studied the case of high-
dimensional response (the data matrix) and regularized the model by means of a factor 
analysis approach [10]. These papers might offer a good starting point for development of 
such approaches in metabolomics. Another interesting line of research would be to reduce 
the number of variables in the data by grouping metabolites that share common biological 
function (e.g. are related to each other via the same metabolic pathway) Subsequently 
traditional multivariate methods such as a mixed model could be applied. This strategy is 
similar to gene set enrichment and some initial approaches have been proposed in 
metabolomics [11, 12]. Currently, however, application of enrichment techniques is 
extremely challenging since a large number of metabolites in body fluids still remain 
unknown. However, this bottleneck has been recognized and much effort is undertaken to 
improve metabolite identification [13]. Therefore, it is expected that metabolite enrichment 
strategies will become more feasible in the future. 
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Figure 7.1   The concept of health monitoring using (a) population-based reference values for the relevant 
biomarker, and (b) personalized reference values. 
7.2.3 Statistical modeling: personalized health monitoring 
As shown in figure 7.1, longitudinal experiments also offer interesting possibilities for 
health monitoring by SHM. Firstly, by monitoring the physiological status of an individual 
through time the emergence of a disease may be detected before symptoms occur allowing 
for early and efficient treatment (see figure 7.1a, and application 3 in section 1.1.2) [14-16]. 
Secondly, longitudinal data may offer the possibility to compare abnormal/disease states to 
healthy states of the same individual instead of population estimates as in chapters 5 and 6 
(figure 7.1b). Note that the expected healthy states or normal reference values were referred 
to as NOC (normal operating conditions) in these chapters. Based on the results of  
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Figure 7.2   Relative concentration of pyruvic acid in urine (μmol/mmol	   creatinine) as observed in 5 
individuals at 16 time points in January 2014. It is clear that the clinical reference values indicated by the black 
dotted lines match the observed metabolite concentrations for the population (grey squares and red dots), 
but are far from optimal for the individual marked in red. The red lines indicate more optimal personal 
reference values (NOC) for this specific individual.  Such personal reference values will allow earlier and more 
accurate diagnostics. 
a small pilot study4 we expect that estimation of individual NOC’s will allow for detection of 
subtle temporal abnormalities that would normally be hidden in the noise of the inter-
individual variation. This is demonstrated in figure 7.2 for univariate analysis of the data 
from the pilot study, and in figure 7.3 by multivariate SHM analysis of the same data. More 
research is required to thoroughly test this hypothesis. Currently, several longitudinal 
studies that monitor the health status of individuals are under way, for example by the 
Stanford center for genomics and personal medicine. It would be extremely interesting to 
analyze the acquired data by SHM to compare individual and population estimates of the 
NOC. 
                                                                  
4 In the pilot study 5 healthy individuals were followed for 1 month (January 2014). The individuals all lived in the 
Nijmegen area and were matched in terms of age, ancestry, etc. For each individual, urine samples were collected 
at 16 time points. These samples were subsequently measured by 1H-NMR metabolomics according to the 
protocols described in chapters 5 and 6. The medical ethical committee of the Radboud University Medical Center 
in Nijmegen approved the study (registration number 2012/350). 
5 A cross-validation procedure was used to estimate Q-values for the samples that were used to train an SHM 
model. Additionally, the sample corresponding to dot B in the figure was not used to train models. For 
construction of the SHM models it was assumed that samples taken at different time points for the same individual 
were independent. Small to modest autocorrelations derived under stationarity at various lags seems to support 
this claim. In order to estimate these autocorrelations, the unevenly sampled time series were first evenly 
resampled using a spectral approach based on the Lomb periodogram [14]. 
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Figure 7.3   Analysis of the pilot project data with two different SHM models, namely (a) a population SHM 
model and (b, c) a personalized SHM model5. Similar to chapter 5, the Q-statistic was used to compare the 
metabolic profile of a sample to that of healthy controls in a multivariate manner where high Q-values indicate 
large differences. In panel (a) measurements of all individuals were used as healthy controls to train the SHM 
model and define NOC for the population (red horizontal line), where log(Q) indicates the natural logarithm of 
Q. The NOC matched the population well, but was, for example, too high for individual 3. In panels (b, c) 
measurements of individual 3 were used to construct the SHM model and define personalized NOC for that 
individual. The NOC were clearly more optimal for individual 3 compared to the population model. 
Additionally, the high Q-values of subjects 1, 2, 4, and 5 suggested that the personalized model described 
unique normal metabolic variation in individual 3; unlike the population model many normal measurements 
of the other individuals were clearly outside the NOC. These observations suggest that the use of personalized 
NOC would allow for earlier and better detection of subtle metabolic abnormalities in an individual. Subject 3 
became ill during the test period (the flu) In panel (c) his Q-values are shown for all 16 time points with respect 
to the personalized NOC. It is interesting to see that an elevated Q-value (dot A) could already be observed 1.5 
day before the individual felt sick or any clinical signs or symptoms of the flu became apparent (dot B). This was 
not observed when the SHM model was based on the population (panel a). 
 
Chapter 7 
 184 
Many challenges remain for application of SHM for longitudinal health monitoring. For 
example, the optimal sampling frequency (days, weeks, months) needs to be estimated. The 
influence of natural shifts in metabolism, e.g. due to aging, on the performance of the SHM  
model also needs to be evaluated, and, if required, corrections for this need to be 
incorporated in the model. Additionally, it is important that the SHM method flags 
abnormal temporal events related to disease, but ignores abnormalities due to other 
environmental factors such as diet or medication. These “unimportant” abnormalities need 
to be identified and a way to cope with them must be found, e.g. by ignoring the variables 
associated to them. 
 
Due to the close connection to industrial process monitoring it is expected that many ideas 
for longitudinal analysis developed in this field can also be useful for SHM. The methods 
developed in chapters 5 and 6 are essentially multivariate extensions of the so-called 
Shewhart control chart, which is the most popular chart in industry [17]. This chart has 
sometimes difficulty to detect small process changes. Alternative charts to detect such 
changes have been developed. Examples include the exponentially weighted moving average 
(EWMA) and the cumulative sum (CUSUM) charts [17]. In contrast to the Shewhart chart, 
these methods do not only use the current observation at each time point, but also consider 
historical information. It has been shown that the EWMA and CUSUM charts may detect 
small changes more quickly compared to the Shewhart chart, but large changes more slowly. 
Since many metabolic disruptions are expected to be rather subtle it is interesting to explore 
the use of EWMA, CUSUM, and other techniques for SHM. Multivariate generalizations of 
these methods with regularization by PCA (similar to the approach in chapter 5) have been 
proposed in literature [17]. The model proposed in chapter 6 can also be extended for 
EWMA and CUSUM analysis. The Shewhart, EWMA and CUSUM approaches all assume 
that the observations in time are exchangeable (i.e. uncorrelated). However, observations in 
time series are usually correlated to each other. Ignoring such autocorrelation can have an 
enormous impact on the performance of the charts. Therefore, this issue should be 
investigated with SHM. A possible solution is to fit a time series model to the data or to use 
a dynamic PCA approach. [17]. Finally, we would like to remark that the proposed SHM 
models (as well as the rMANOVA model developed in chapter 4) rely on the normal 
distribution. However, it is unlikely that metabolomics data follows this distribution, e.g. 
because a metabolite concentration cannot be detected below the lower limit of detection of 
the analytical technique that is used to measure it. Control charts have been developed for 
non-normal data. For example, Chang et al suggested a simple scaling of the data by 
“weighted standard deviations” to correct for skewed populations [18]. This method is 
directly applicable to the SHM models developed in chapters 5 and 6. Due to the close 
connection between the SHM and rMANOVA models via the Mahalanobis distance, it is 
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expected that this scaling method can also be used to extend rMANOVA to the non-normal 
case.  
7.2.4 Concluding remarks 
This thesis has focused on development of data analysis methods for high-dimensional data 
such as metabolomics data. Although work mainly centered on 1H-NMR data, the proposed 
methods are general and also applicable to other data types and possibly much larger data 
sets. For example, rMANOVA and SHM hold great promise in “next generation” untargeted 
metabolomics where around 10000 signals derive from a single blood sample by techniques 
such as LC-MS using a quadrupole-time-of-flight mass spectrometer. Clearly, data analysis 
is indispensable for interpretation of such large data. Similarly, the techniques may also be 
used for analysis of data from (a combination of) other relevant omics technologies such as 
genomics, transcriptomics, glycomics, or proteomics.  
 
Due to the increasing dimensionality of data sets, further development of the regularization 
approaches that were reviewed and developed in this thesis is crucial. The combination of 
rMANOVA with variable selection via e.g. a penalized approach as used in chapter 6 seems 
an interesting avenue for further research. Similarly, the sparse SHM model developed in 
chapter 6 may benefit from the regularized estimator of the covariance matrix that was used 
in chapter 4.  
 
Independent of what kind of regularization is applied it is important to keep in mind that 
most untargeted metabolomics studies are explorative in nature due to the low number of 
samples that are considered. Obviously, subsequent validation of e.g. a discovered 
biomarker on larger populations is required to truly to assess its relevance and reliability 
before it can be used as e.g. a diagnostic tool [19]. This is also true for the proposed SHM 
approach. 
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In de huidige gezondheidszorg zijn diagnostiek en behandeling meestal gericht op de 
“modale” patiënt. Dit heeft tot gevolg dat diagnostiek en behandeling succesvoller kunnen 
zijn voor de ene patiënt dan voor de andere patiënt. Met de snelle ontwikkelingen op het 
gebied van hoog-dimensionale analytische technologieën hoopt men hier verbetering in te 
brengen. Met deze technieken kan uiterst gedetailleerde informatie van een patiënt worden 
verkregen op moleculair niveau. Verwacht wordt dat dit zal resulteren in aanzienlijke 
vooruitgang in de gezondheidszorg. Allereerst kan een beter begrip van biologische 
processen worden verkregen, waarvan de mechanismen nu nog onduidelijk zijn. Verder kan 
met de nieuwe gedetailleerde kennis een meer persoonlijke gezondheidszorg worden 
gerealiseerd, waarbij diagnostiek en behandeling worden afgestemd op unieke moleculaire 
karakteristieken van een individuele patiënt. 
 
Zoals beschreven in hoofdstuk 1 was het doel van het onderzoek beschreven in dit 
proefschrift om verschillende problemen in de analyse van hoog-dimensionale data voor 
gepersonaliseerde gezondheidszorg op te lossen of nader tot een oplossing te brengen. 
Hierbij heeft het onderzoek zich vooral gericht op de analyse van zogenaamde “untargeted 
metabolomics” experimenten waar hoog-dimensionale technieken worden gebruikt voor 
het meten van de concentratie van een groot aantal kleine moleculen (metabolieten) in een 
monster, bijvoorbeeld urine of bloed. Verwacht wordt dat deze technieken steeds 
belangrijker worden voor gepersonaliseerde gezondheidszorg omdat concentraties van 
metabolieten in een monster zeer gedetailleerde informatie over het fenotype van een 
patiënt verschaffen. Dergelijke experimenten en technieken resulteren echter in zeer 
ingewikkelde data. Op dit moment schieten de mogelijkheden om deze data te analyseren te 
kort. Ontwikkeling van nieuwe analyse methoden is noodzakelijk.  
 
Voorbewerking van data is een cruciale eerste stap in data analyse om ongewenste variatie 
in de data, zoals verschuivingen van de basislijn of piekpositie, te verwijderen. Dergelijke 
artefacten kunnen de relevante biologische informatie in de data volledig maskeren. Op 
basis van analyse van een “Fourier transform – Infrared benchmark data set” wordt in 
hoofdstuk 2 aangetoond hoe lastig het kan zijn om geschikte methoden voor data 
voorbewerking te kiezen voor een specifieke data set. Slechts enkele van de potentieel 
geschikte voorbewerkingsmethoden resulteerden in betere resultaten na analyse, terwijl in 
veel gevallen de methoden juist averechts werkten. Bovendien werd aangetoond dat de drie 
veelgebruikte strategieën voor de keuze van  geschikte voorbewerkingsmethoden ernstige 
nadelen vertonen: ze vergen onoverkomelijk veel rekentijd of geven misleidende resultaten. 
Het is duidelijk dat efficiëntere strategieën moeten worden ontwikkeld voor de keuze van  
voorbewerking van hoog-dimensionale data.  
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De volgende stap is het opstellen van een statistisch model, bijvoorbeeld om groepen 
monsters met elkaar te vergelijken of om een ziekte te diagnosticeren. Zoals beschreven in 
hoofdstuk 3 zijn veel traditionele statistische methoden niet direct toepasbaar op 
metabolomics data, of zijn hun resultaten onbetrouwbaar. Een manier om deze problemen 
te omzeilen is om in het model structuur aan de data op te leggen met als doel de variantie 
van parameterschatters te verlagen ten koste van een (hopelijk geringe) (toename in) 
onzuiverheid. Dit staat bekend als regularisatie. Hoofdstuk 3 beschrijft recente regularisatie 
methoden die van nut kunnen zijn voor de analyse van metabolomics data. Meer specifiek 
wordt aandacht besteed aan geregulariseerde schatters van de covariantie matrix, aangezien 
deze matrix in veel statistische methoden een belangrijke rol speelt. Vervolgens wordt het 
gebruik van een “l1-norm constraint” beschreven voor het aanpassen van een model aan 
data in combinatie met selectie van variabelen. De regularisatie methoden beschreven in 
hoofdstuk 3 zijn breed toepasbaar en vormen de basis voor verdere statistische analyse zoals 
beschreven in hoofdstukken 4,  5 en 6.  
 
De eerste toepassing van regularisatie wordt beschreven in de context van  analyse van 
metabolomics data die verkregen is volgens een experimentele proefopzet. Dergelijke 
experimenten zijn belangrijk voor gepersonaliseerde gezondheidszorg om de invloed van 
specifieke factoren en interacties op het metabolisme te onderzoeken om een beter begrip 
van de onderliggende biologische processen te verkrijgen. In hoofdstuk 4 wordt 
bijvoorbeeld het effect van verschillende diëten op het metabolisme van metabool syndroom 
patiënten onderzocht. Multivariate variantie analyse (MANOVA) is een traditionele analyse 
methode voor data verkregen binnen een experimentele proefopzet.  Deze methode kan 
echter doorgaans niet worden toegepast op data van metabolomics experimenten omdat 
een groot aantal variabelen (metabolieten of pieken) wordt gemeten op een betrekkelijk 
klein aantal monsters. Daarom is onlangs ANOVA simultaneous component analysis 
(ASCA) geïntroduceerd. In hoofdstuk 4 wordt aangetoond dat binnen het ASCA model 
impliciet wordt verondersteld dat metaboliet concentraties ongecorreleerd (onafhankelijk 
onder normaliteit) zijn en dezelfde variantie hebben. Deze onrealistische veronderstellingen 
verminderen het onderscheidend vermogen (power) van ASCA en belemmeren de 
praktische interpretatie. Daarom wordt in hoofdstuk 4 een verbeterde aanpak voorgesteld; 
geregulariseerde MANOVA (rMANOVA), MANOVA in combinatie met een recent 
geïntroduceerde geregulariseerde schatter van de (binnen-groep) covariantie matrix. In 
feite is rMANOVA een gewogen gemiddelde van ASCA en MANOVA. Met behulp van 
gesimuleerde data wordt aangetoond dat rMANOVA een hoger onderscheidend vermogen 
heeft dan ASCA onder een breed scala van mogelijke verschillen tussen groepen. Bij 
toepassing van rMANOVA en ASCA op urine 1H-NMR metabolomics data, afkomstig uit 
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de eerder genoemde voedingsinterventie studie voor metabool syndroom patiënten, vindt 
rMANOVA meer verschillen tussen groepen dan ASCA. 
 
In traditionele metabolomics studies worden groepen van monsters met elkaar vergeleken, 
zoals patiënten met een specifieke ziekte versus gezonde controle patiënten. Zoals betoogd 
in hoofdstukken 1, 5 en 6 kan deze aanpak onpraktisch zijn voor gepersonaliseerde 
gezondheidszorg en is een paradigmaverschuiving van populatie modellen naar meer 
gepersonaliseerde modellen vereist. In hoofdstuk 5 wordt aangetoond dat ideeën uit de 
industriële proces controle nuttig zijn in dit opzicht. Op basis van deze ideeën wordt het 
concept van “statistical health monitoring” (SHM) geïntroduceerd. SHM kan worden 
gebruikt om automatisch de respons te detecteren (of misschien beter; de afwijking in de 
respons) die veroorzaakt wordt door een ziekte in een individuele patiënt. Dit wordt bereikt 
door de meetgegevens van een individuele patiënt (n = 1) te vergelijken met die van een 
groep controle monsters. Vervolgens identificeert het SHM model belangrijke verschillen 
tussen de meetgegevens van de controle groep en die van de patiënt. Een belangrijk 
voordeel is dat SHM alleen gegevens van controle monsters nodig heeft. Daarom is het 
SHM model geschikt om afwijkingen als gevolg van verschillende mogelijke ziektes 
(waaronder zeldzame ziektes) te diagnosticeren. In hoofdstuk 5 wordt aangetoond dat 
verschillende “inborn errors of metabolism” (IEM, stofwisselingsziekten) kunnen worden 
gediagnosticeerd met 1H-NMR metabolomics in combinatie met SHM. Diagnostiek van 
deze ziektes met traditionele populatie-modellen is lastig omdat rekening moet worden 
gehouden met een groot aantal ziekten en er meestal niet genoeg patiënt monsters 
beschikbaar zijn.  
 
SHM maakt gebruikt van de “Mahalanobis distance” (MD) in combinatie met regularisatie 
via principale componenten analyse (PCA) om de gegevens van een  patiënt  met die van 
controles te vergelijken. SHM is ook toepasbaar wanneer het aantal controle samples kleiner 
is dan het aantal variabelen in de data set, vanwege de PCA regularisatie. Een nadeel is 
echter dat deze aanpak kan zorgen voor wat in de industriële proces controle als het 
“smearing effect” wordt omschreven. In feite een gevolg van het feit dat de associatie tussen 
variabelen voor zieke en gezonde patiënten niet noodzakelijk dezelfde is. Daarom wordt in 
hoofdstuk 6 een alternatieve SHM aanpak geïntroduceerd. Bij deze aanpak wordt de MD 
geregulariseerd via variabele selectie in plaats van via dimensie reductie. Variabele selectie 
wordt gerealiseerd door de MD te schatten onder een “l1-norm constraint”. Op basis van 
gesimuleerde data wordt aangetoond dat het resulterende sparse SHM model beter 
verschillen tussen controles en een patiënt kan aantonen. Het model wordt ook met succes 
toegepast op 1H-NMR metabolomics data om verschillende IEM te diagnosticeren. 
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Data van hoog-dimensionale technologieën werpen veel problemen op voor een succesvolle 
data analyse. De belangrijkste bijdrage van het onderzoek beschreven in dit proefschrift 
bestaat uit een zorgvuldige evaluatie van huidige strategieën om de data voor te bewerken 
en de introductie van drie nieuwe statistische methoden, namelijk rMANOVA, SHM en 
sparse SHM, voor de analyse van metabolomics data voor gepersonaliseerde 
gezondheidszorg. De nieuwe methoden zijn met succes toegepast op urine 1H-NMR 
metabolomics data om het effect van vier diëten op het metabolisme van metabool 
syndroom patiënten te toetsen, en om de gezondheidstoestand van individuele patiënten te 
inspecteren en verschillende zeldzame ziektes te diagnosticeren. De resultaten geven aan dat 
de nieuwe methoden grote potentie hebben voor gepersonaliseerde gezondheidszorg. 
Vervolg studies zijn echter vereist om resultaten verder te valideren en om de bruikbaarheid 
van de methoden in andere toepassingen te bestuderen. 
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